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ABSTRACT
Atrial fibrillation (AF) is the leading cause of ischemic stroke and is the most commonly 
observed arrhythmia in clinical cardiology. Catheter ablation of AF, in which specific regions 
of cardiac anatomy associated with AF are intenionally injured to create scar tissue, has 
been honed over the last 15 years to become a relatively common and safe treatm ent option. 
However, the success of these anatomically driven ablation strategies, particularly in hearts 
that have been exposed to AF for extended periods, remains poor. AF induces changes 
in the electrical and structural properties of the cardiac tissue that further promotes the 
permanence of AF. In a process known as electroanatomical (EAM) mapping, clinicians 
record time signals known as electrograms (EGMs) from the heart and the locations of 
the recording sites to create geometric representations, or maps, of the electrophysiological 
properties of the heart. Analysis of the maps and the individual EGM morphologies can 
indicate regions of abnormal tissue, or substrates that facilitate arrhythmogenesis and AF 
perpetuation. Despite this progress, limitations in the control of devices currently used 
for EAM acquisition and reliance on suboptimal metrics of tissue viability appear to be 
hindering the potential of treatment guided by substrate mapping.
In this research, we used computational models of cardiac excitation to evaluate param­
eters of EAM that affect the performance of substrate mapping. These models, which have 
been validated with experimental and clinical studies, have yielded new insights into the 
limitations of current mapping systems, but more importantly, they guided us to develop 
new systems and metrics for robust substrate mapping. We report here on the progress in 
these simulation studies and on novel measurement approaches that have the potential to 
improve the robustness and precision of EAM in patients with arrhythmias.
Appropriate detection of proarrhythmic substrates promises to improve ablation of AF 
beyond rudimentary destruction of anatomical targets to directed targeting of complicit 
tissues. Targeted treatm ent of AF sustaining tissues, based on the substrate mapping 
approaches described in this dissertation, has the potential to improve upon the efficacy of 
current AF treatm ent options.
For all those who have inspired and supported me.
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CHAPTER 1
MULTISCALE MODELS OF SUBSTRATE  
M APPING
The presence of cardiac scarring or fibrosis is a topic of great interest and study in 
cardiac electrophysiology, primarily because it can lead to and exacerbate life-threatening 
arrhythmias, such as atrial fibrillation or ventricular tachycardia [1, 2]. Normal cardiac 
conduction depends on organized propagation of excitation waterfronts. The presence of 
inexcitable scar tissue or regions of fibrosis—which we define very broadly as pathological 
changes in the nature and volume of the extracellular matrix (see Section 3.4.2)—can slow, 
disrupt, and detour normal activation sequences and may create a substrate in which an 
arrhythmia can initiate. For example, in cases of cell death incurred following myocardial 
infarction, scar tissues can form an anatomical substrate conducive to what is known as 
macroreentrant ventricular tachycardia (VT) [3]. Fibrosis does not generally render tissue 
completely inexciatable, but partially decouples myocytes, which increases intracellular 
resistance and renders conduction pathways more tortuous. The effect of these changes is 
slower and less uniform spread of activation impulses, which creates an ideal substrate for 
arrhythmogenesis, as seen, for example, in atrial fibrillation [4, 5]. Regardless of whether the 
diseased substrate is in the ventricles or atria, these arrhythmias may present as paroxysmal 
episodes that resolve quickly, or they may persist and require medical intervention, in the 
form of drugs or electrical cardioversion, to restore sinus rhythm. The mechanisms by which 
scarred and fibrotic substrates facilitate reentry may differ, but they share the common 
feature of an abnormal substrate disrupting normal impulse propagation in a manner 
that increases the propensity for arrhythmogenesis. Consequently, efforts to improve the 
treatment of persistent VT and atrial fibrillation (AF) have focused on the identification 
and targeted treatm ent of diseased, fibrotic substrates [6, 7].
Identification of abnormal cardiac substrates currently occurs by means of two orthogo­
nal imaging modalities: magnetic resonance imaging (MRI) and electroanatomical mapping 
(EAM). Various groups, including ours, have shown that late gadolinium-enhanced (LGE)
2MRI can identify scarring and fibrosis in both the ventricles and atria (Fig. 1.1 A and 
B) [8, 9, 10, 11]. These studies indicate that the location, extent, and presentation of these 
abnormal substrates contribute to the initiation and entrenchment of cardiac arrhythmias. 
As yet, however, analysis of MRI images cannot characterize the specific triggers, pathways 
of reentry, or mechanisms that are critical to arrhythmogenesis in an individual heart.
The current gold standard for identifying and targeting proarrhythmic cardiac substrates 
is electroanatomical mapping (EAM). A type of EAM known as substrate mapping is 
tailored to the identification of proarrhythmic substrate based on electrical signals recorded 
from the cardiac tissue. Specifically, electrodes are navigated to the surface of the heart 
(both the more typical inner surface, endocardium, or the outer surface, epicardium) 
to record the local electric potentials (Fig. 1.1 C). Numerous studies have shown that 
disruption of normal cardiac tissue affects the conduction of excitation wavefronts through 
the myocardium and consequently changes the morphology of electric potentials in the 
vicinity of that disruption [12, 13, 14, 15, 10]. When the spatial positions of these electrodes 
are recorded and the morphology of electrograms (EGM) is captured, a map of cardiac tissue 
health can be constructed. Maps generated during sinus rhythm, i.e., regular activation of 
the heart, or during arrhythmia have been used to identify regions with arrhythmogenic
Fig. 1.1. Examples of cardiac substrate characterization using MRI and EAM. A. Late 
gadolinium-enhanced (LGE) MRI of a human left atrium shows the formation of scar tissue 
3 months following an ablation procedure for atrial fibrillation. B. Segmentation and image 
analysis of the MRIs allows visualization of regions of scarring or structural remodeling (red 
and white regions in this image). C. Voltage map of swine right atrium shows the creation 
of two point lesions by radio frequency ablation (purple spheres). Electrograms acquired 
in regions surrounding the ablation lesions contain low bipolar amplitude activation signals 
(< 1.5 mV), indicating that normal cardiac conduction has been disrupted.
3properties and to propose targets for ablation to restore and maintain sinus rhythm. How­
ever, various challenges limit the efficacy of clinical substrate mapping, and a major goal 
of this research was to combine experimental and simulation approaches to address some of 
these challenges.
As an example of the challenges of EAM, little is known about the impact of electrode 
size, configuration, or orientation on the accuracy of EAM-based assessment of the my­
ocardium. Furthermore, robust experimental characterization of these parameters is limited 
due to challenges associated with controlling the interaction of recording devices, cardiac tis­
sue, and activation wavefronts. However, emerging clinical technologies, combined with the 
ability to create realistic computational models of cardiac propagation and measurement, 
have the potential to overcome many of the current limitations associated with substrate 
mapping. The role of computational modeling is of special interest in this research. The 
National Institute of Health (NIH), Food and Drug Administration (FDA), and National 
Science Foundation (NSF) are committed to the development of “predictive, computational 
models that encompass multiple biological and behavior scales” in order to “efficiently 
and effectively address the challenges of understanding multiscale biological and behavioral 
systems” [16]. According to the FDA “[the] development of predictive models ... that 
advance our understanding of the performance of medical products in humans are of greatest 
interest” [16]. These ambitions apply especially well to the use of simulation in cardiac 
electrophysiology, which is a rapidly evolving field that depends heavily on medical devices 
and drugs. For example, specific features of intracardiac EGMs acquired during EAM 
procedures, e.g., low bipolar voltage, high dominant frequency, etc., have been associated 
with diseased cardiac substrate that causes life-threatening cardiac arrhythmias [13, 17]. 
However, the devices used to acquire these signals are often optimized for tasks other 
than the detection of diseased tissue, e.g., radio-frequency energy delivery for ablation 
therapy. Thus, there is a need to identify weaknesses in current measurement approaches 
and design new instrumentation and interpretation of measured signals from the heart. 
Multiscale computational models of mapping systems used for substrate characterization 
can help improve the selection of the most appropriate tools for a given substrate mapping 
application and predict the consequences of suboptimal choices.
Multiscale simulation of cardiac electrical activity is a relatively well-evolved approach 
with many tools and techniques that enable the modeling of a wide range of scenarios. For 
example, with an approximation and numerical scheme known as the bidomain [18, 19], 
it is possible to create computational models of both the diseased myocardium and rep­
4resentations of mapping devices, proposed or in current clinical use. Results from such 
studies can efficiently and effectively enhance our understanding and the performance of 
mapping technologies [20, 21, 22]. The cardiac bidomain model has been widely adopted 
in cardiac research for its ability to translate phenomena that occur on a cellular level 
to the tissue and whole organ levels. Bidomain simulations of cardiac excitation and 
propagation can incorporate relevant features of both the cellular ionic currents and the 
myocardial substrate to produce realistic waves of excitation and extracellular electric 
potentials that reflect the biophysics of proarrhythmic substrates (Fig. 1.2). The bidomain 
formulation is a mathematical description of the relationship between the transmembrane 
potential ($ m) and electric potential in the extracellular domain ($ e). In this formulation, 
conductivity values are assigned to the intracellular and extracellular domains to form a 
framework in which solving the for every element in the model allows for calculation 
of $ e. is first calculated using models of ion channel kinetics in the cellular membrane. 
These models simulate action potentials based on the behavior of ion channels in different 
tissue types, for instance, Luo-Rudy (ventricular myocyte) or Coutemanche-Ramirez-Nattel 
(atrial myocyte) [23, 24]. Once $ e has been computed, it is used as the initial conditions 
from which the next iteration of can be solved using the membrane model. In this
Fig. 1.2. Simulation of impulse propagation through anatomical models of cardiac 
tissue. The left panel shows an example of simulated propagation of excitation through 
a patient-specific model of human atria derived from MRIs. The gray shafts visible in the 
left atrium through the right inferior pulmonary vein ostia represent a catheter sampling 
intracardiac electrograms at two different orientations. The right panel contains a model of 
ventricular excitation in a rabbit heart when paced from the left ventricular apex.
5manner, the bidomain formulation permits external stimuli to modulate the behavior of 
the ionic model and to set in motion a wave of cardiac excitation through the simulated 
cardiac medium. These models can incorporate many salient features of cardiac conduction, 
including anisotropy and regions of passive conductivity by altering conductivities or the 
properties of the membrane model.
To pursue the aims of this research, we have capitalized on the capabilities of the 
bidomain simulation to test substrate mapping systems and then validated the results 
through experimental and clinical mapping studies as outlined in Fig. 1.3. To conduct 
the simulation studies, we utilized the Cardiac Arrhythmia Research Package (CARP), a 
robust implementation of the bidomain model [20]. Using this powerful framework, we 
constructed virtual “test beds” in which existing approaches to substrate mapping were 
assessed for accuracy, and novel techniques for substrate characterization were explored. 
We recorded experimental and clinical electrograms and used them to validate our sim­
ulation studies. The investigators and facilities of the Cardiac Arrhythmia Research and 
Management (CARMA) Center and the Scientific Computing and Imaging (SCI) Institute 
of the University of U tah generously provided invaluable expertise and resources to carry 
this work to fruition.
1.1 Research Aims
This dissertation is comprised of three major projects that focused on the use of multi­
scale computation models to evaluate electrophysiological mapping systems. The research 
aims address some of the clinically relevant challenges of EAM described above by assessing 
the performance of current clinical measures, suggesting new, or refined, approaches for 
cardiac substrate characterization. In limited cases, we also provided proof of concept for 
these novel techniques using animal and human experiments.
1.1.1 A im  1: C haracterize V oltage M apping Perform ance
Voltage mapping is a valuable tool in the clinical electrophysiology laboratory for charac­
terizing regions of diseased myocardium. Electrically active myocardium generates electric 
currents and fields that emanate throughout the surrounding tissue and media, generating 
measurable voltages [25]. The strength of these voltages is a function of the mass of 
depolarizing myocytes and proximity of the electrode(s) to moving wavefronts that separate 
depolarizing from still resting tissue. Consequently, regions of scar tissue that do not 
activate, or tissues in which conduction has been impaired, will generate lower extracellular 
voltages than healthy tissue, in the extreme insulating the electrode and producing no
6discernible voltage. A voltage mapping study utilizes a catheter, often a dual purpose 
mapping and ablation catheter, to measure the electric potential difference, or voltage, 
between a probing electrode and a reference. Cardiac tissue that generates low currents 
during activation will appear as a region of low amplitude electric potentials in voltage 
mapping maps. The voltage recorded between the probe and reference will also depend on 
the positioning of the electrodes relative to the electric field (the gradient of extracellular 
voltage) generated by the propagation of activation impulses.
Bipolar EGMs are one type of extracellular voltage recorded from catheters in which 
the probing electrode and the reference are positioned a few millimeters apart (see Section 
2.4.2). Such signals have high sensitivity for local tissue properties and are, consequently, 
most often used for clinical voltage mapping studies. The spatial proximity of the electrodes 
provides an advantageous feature known as “common mode rejection” in which the effect of 
any measured far field signal, i.e., electric fields generated by distant sources, is minimized 
in the bipolar EGM. Localized sensing permits improved discrimination between healthy 
and diseased tissue. During a modern clinical voltage mapping study, a navigation system 
tracks the location of the catheter in real time, permitting annotation of the local voltages 
throughout the heart for display and analysis. In this manner, regions of scarring following 
myocardial infarction and regions of atrial structural remodeling associated with atrial 
fibrillation have been detected [13, 15, 10]. However, the orientation of the electrodes with 
respect to the tissue and to the activation wavefront will affect the voltages measured in 
the bipolar EGMs. We hypothesized that the performance of clinical mapping and ablation 
catheters depends on the orientation of the recording electrodes with respect to  activation 
wavefronts and the tissue and that the resulting errors will reduce sensitivity and specificity 
of such mapping studies.
The nature of percutaneous EAM studies, especially the inability to visualize directly 
the heart or mapping electrodes, precludes robust measurement of catheter orientation with 
respect to the cardiac anatomy. Estimation of the spatial orientation of a mapping catheter 
with respect to an excitation wavefront is even more limited due to the challenges associated 
with measuring and characterizing accurately an excitation wave. Specifically, robust de­
termination of activation impulse direction requires either a high-resolution, multielectrode 
array for simultaneous acquisition during a single beat or sequential high-density activation 
mapping during a stable, repeated activation pattern. However, even with sufficiently 
high resolution, to determine the relative alignment of the catheter and activation wave, 
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Fig. 1.3. Workflow for construction and validation of multiscale models of cardiac 
electrophysiology. The systems of cardiovascular disease in this research were explored 
using two parallel paths of investigation. To the extent possible, the computational 
models and experimental models implemented the same features of pathological myocardial 
substrate, i.e., lesion, or slowing of impulse propagation, and the same electrode geometries. 
Electrograms from each model were processed in the same manner for both paths, and 
features of the EGMs from both models were cross validated.
8and interbeat variability, could obscure the spatial relationship between the catheter and 
activation impulse.
To access the necessary information, we constructed a computational model of cardiac 
excitation and simulated mapping and ablation catheters Computational models allow for 
explicit and virtually limitless control of variables of interest. In this case, we simulated an 
activation wavefront in a model of myocardial tissue and positioned the measurement elec­
trodes of the catheter through an exhaustive sampling of possible orientations with respect 
to the parameters of interest. To the extent possible, we validated these computational 
models with the use of clinical mapping devices through in vivo experimentation with 
large mammals. The results of these studies helped us to parameterize the contribution 
of geometric factors to error in the ability of substrate mapping strategies to classify 
arrhythmogenic tissues.
1.1.2 A im  2: M apping of M ultip le A ctivation  P atterns
A further limitation of the majority of current techniques for clinical substrate mapping 
is that they capture electrical activity passively, with the measurement system as bystander. 
Specifically, whether EGMs are acquired in sinus rhythm or during arrhythmic activity, 
the activation sequence of the local tissue is an uncontrolled parameter. This point is 
especially pertinent given that ectopic beats or other forms of triggered activity, known to 
be critical factors in arrhythmogenesis, initiate activation patterns that differ from sinus 
rhythm activation (see Section 2.3.1) [26]. These aberrant activation patterns, initiated 
by the ectopy, may unmask proarrhythmic substrates that are innocuous during sinus 
conduction. For example, anatomical reentry, a common mechanism for the initiation 
of reentrant tachycardias, typically will not occur under conditions of sinus activation. 
This particular type of proarrhythmic substrate often requires the interplay of ectopy and 
unidirectional conduction block, due to refractory tissue, to precipitate an arrhythmia (see 
Section 2.3.2).
In this aim, we addressed this need for more revealing substrate mapping by developing 
and demonstrating the feasibility of a measurement and analysis approach based on con­
trolled activation patterns stimulated and recorded from a trackable, multielectrode array, 
in this case what is known as a “lasso catheter” . This approach is loosely related to a 
more coarse-grained application of pacing currently used to localize ectopic sources that are 
responsible for episodes of ventricular tachycardia (VT). In these “pace mapping” studies, a 
catheter is navigated to suspected sites of ectopy and interrogates each site through pacing. 
If the ECG waveform (12-lead electrocardiography) recorded during the pacing sufficiently
9matches previously recorded, spontaneously ectopic ECGs, it is assumed the pacing location 
corresponds to  the site of ectopy and the tissue can be ablated. However, in the pacing 
protocol we have developed, we analyzed not ECGs but rather electrograms EGMs recorded 
in proximity to each of a sequence of pacing sites to  infer the properties and potential for 
arrhythmogenesis of the local tissue. Progressively pacing from each electrode on the array 
produces unique activation patterns through the local myocardium that can be recorded 
by the other electrodes on the array as the impulse passes. This process helps characterize 
the response of the tissue encompassed by the mapping array to excitation initiated across 
a range of activation patterns. In our studies, this examination of the tissue response to 
multiple activation patterns facilitated robust characterization of local tissue properties 
and revealed proarrhythmic substrates that were poorly discerned during sinus rhythm or 
arrhythmia-based substrate mapping. Identification of such proarrhythmic substrates will 
aid the development of next-generation therapies for diseases such as atrial fibrillation.
We evaluated conduction of activation in both longitudinal and transverse directions 
relative to the underlying fibers of the myocardial tissue as an initial effort towards ro­
bust characterization of proarrhythmic substrate with the multiple activation mapping 
technique. We used conduction velocity (CV) as a metric because it is a key factor in 
determining whether tissue may support reentry. More specifically, transverse CV has 
been shown to play an important role in wave break which, in turn, converts rapid but 
stable tachycardias into acutely life-threatening fibrillation (see Section 2.3.3) [27]. Previous 
studies have implemented pacing and recording strategies to assess conduction velocities or 
conduction times of cardiac tissue [28, 29]. However, these studies assessed CV at sites 
remote from the pacing sites with a mapping catheter, making it unclear if the velocities 
recorded represent longitudinal or transverse conduction, or some combination of the two. 
To date, no previous study has recovered transverse conduction velocities during clinical 
electroanatomical mapping.
A further factor that motivated our study and provides a feasible translational pathway 
is the appearance of a new generation of trackable multielectrode recording devices that has 
entered the market for clinical use, e.g., loop or basket catheters. Loop catheters, in partic­
ular, have achieved significant clinical adoption for evaluation of lesion patency surrounding 
the pulmonary veins in ablation of atrial fibrillation. The ubiquitous deployment, electrode 
tracking ability, and two-dimensional configuration of this devices make it an ideal candidate 
for attempting multiple activation pattern mapping in a clinical setting. In achieving 
this aim, we explored the feasibility of longitudinal and transverse CV measurement in
10
the multiple activation pattern mapping paradigm using both computational models and 
clinical testing. W ith this novel approach for extracting features of impulse propagation in 
the clinical setting, results from this study will help clarify the role of conduction anisotropy 
in the development of reentrant arrhythmias.
1.1.3 A im  3: Sim plified C onduction V elocity  M easurem ent
The CV of cardiac excitation, and specifically its anisotropy, is a key indicator of 
myocardial viability, and yet it is underutilized for substrate mapping studies. To appreciate 
the value of clinical characterization of CV, it is critical to understand the vital role that 
rapid propagation of excitation plays in the prevention of arrhythmia-inducing reentry. 
Healthy myocardial tissue manifests two essential traits that impede the occurrence of 
reentry, namely refractoriness and rapid conduction of sinus activation. Refractoriness 
refers to the period following depolarization in which cardiac tissue is unable to fire another 
action potential until the transmembrane potential returns to rest and fully recovers. CV 
describes the rate at which an action potential propagates through the myocardium. Thus, 
the combination of the conduction velocity and the duration of the refractory period together 
determine the minimum path length, or wavelength, that a circuitous activation pattern 
must undergo in order for activation to perpetuate rather than block before completing 
a full cycle. Alterations in both parameters, i.e., shortening of the refractory period and 
slowing of conduction velocity, contribute to the clinical presentation of arrhythmias. We 
focused on a novel approach to measuring conduction velocity for this aim.
Cardiac CV is anisotropic and is influenced by numerous factors, including orientation 
and connectivity of myocytes. In healthy myocardium, extensive end-to-end coupling 
between adjoining myocytes permits rapid conduction of activation in the direction of the 
long axis of the cells that results in coordinated and efficient cardiac function. However, 
remodeling of the cardiac substrate due to aging, disease, or injury response can impact the 
connectivity of myocytes and alter the properties of conduction [30]. The longitudinal and 
transverse conduction velocities (along and across the fiber orientation, respectively) exhibit 
a differential response to substrate remodeling in a manner that is proarrhythmic [30, 31, 5].
Current techniques for measuring CV require an electrode configuration of known geom­
etry and the assignment of activation times from acquired EGMs. W ith this information, 
it is possible to determine the time of wave propagation from one electrode to another 
over a known distance. However, the computation of activation times can be complicated 
by signal noise, such as multiple rapid deflections within the same QRS complex or EGM 
fractionation [32]. Additionally, the calculation of longitudinal and transverse CVs requires
11
the assessment of activation times from multiple channels, making it an error-prone and 
laborious process [33]. Recent progress by a collaborator, Dr. Anders Peter Larsen of 
the Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), has 
demonstrated a simplified means for measuring the longitudinal and transverse aspects of 
conduction velocity using what is known as a plaque electrode array, i.e., a dense array of 
electrodes with regular spacing of 1-5 mm. This method obviates the necessity of assigning 
activation times to  electrograms from multiple electrodes by condensing properties of the 
spread of activation into a single signal, which Dr. Larsen termed the “mean Laplacian 
electrogram” (MLE), from which conduction velocities can be readily identified. The focus 
of this aim was to extend the preliminary efforts of Dr. Larsen into a model that could 
explain the behavior of the MLE, and to  develop approaches for sampling MLE recordings 
with clinically feasible electrode arrays. Development of simplified strategies for measuring 
CV and for characterizing conduction anisotropy would assist the translation of critical 
experimental tools into clinical use. The MLE signal facilitates the measurement of direct 
indicators of substrate arrhythmic potential in a rapid and robust manner.
1.2 Organization of Dissertation
The following chapters in this dissertation are comprised of two background chapters 
on the basic aspects of cardiac electrophysiology relevant to  these aims and of the primary 
arrhythmia of interest for substrate mapping approaches: atrial fibrillation. These chapters 
are followed by a previously published background chapter covering the use of clinical 
imaging modalities in the study and treatm ent of atrial fibrillation [34]. Following the 
background chapters are three chapters containing additional published work that resulted 
from each of the research aims detailed in the previous section. The final chapter summarizes 
the findings of this work and presents future directions that have emerged from the results 
to  date.
CHAPTER 2
CARDIAC ANATOMY AND  
ELECTROPHYSIOLOGY
The heart contracts and pumps blood. The pressure generated by contraction causes 
blood to flow through vessels that permeate the body and transport nutrients to the 
body. Pump, pressure, flow, and transport are the fundamental aspects of circulatory 
and cardiovascular function. These mechanical phenomena, which are characteristic of the 
outward appearance of cardiac function, belie our modern conception of the heart as, first 
and foremost, an electrical organ. Electricity flows through its tissues, and regulates the 
mechanical function of the heart. W ithin the heart is an exquisite electrical apparatus with 
intricate mechanisms for timing, failure prevention, and intrinsic response to demand.
The rhythm of cardiac excitation is remarkably stable. Over the course of the average 
human life (approximately 75 years), the heart will excite around 3 x 109 times, often 
with no clinically relevant rhythm disturbance. However, the first rhythm disturbance that 
many people experience will also be their last. According to the Center for Disease Control, 
2,596,993 people died in the United States in 2013 [35]. Of those deaths, nearly one in four 
was attributed to heart disease, of which half were caused by sudden cardiac death. In 
most cases of cardiac arrest (cessation of beating), a cardiomyopathy, e.g., ischemia, creates 
conditions within the heart that render it susceptible to arrhythmogenesis. Regardless of the 
contributing factors, it is clear that the electrical function of the heart is essential to health 
and well-being. In this chapter, we will review the basic aspects of cardiac electrical activity, 
the fundamentals of cardiac arrhythmias, and the biophysics of electric field generation and 
measurement.
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2.1 Ions and the Generation of Excitability and Contractility
2.1.1 M em brane P otentia ls
The basis of electricity in the heart starts with the cell membrane. Cardiac myocytes are 
surrounded by a plasma membrane composed of a phospholipid bilayer that is selectively 
permeable to ions. The movement of ions across the membrane is regulated by ion channels, 
proteins embedded in the plasma membrane, that are generally specific to a particular 
ion species. These channels have mechanisms that close, open, or inactivate them from 
conducting ions in order to maintain homeostatic intracellular ion concentrations. At 
physiological pH, proteins and DNA that reside within the intracellular space carry an 
overall negative charge that attracts cations into the cell. K+ has the highest conductivity 
through its channel proteins and consequently has a substantially higher intra- than ex­
tracellular concentration. However, the resulting concentration gradient of K  + counteracts 
the ability of potassium to balance the negative electrical gradient caused by the negatively 
charged macromolecules by exerting an outward force on potassium ions. Consequently, 
the K  + achieves what is known as Donnan equilibrium, in which the force generated by 
the transmembrane potential opposes and balances the force of diffusion generated by the 
concentration gradient (Fig. 2.1). Because K  + has the highest membrane permeability, 
the transmembrane resting potential is closest to the equilibrium or “reversal” potential 
of potassium. Other ions also contribute to the resting membrane potential, including 
N a+, Ca++, and Cl - , but their permeability is much lower that of K +. A typical resting 
membrane potential for a cardiac myocyte is approximately -90 mV [36].
The Nernst equation can be used to determine the electric potential that will arise given 
the concentration gradient of a particular ion species. For example, if the intracellular 
and extracellular concentration of K  + is known ([K+}i and [K+]o, respectively), then the 
reversal potential E K+ of potassium can be calculated as:
E =  R T ln [K +]o ( 2 nE k + =  z F ln [K+]i ' (21)
where R is the universal gas constant (8.314 J /Kmol) ,  T  is the absolute tem perature (K), 
z is the charge of the ion species (+1 for potassium), and F  is the Faraday constant (96485 
J /Vmol) .  W ith the equilibrium potential (Ex) of a particular ion (X) and the membrane 
potential (Vm), it is possible to determine the driving force (VDF) that will act to drive the 
ion to move into or out of a cell.
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Fig. 2.1. Generation of cardiomyocyte membrane potential. The presence of membrane- 
impermeable macromolecules with net negative charge in the intracellular space draws 
cations to migrate into the cell. Selective membrane permeability dictates that potassium 
(K  +), with high membrane permeability, collects in the intracellular space at much greater 
concentrations than other cations (sodium (Na+) or calcium (Ca++)). Ultimately, a 
Donnan equilibrium is established between the electric and concentration gradients, and 
cardiac myocytes rest at «  -90 mV. Top - Relative concentrations of ion species in the 
intra- and extracellular spaces. Intra- and extracellular Ca++ concentrations are roughly 
equivalent except that intracellular Ca++ is sequestered in the sarco-endoplasmic reticulum 
(gray sphere), functionally generating a large inward Ca++ concentration gradient. Bottom 
- Black arrows indicate the magnitude of the reversal potential for the existing concentration 
of each ion species in mV. Outlined arrows indicate the direction and magnitude of the 
driving force (Equation 2.2) acting on each ion species.
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V d f  =  Vm — Ex. (2.2)
The Goldman-Hodgkin-Katz (GHK) equation describes the resting membrane potential 
in terms of the concentrations of ions and their relative permeability (Pion):
E =  R T P k  [K+]0 +  PNa[Ng+]o +  Poi[Cl- ]l 3)
m F  P k  [K+]i +  PNa[Na+]i +  Pci[C l- ]o . ( °
The GHK equation can be interpreted as the resting potential being the sum of the 
concentration gradients for each ion times the permeability of the respective ions. Ions 
for which the permeability is zero, or is negligibly small, i.e., calcium channels at resting 
membrane potential, do not significantly contribute to the transmembrane potential and 
drop out of the GHK equation. The GHK predicts how changes in the permeability of a 
particular ion, as seen during action potentials, will affect the membrane potential [36].
2.1.2 A ction  P otentia ls
2.1 .2.1 E xcitation
From its resting or fully recovered state, every myocyte in the heart is capable of 
firing an action potential. An action potential begins with the rapid depolarization of 
the membrane potential due to a sudden increase in the conductance of voltage-gated 
N a+ channels in the cellular membrane (Fig. 2.2). This increase in conductance occurs 
when the membrane potential reaches a critical threshold and voltage-gated N a+ channels 
open, allowing N a+ to flow into the cell down the concentration and electrical gradients. 
Shortly after opening, the N a+ channels begin to inactivate. This initial depolarization 
is known as phase 0 of the action potential. Phase 1 is characterized by an initial partial 
repolarization of the transmembrane potential due to the outward flow of K  + down its 
concentration and newly formed electrical gradient through open K  + channels. Phase 2 of 
the action potential is known as the plateau. During phase 0, depolarization of the myocyte 
voltage-dependent L-type C a2+ channels begin to open and the resulting inward current of 
C a2+ now counterbalances the outward flow of K  +. The plateau phase may last upwards 
of 200 ms but eventually ends as C a2+ channels close in a time-dependent manner. The 
closure of the C a2+ channels initiates the start of phase 3 in which the uncontested outward 
flow of K  + causes a rapid repolarization of the transmembrane potential to -90 mV. Phase 
4 starts when the cell has reached the resting membrane potential and the membrane starts 
a recovery phase, which must be complete before the next activation impulse can trigger 
excitation.
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Fig. 2.2. Phases of the cardiac action potential and associated changes in ion channel 
permeabilities. Adapted with permission from Witchel et al. Cardiovasc. Ther. 2011 [38].
2.1 .2.2 E xcitation-C ontraction  C oupling
Action potentials signal the cardiac myocytes to contract through a process known as 
excitation-contraction (E-C) coupling. E-C coupling is primarily mediated through the 
cellular handling of C a2+. As previously mentioned, depolarization of cardiac myocytes 
initiates the opening of voltage-dependent L-type C a2+ channels. These channels are co­
localized with ryanodine receptors (RyR) that permeate the membrane of the sarcoplasmic 
reticulum (SR). The influx of calcium during excitation raises the local concentration of 
intracellular [Ca2+] that is detected by the RyRs, which then open to release even more 
C a2+ from its storage in the SR. This positive feedback loop release system rapidly raises 
the intracellular C a2+ concentration and triggers the actin-myosin contractile mechanism, 
causing cardiac contraction. Re-uptake of C a2+ begins almost as soon as there is a rise in
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intracellular C a2+ and includes several pumps and exchangers located in the cell and SR 
membranes. The result is a restoration of intracellular C a2+ and the SR loaded and ready 
for the next action potential [37].
The calcium handling of E-C coupling is critical to both cardiac mechanical and electro- 
physiological function. The processes involving C a2+ signaling are relatively slow because 
they require diffusion of calcium to specific binding sites to initiate the myofibril contrac­
tion. As a result, muscular contraction begins over 50 ms after a myocyte depolarizes, 
whereas depolarization itself often requires only a few milliseconds. This slow step creates 
a vulnerability where the dynamics of calcium handing can become impaired, especially at 
very fast activation rates. In situations of rapid activation, the mechanisms that regulate 
C a2+ concentration, such as the sodium-calcium exchange current and the uptake of cal­
cium via the energy consuming SERCA2a pump, can fall behind. These excursions from 
normal physiological calcium homeostasis can significantly alter the properties of cardiac 
electrophysiology and lead to proarrhythmic, triggered activity (further detail provided in 
Section 2.3.1.)
2.1 .2 .3  R epolarization  and R efractoriness
The return of the transmembrane potential to rest following activation (phase 3 of the 
action potential) is known as repolarization. One critical feature of myocyte excitability 
is that a myocyte cannot fire a new action potential until it has fully repolarized and a 
period of recovery has passed. This property, known as refractoriness, is a critical feature 
for maintaining organization of electrical activity in the heart. The refractory period, or the 
time from myocyte depolarization (phase 0) to completed repolarization (end of phase 3), 
ultimately regulates the frequency at which action potentials can be fired. The prolongation 
of the action potential caused by the inward calcium current during phase 2 contributes to 
an increase in the duration of the refractory period. At the whole organ scale, under normal 
conditions, the refractory period lasts longer than the time it takes for total activation of 
the ventricles, thus ensuring that only one activation sequence occurs in the heart at a time.
2.2 Cardiac Anatomy and Cardiac Conduction
2.2.1 B asic Cardiac A natom y
The human heart is a four-chambered organ comprised of two atria and two ventricles. 
The atria, smaller and situated above the ventricles, receive blood flowing into the heart, 
and the ventricles pump the blood away from the heart. Another simple means of classifying 
the heart's structural components is based on whether the chambers are on the left or right
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side. The right side receives systemic venous return and pumps deoxygenated blood to the 
lungs. The left side receives pulmonary venous return and pumps oxygen-rich blood into 
the systemic circulation. See Fig. 2.3 for a depiction of major anatomical features of the 
heart.
2.2.2 T he Cardiac Syncytium
At a cellular level, the organization of myocytes in cardiac tissue has a profound impact 
on the spread of action potentials. Most cardiac myocytes are striated like typical muscle 
cells with sarcomeres comprised of contractile fibers. Cardiomyocytes tend to group in 
bundles or sheets in which the long axes of neighboring cells align in parallel to form an 
anisotropic media. The elongated cells connect end to end with each other, often including 
bifurcations leading to interactions with multiple other cells at regions known as intercalated
Fig. 2.3. Four-chamber view of the heart. A segmentation of a human heart derived from 
an MRI shows the four major chambers of the heart. RA =  Right Atrium, RV =  Right 
Ventricle, LA =  Left Atrium, LV =  Left Ventricle, PV =  Pulmonary Veins.
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disks. At the intercalated disk, channel proteins known as gap junctions form a patent 
connection from cell to cell through which ions can flow freely (Fig. 2.4). When an action 
potential is generated, it is communicated to surrounding cells through the gap junctions. 
Myocyte depolarization creates an electrical gradient between the activated cell and its 
unexcited neighbors. Positive cations will begin to move down this gradient through the gap 
junctions, and, if sufficient current is communicated, the unexcited neighbors will achieve 
their firing potentials and depolarize. The anisotropic organization of myocytes and the 
localization of the intercalated disks at the ends create lower resistance to the flow of ions 
along the long axis of the myocytes. Consequently, the spread of action potentials in cardiac 
tissue is also highly anisotropic [39, 40, 41].
Because the intracellular space of myocytes are linked by these connections, cardiac 
tissue is frequently referred to as a syncytium, meaning a single cytoplasmic mass. Each 
myocyte is eventually connected to every other myocyte so that a stimulus anywhere in the 
heart will result in the rest of the heart eventually responding.
Fig. 2.4. Organization of human myocardial syncytium. The structure of cardiac tissue as 
seen under backscattered electron imaging of normal human left ventricular cardiomyocytes. 
A. Intercalated discs (arrows) define the boundaries between independent myocytes, and 
sarcomere striations throughout the myocytes define the contractile units. Bar=50 ^m; 
magnification x600. Modified with permission from Kanzaki et al. Circ. 2010. [42]
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2.2.3 C onduction System
To function properly as a pump, the heart must autonomously generate action potentials 
and broadcast these impulses throughout the entire myocardium in order to coordinate 
contraction. All cardiac myocytes are capable of firing an action potential, but they require 
a stimulus for the voltage-dependent N a+ channels to open and commence depolarization. 
Specialized myocytes and regions of myocytes within the heart, known as the cardiac 
conduction system, initiate excitation and conduct action potentials throughout the heart 
with timing that ensures efficiency of contraction (Fig. 2.5). The initial excitation of the 
heart occurs high in the right atrium in a region known as the sinoatrial (SA) node. The 
myocytes in this region of the heart have higher concentrations of a mixed N a +-C a + channel 
( I f ) that allows cation leakage into SA nodal cells during the resting phase, causing slow 
depolarization of the SA node until it reaches the critical threshold for voltage-dependent 
N a+ channels to open and fire an action potential [43]. This leak, known as the funny 
current, can be directly modulated through neurohormonal mechanisms to increase or 
decrease the heart rate by changing the conductance of the funny channels. Specifically, 
catecholamines and acetylcholine act on the funny current to cause I f  channels to begin 
opening at earlier or later stages of repolarization, respectively [44, 45]. Early activation of 
the funny current decreases the diastolic interval and accelerates heart rate.
In a normal heart beat, action potentials begin in the SA node. Once an action potential 
is generated in the SA node, it is communicated to surrounding tissues in the atria, causing 
both upper chambers of the heart to depolarize. However, the activation impulse does 
not immediately pass to the ventricles. During atrial activation, a region of tissue known 
as the atrioventricular (AV) node, which serves as the gateway to the only conduction 
path to the ventricles, is stimulated. The AV node conducts action potentials slowly and 
momentarily delays the activation of the ventricles while the atria activate [47, 48, 49]. This 
delay allows the atria to fully contract for maximum precontraction filling of the ventricles. 
After passing through the AV node, an action potential impulse enters the His-Purkinje 
system, a network of myocytes specialized for rapid impulse conduction that interlaces the 
ventricles. The His-Purkinje system functions to rapidly distribute action potential impulses 
throughout the ventricles to synchronize contraction in order to generate efficient pumping. 
The morphology of the action potentials changes as impulses progress through the elements 
of the conduction system. The morphology of the transmembrane potential in a given region 
reveals characteristics of the activating tissue and its role in cardiac function (see Fig. 2.5). 
For example, the slow conduction of the AV nodal action potential impulses is predictable
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Cardiac Excitation
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interval Segm ent
Fig. 2.5. Action potentials of the conduction system during cardiac excitation. The 
four-chamber view of the heart depicts the various elements of the cardiac conduction 
system and approximate activation times of regions throughout the heart (overlain num­
bers in milliseconds). The time signals on the right depict representative action po­
tentials from the respective regions of cardiac conduction (A-G). The timing of these 
action potentials is referenced to the features observed on a body surface ECG (bottom 
right). Modified, with permission, from the Atlas of Human Cardiac Anatomy website: 
h ttp://w w w .vhlab.um n.edu/atlas/. [46]
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from the AV nodal action potential (Fig. 2.5D) in which the phase 0 upstroke of the action 
potential has a lower slope than working atrial myocytes [50]. As discussed in Section 2.2.4, 
the upstroke rate of the action potential is indicative of how fast downstream myocytes will 
be depolarized by the activation wave, and consequently determines how fast the wave will 
propagate.
2.2.4 A ction  P otentia l Propagation
The coupling and organization of the cardiac syncytium have a direct impact on the 
properties of action potential propagation. The elongated shape and size of cardiomyocytes, 
the localization and resistance of gap junctions, and the alignment of the myocytes, discussed 
in Section 2.2.2, all influence the spread of action potential impulses. These features 
influence such phenomena as the rate of depolarization and the resistance to the flow of 
ions from cell to cell. Variations of these properties will manifest as changes in the rate of 
action potential propagation through the cardiac tissue. For example, impulse propagation 
will progress faster down the long axis, or longitudinal direction, of the muscle fibers than 
it will perpendicular to the long axis, or transverse direction [39, 40, 41]. This property, 
known as conduction anisotropy, is critical to proper coordination of cardiac excitation and 
contraction. Conduction anisotropy is routinely characterized as the ratio of conduction 
velocity (CV) in the longitudinal direction to the transverse direction. Perturbation of the 
anisotropy or rate of action potential propagation through changes to the connectivity and 
organization of the myocardial syncytium can facilitate the development of life-threatening 
cardiac arrhythmias [30, 51, 14].
In principle, these characteristic features of myocardial tissue influence four properties 
that determine the rate of impulse propagation. The first property is the rate of excitatory 
depolarization or dV/d t  of the transmembrane potential during excitation. This behavior 
is regulated by membrane channels that carry the inward depolarizing currents, including 
the current passing through gap junctions from proceeding myocyte depolarization and 
voltage-gated Na+ (INa). The intracellular resistance to current flow is the second property. 
This resistance is an accumulation of the cytosolic and gap junction resistance in series. The 
third property is the capacitance of the membrane. Cation migration downstream from 
depolarized myocytes through gap junctions will displace charge to create a return current 
that completes the circuit; otherwise no current could flow. This outward displacement 
current is strongly influenced by the capacitive nature of the cell membrane, in which cations 
are forced away from the extracellular membrane by the positive charge accumulating in 
the intracellular space. The fourth property is the resistance of the extracellular space
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to current flow. Numerous pathological processes can affect one or more of these tissue 
properties and alter the nature of action potential propagation. For example, phenomena 
such a edema or fibrosis can alter the nature of the extracellular space and the extracellular 
resistance. However, the nature of these changes may also affect the coupling of myocytes 
and consequently increase the intracellular resistance as well [52].
The rate at which action potential impulses propagate through the myocardium is a 
primary factor in determining whether a region of tissue is susceptible to the formation 
of arrhythmias (see Section 2.3.1) [53, 31]. Because of the relationship between CV and 
arrhythmogenesis, the measurement of CV has become a common experimental metric 
for characterizing proarrhythmic potential of influences ranging from common cardiomy­
opathies to investigational medications. Towards that end, a variety of experimental ap­
proaches have been developed to measure the longitudinal and transverse aspects of CV. 
Currently, two types of systems are most frequently used to characterize the rate of action 
potential propagation: electrode arrays and optical mapping.
Electrode arrays come in many shapes, forms, and sizes. Sock, plaque, loop, and needle- 
based electrode arrays have been used for the measurement of CV. However, a few key 
requirements determine whether an electrode array is suitable for the measurement of CV. 
First, the electrode array must have many, at the very least three, noncolinear electrodes 
that can record cardiac excitation remote from the site of activation. Measurement of CV is 
typically performed following the creation of an action potential impulse induced by pacing, 
or external electrical stimulation of the myocardium. The spread of activation away from a 
paced site will form an elliptical wavefront with the long axis of the ellipse lying along the 
direction of the myocytes, i.e., longitudinally. Recording electrodes surrounding the pacing 
site can then sense the local cardiac excitation. Second, the positioning of the electrodes 
relative to the pacing location must be known to calculate the velocity based on the distance 
traveled by the wave and the timing of its arrival (Fig. 2.6).
Optical mapping is another common technique used to measure the CV in which a 
voltage sensitive dye is introduced into the myocardium to reveal the action potential 
propagation. Voltage sensitive dyes are chemicals that exhibit shifts in spectral properties 
in response to changes in the local electric potential, i.e., the arrival of an action potential. 
These shifts in the spectral properties can be detected and recorded with digital camera 
technology at high temporal and spatial resolution. For an in-depth treatment of the 
capabilities of optical mapping, please refer to review articles by Herron et al. (2012) [55], 
and Boukens and Effimov (2014) [56].
24
Fig. 2.6. Cardiac excitation recored from a dog heart with a 13 by 16 electrode plaque 
array (0.5 mm electrode spacing). A. Activation times computed for every electrode 
after excitation induced by pacing from an electrode at the center of the plaque. B. 
Vectors representing estimation of direction and velocity of conduction computed with 
a neighborhood least square fit on a 3 by 3 stencil over the array. C. Isochrones with 
2 ms spacing indicating anisotropic action potential propagation. Black and blue arrows 
indicate direction longitudinal and transverse conduction, respectively. White stars on B 
and C indicate the pacing site. Image used with permission from Linnenbank et al. Front. 
Physiol. 2014 [54].
Regardless of the recording strategy, an essential element of measuring CV is the ability 
to detect the time of arrival of the action potential to the site of the recording element. In the 
analysis of unipolar electrograms (EGM), the activation time is traditionally annotated at 
the time of maximum negative slope during activation [57, 30]. The timing of this feature has 
been shown to correlate strongly with the upstroke of the transmembrane potential in the 
local myocytes. However, unipolar electrograms are prone to fractionation, the disruption 
of prototypical waveform morphology due to far field electric potentials or discontinuity in 
the activation wavefront [58]. In cases of fractionation, the change in EGM morphology will 
interfere with appropriate detection of activation time. Enhanced filtering and recording 
strategies have been developed to overcome challenges associated with detecting activation 
times from unipolar EGMs. One method that can be used on dense electrode arrays with 
small interelectrode spacing, as will be discussed in Section 2.4.2, utilizes the spatial rather 
than temporal derivative of electrograms over the array to determine activation times [59, 
32].
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2.2.5 Cardiac R hythm
The rhythm of cardiac excitation is critical to proper function and the health of the 
heart. Regular cardiac activation stimulated by the SA node is known as sinus rhythm. 
During sinus rhythm, each myocyte will activate only once. Maintenance of regular cardiac 
activation allows for optimal cardiac pumping function through synchronized contraction 
of the myocytes. Irregular activation patterns or action potentials initiated from locations 
other than the SA node are known as arrhythmias. Many different forms of arrhythmias 
exist and may act to speed, slow, or completely disrupt excitation of the heart. Some 
arrhythmias are acutely life threatening and require immediate medical intervention. Others 
may go unnoticed and are of negligible clinical relevance. Regardless of their immediate 
implications, many common mechanisms are involved in the development of the various 
arrhythmias. Section 2.3 will cover commonly recognized mechanisms of arrhythmogenesis.
2.3 Mechanisms of Arrhythmogenesis
Cardiac arrhythmias are disruptions of the normal activation sequence of the heart. The 
disruptions include ectopy, when an action potential impulse originates somewhere other 
than the SA node; reentrant activity, repetitious circulation of activation; and fibrillation, 
complete disruption of excitation synchrony. Various risks attend different arrhythmias. 
For example, hemodynamically unstable ventricular tachycardia (VT) and ventricular fib­
rillation (VF) can cause sudden cardiac death through termination of systemic blood flow 
and the resulting cerebral anoxia. Atrial fibrillation creates an enhanced risk for ischemic 
strokes, ^fivefold throughout all ages, when loss of functional contraction in the atria allows 
blood to pool and clot [60].
2.3.1 Triggers and Substrates
A mechanistic model of arrhythmogenesis relying on triggers that initiate irregular 
conduction pathways and a substrate in which the atypical conduction can perpetuate has 
been used to explain much of the arrhythmic behavior that is observed clinically. A trigger 
is electrical activity that originates from a location other than the SA node, which may come 
in the form of ectopy or afterdepolarization events [37]. Ectopic beats are classified either 
as premature atrial or ventricular contractions (PAC and PVC, respectively). Both PACs 
and PVCs occur commonly and in the absence of a proarrhythmic substrate are generally 
considered clinically insignificant. Afterdepolarizations also are autonomous depolarizations 
of the myocytes that induce nonsense conduction patterns. These depolarizations also come 
in two varieties, early and late. Early afterdepolarizations (EAD) occur during phase 2 or
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phase 3 of the action potential with an augmented opening of calcium (possibly I Na too), 
typically under conditions of prolonged action potential duration [61, 62]. If the membrane 
potentials of surrounding myocytes have sufficiently repolarized, the EAD may capture 
that tissue and induce an action potential impulse. Delayed afterdepolarizations (DAD) 
occur during phase 4 of the action potential immediately after the membrane potential has 
returned to rest. DADs occur when the sarcoplasmic reticulum becomes overloaded, due 
to increased cytosolic calcium concentration, and spontaneously release Ca2+. This sudden 
increase in intracellular Ca2+ creates a depolarizing current through an ion channel known 
as the sodium potassium exchanger that can cause N a + channels to open and depolarize the 
myocyte [63]. The nonsinus activation patterns initiated by ectopy or triggered activity will 
typically disrupt contraction for only one beat. After the triggered activity, sinus activation 
and normal cardiac function will resume. If this triggered activity becomes repetitious, it 
may lead to  the induction of paroxysmal episodes of arrhythmias such as AF or VT. Under 
condition of continuous triggers, medication or treatm ent may be required to  reduce the 
risk of more serious arrhythmias.
In the presence structural heart disease, i.e., a proarrhythmic substrate, triggered ac­
tivity becomes much less benign as it can greatly increase the likelihood of reentrant 
arrhythmogenesis. There are numerous forms of arrhythmogenic substrates. Some ar- 
rhythmogenic substrates are purely anatomical. For example, in some hearts, a second 
conductive pathway, besides the AV node - His bundle pathway, exists between the atria 
and ventricles. W ith this second pathway, a loop of rapid electrical excitation, known 
as reentry, can occur when ventricular excitation conducts back up into the atria. Other 
arrhythmogenic substrates develop because of restructuring of the cardiac syncytium in a 
manner that disrupts conduction. Examples of this restructuring include scar formation 
that occurs following myocardial ischemia or fibrosis that is associated with aging and 
valvular dysfunction [64, 65, 66, 67, 30]. These regions of nonconductive tissue create a 
feature that electrical activity can circle to generate reentry.
2.3.2 A natom ical R eentry
W ith triggers and a substrate in place, the setting for reentrant arrhythmias is in 
place. However, as mentioned previously, the cardiac conduction apparatus is remarkably 
robust, and a particular set of circumstances is required for the development of reentry [53]. 
One essential feature of reentry initiation is known as unidirectional block. Block of an 
action potential impulse can occur for a number of reasons, including collision of two 
action waves; collision with inexcitable tissues, i.e., refractory or scarred; or if insufficient
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depolarizing current is generated to depolarize downstream myocytes. Atrioventricular 
nodal reentrant tachycardia (AVNRT), an arrhythmia that produces an abnormally rapid 
heart rate, provides a classic example of how unidirectional block can lead to reentry [68, 69]. 
In the AV node, two pathways of conduction can develop due to a dissociation of conductive 
tissues. One of these pathways tends to conduct faster than the other (Fig. 2.7). When 
sinus activation captures the AV node, both pathways conduct the action potential impulse, 
but the fast pathway captures the His bundle whereas the slow pathway blocks when it 
reaches the His. However, because of the interplay among conduction velocity, rate of 
depolarization, and action potential duration, the slow conducting pathway has a shorter 
refractory period than the fast pathway. Consequently, if triggered activity causes an early 
action potential impulse to stimulate the AV node, it may find the fast pathway refractory, 
and conduct only down the slow pathway [70]. The activation in the slow pathway can then
Sinus Rhythm Atrial Ectopy Ectopy to AVNRT
Fig. 2.7. Mechanism of A-V nodal reentrant tachycardia. Each part of the figure is shown 
as an atrium, A-V node (which is divided into an alpha (a) and beta (5) pathway), His 
bundle, and bundle branches. In the left panel, sinus rhythm is present, and the mechanism 
of the resulting QRS is shown. In the center, the response of the A-V node to a single atrial 
premature beat with a single atrial echo is depicted. In the right panel, the initiation of 
supraventricular tachycardia with an atrial premature beat is shown. See text for discussion 
of the interaction of trigger and substrate in arrhythmogenesis. PAT =  paroxysmal atrial 
tachycardia; RBB =  right bundle; LBB =  left bundle branch. Reproduced with permission 
from Josephson and Kastor. Ann. Intern. Med. 1977 [69].
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stimulate both the His and the tail end of the now excitable fast pathway. Because the 
fast pathway has regained excitability, it does not block in the retrograde direction, and 
activation can circle back to the slow pathway and form a reentrant circuit. In this manner, 
heterogeneity in the tissue refractoriness coupled with triggers can lead to reentry.
As displayed in the central image of Fig. 2.7, a circuitous pathway alone is insufficient 
for the initiation of reentry. It is possible that after the previously mentioned retrograde 
activation of the AV nodal fast pathway, the slow pathway will be refractory and unable 
to conduct the returning wave of excitation. Based on the conduction velocity (CV) of the 
action potential impulse and the effective refractory period (ERP) of the tissue, there is a 
minimum path length that can support the perpetuation of a reentrant circuit. Known as 
the wavelength (A), this path length can be determined by the product of the circuit’s CV 
and ERP [53, 31].
A =  C V  x ERP.  (2.4)
Consequently, if the wavelength of the dissociated AV nodal circuit is too short, con­
duction will block and sinus rhythm will resume.
2.3.3 Functional R eentry
The reentry discussed to this point has focused on circulating electrical activity that 
moves around anatomical features or through accessory pathways. Known as anatomi­
cal reentry, it is the primary driver of a class of arrhythmias known as macroreentrant 
tachycardias, e.g., atrial flutter, AVNRT, Wolf-Parkinson-White syndrome, and ventricular 
tachycardia. Another type of reentry, known as functional reentry, manifests in fibrillation 
arrhythmias, i.e., atrial and ventricular fibrillation, and relies on slightly different mecha­
nism to produce circuitous activation patterns. Functional reentry is subject to the same 
conditions as anatomical reentry in that the reentry will terminate if it meets with refractory 
tissue. However, the functional reentry does not depend on a discrete conduction pathway 
or structural substrate to define its circuit. Instead, a refractory singularity is established 
around which a circulating wave can propagate [71, 72, 73, 74]. This type of conduction, 
often known as a rotor, can anchor its refractory core to features of the cardiac substrate, 
such as scar tissue, but it has also been observed to meander around the myocardium. 
A possible mechanism of initiation for functional reentry known as wave break has been 
suggested, but this and many other aspects of functional reentry remain topics of active 
research. The basis of wave break initiation of reentry relies on a fundamental property
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of cardiac conduction: the reliance of action potential propagation on depolarizing current 
flowing downstream to activate resting tissues.
The next critical aspect of wave break is attributable to the dependence of downstream 
activation on the characteristics of upstream propagation. Specifically, the curvature of an 
action potential wavefront determines the speed with which it can propagate [75]. Inde­
pendent of tissue anisotropy, wavefronts with high curvature can be accelerated or slowed 
depending on whether the wavefront is concave or convex relative to the downstream tissue 
(Fig. 2.8). As discussed in Section 2.2.2, depolarization of myocardium outside of the SA 
node is primarily dependent on upstream activation, in which positive ions from depolarized 
cells are communicated to resting myocytes through gap-junctions. Consequently, when 
multiple myocytes combine to depolarize a downstream myocyte, it will depolarize faster 
and speed propagation. This same effect can occur with a concave wavefront in which 
current is being injected into a small region from surrounding depolarized myocardium. The 
opposite, however, will occur with a convex wavefront. In this case, upstream myocytes must 
each facilitate the depolarization of multiple downstream myocytes. Each resting myocyte 
receives a relatively reduced amount of current, which delays depolarization and slows 
conduction velocity. In a condition known as current-source mismatch, if the curvature 
is too high and the depolarizing current too low, conduction will block. Current-source 
mismatch is an alternative mechanism for unidirectional conduction block as described in 
the previous section. In cases where complete block does not occur, the conduction velocity 
will slow.
Fig. 2.8. Effect of wavefront geometry on propagation velocity 9. 9q denotes the steady-state 
velocity in a one-dimensional medium. Used with permission from Fast and Kleber. 
Cardiovasc Res. 1997 [27].
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The consequences of wavefront curvature can combine to facilitate functional reentry by 
means of wavebreak. When a wavefront passes a sharp end of an obstacle to conduction, 
such as scar tissue (see Fig. 2.9) [27], the wave front can detach from the obstacle in a 
manner that the leeward tissue will not activate. The failure of the leeward tissue to 
activate can be explained by the high curvature the wavefront would need to  negotiate 
in order for attached activation to propagate around the sharp edge of the obstacle. The 
high curvature causes activation to block in the leeward direction, leaving the activation 
front to spiral back in order to  capture the unexcited tissue. At the leading edge of the 
pivoting spiral wave is a singular point at which resting, exciting, and refractory tissues 
intersect (annotated with a P in Fig. 2.9B). The radius of this spiral wave will reflect the 
ability of the wavefront to  produce sufficient current to  depolarize tissue both in the normal 
direction to the wavefront and laterally. This radius is known as the pivot radius (Rp). If 
Rp is larger than the wavelength of the local myocardium (Equation 2.4), the spiral wave 
may perpetuate around the singularity. Spiral waves, also commonly referred to  as rotors, 
have been observed with a variety of recording strategies. In some cases, this functional 
reentry has been observed to  anchor, possibly to some underlying substrate, in place, and 
other studies have described a meandering of the rotor position. Variations in the stability 
of rotors have also been observed. In some cases, an initial rotor has been observed to 
spawn new rotors and disappear. In other instances, a primary rotor spins off smaller spiral 
wavelets that are subsidiary to the central rotor. Regardless of the spatial and temporal 
stability of the functional reentry, the presence of rotors inevitably heralds the initiation of 
fibrillation in which virtually all rhythmic cardiac excitation has ceased.
2.4 Bioelectricity
As discussed to this point, gradients in the distribution of charged atoms and molecules 
in biological tissues generate electric potentials. Resistive elements, or channels, in the cell 
membrane allow these charges to migrate in a manner that generates current. The changes 
in resistance, i.e., permeability, that occur during an action potential cause changes in the 
local electric field that can be measured. The measurement of cardiac bioelectric potentials 
generated by cardiac excitation was started by Einthoven and continues as a critical aspect 
of clinical cardiology and medicine in general to this day [76, 77]. The study of potentials 
that arise from the heart is known as electrophysiology. This section will provide a brief 
background to the physics, techniques for measurement, and basic strategies for analyzing 
features of bioelectric potentials.
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Fig. 2.9. Detachment of an excitation wave from the sharp edge of an unexcitable obstacle. 
Used with permission from Fast and Kleber. Cardiovasc Res. 1997 [27].
2.4.1 E lectric Fields and P otentia ls
Ions in the biological media carry a charge that generates an electric field, which is a 
force that attracts or repels other charges depending on polarity. The electric field (E ) at 
any given point (r) is a function of the density of charged particles (qj) whose electric fields 
superimpose on that point from their respective locations (fj).
N
E  (r) =  £  Ei(r) 1
N r — ri
i=l 4ne° j= l |r -  Vi I3
(2.5)
where e° is the permittivity of the medium. Under these conditions, the force (F) exerted 
on a charged particle at position r is simply the product of the charge of that particle and 
the electric field:
F  =  qE. (2.6)
A consequence of the superposition of electric fields is the possible scenario in which 
charges surround a point in space such that the sum of all the forces, repellant or attractive, 
is zero. In this scenario, there is no electric field at that point. Similarly, when charged 
particles are uniformly distributed through a conductive medium, such as the intra- or 
extracellular spaces, and there is no difference in the potential energy of a charge particle
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across that domain, the force of the electric field is zero. However, differences in ionic con­
centrations that exist across cell membranes generate an electric field. This transmembrane 
gradient in potential energy of a charged particle is known electric potential (0).
E  =  - V 0 .  (2.7)
An inherent property of conductive medium is that charges will move when acted upon 
by an electric field to create a current. The magnitude of the current density (J) will be 
inversely proportional to  the resistance to the movement of that charge as described by 
Ohm’s law,
J  =  a E  =  —aV0.  (2.8)
In Equation 2.8, a is the conductivity (inverse of resistance) of the medium in which the 
charge is moving. When myocytes are at rest and the forces acting on ions in the heart have 
either equilibrated or the resistance to  flow is very high, current flowing across the membrane 
is minimal (with the obvious exception of depolarizing currents in the conduction system). 
However, when an action potential is triggered by an abrupt change in the permeability of 
the membrane to N a + , the current responds proportionately. This injection of current into 
the myocyte reverses the transmembrane potential and gives rise to intra- and extracellular 
electric fields where the gradient electric potential at rest is zero. The gradients in electric 
potential that arise during cardiac excitation between depolarized and resting myocardium 
produce the electric signals that are measured in electrophysiology. The difference in the 
extracellular potential (0e) measured between two points on the body will depend on their 
relative positioning with respect to the excited and resting portions of the myocardium and 
the direction in which the depolarizing wave is moving.
2.4.2 E lectrogram s
Electrograms (EGM) are measurements of the temporal change in electric potential 
between two electrodes. In clinical electrophysiology, electrograms are acquired from various 
locations, including the surface of the skin and the surface of the heart. Regardless of 
electrode location, EGMs can be classified into two basic varieties: unipolar and bipolar. 
All electrograms are a measurement of the electric potential between two electrodes, i.e., 
bipolar. However, in the case of unipolar EGMs, the anodal electrode is either placed 
or computed in a manner so as to  minimize the amount of common electric field sensing 
between itself and the exploratory electrode. The assumption of this practice is that the
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unipolar EGMs will better represent the potential generated by the local current sources. 
This type of local sensing was first achieved by placing one electrode in proximity to heart, 
the probe, and the reference electrode as far away from the heart as possible, e.g., on 
the leg/foot. Later, a common reference was computed by averaging multiple leads in 
an attem pt to remove dependence on the position of the reference. An early example of 
a common reference is Wilson’s central terminal (WCT), which was developed by Frank 
Wilson in 1934 and is frequently used to this day [78]. W ith an indifferent reference, 
unipolar electrograms are well suited to assess whether an electrode is near a current source 
and when cardiac activation arrives at a given location. Unipolar EGMs also display largely 
predictable morphology from point to point as they are not affected by the direction of the 
activation wavefront relative to the probe [79, 80, 81]. However, the large distance between 
the probe and the reference electrodes makes unipolar EGMs susceptible to detection of 
large electric potentials that arise from distant locations, i.e., far-field signals. Because 
electric fields decay rapidly over distance, the local potentials will typically appear more 
prominently in the unipolar EGMs. Under certain circumstances, however, the far-field 
signal can obscure the local potentials of interest or simply generate unwanted noise in the 
EGM, e.g., sensing ventricular activation when recording potentials in the atria.
W ith bipolar EGMs, neither electrode is specifically a reference. Rather, these EGMs 
represent the potential difference along the vector that connects the locations of both 
electrodes. Bipolar electrocardiograms (ECGs) are the basis of the limb leads that were first 
acquired by Einthoven, and also represent the primary EGM used in clinical characterization 
of cardiac surface potentials. The primary advantage of bipolar EGMs, and the reason for 
their wide adoption in clinical electrophysiology, is their insensitivity to far-field potentials. 
Electrophysiological catheters frequently contain numerous small electrodes that are spaced 
at small intervals (2-5 mm). It is between these close electrodes that intracardiac bipolar 
EGMs are acquired. W ith this geometric configuration, the distance between the electrodes 
is very close compared to far-field sources. Returning to the previous example of atrial EGM 
acquisition, when a bipolar EGM is acquired in the atria, the distance between electrodes 
is much smaller than the distance of the pair to the ventricular working myocardium. 
Consequently, even though unipolar EGMs from those same electrodes might sense a very 
strong ventricular potential, the ventricular components of the signal would appear nearly 
identical. In the bipolar EGM, which is measuring the potential difference between the 
two electrodes, the ventricular components would then negate each other in a phenomenon 
known as common mode rejection. Due to the common mode rejection, the bipolar EGM
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is sensitive only to potentials that are produced in proximity to the electrode pair and 
may provide a better characterization of local tissue properties. However, a number of 
limitations arise due to the proximity of the recording electrodes. First, bipolar EGMs 
have a high degree of variability in morphology due to their orientation with respect to 
the activation wavefront (Fig. 2.10) [82]. Depending on which electrode the wavefront 
arrives at the first, the polarity of the bipolar EGM can switch. Additionally, that speed 
of the wavefront relative to the spacing of the electrodes can cause a variable number of 
deflections from the isopotential line. Finally, if the wavefront passes both electrodes at the 
same time, i.e., when the axis of the electrode pair is aligned perpendicular to the direction 
of a planar wavefront, there may be little to no potential difference between the electrodes. 
In this scenario, the bipolar EGM may incorrectly lead an operator to believe a region of 
myocardium is scarred [83, 79]. In this work, the question of bipolar EGM performance in 
characterizing tissue properties features prominently and is the primary subject of Chapter
Plaque electrodes and intracardiac multielectrode mapping arrays, with known elec­
trode geometries, can extend the sampling of electrograms to the examination of spatial 







Fig. 2.10. Change in bipolar electrogram morphology caused by rotation of bipolar 
electrodes around the distal electrode at a fixed point. A. Slab model of cardiac excitation 
in which a planar activation wave, moving from right to left, is sensed by a clinical mapping 
catheter at orientations with respect to the wavefront ranging from —n /2  to n /2  rads. B. 
Bipolar electrograms (n=33) acquired with both electrodes in contact with the tissue at 
increments of approximately 0.05 rads.
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may be assessed as spatial phenomena with many of the same sampling considerations, 
i.e., sampling frequency. For certain applications, such as detection of activation times, 
applications that take into account the dynamics of electrophysiological phenomena over 
the spatial domain have demonstrated greater robustness to  noise than purely temporal 
domain strategies. One approach that capitalizes on the spatial information provided 
by dense electrode arrays is known as Laplacian electrograms [84]. The Laplacian is a 
spatial derivative of the electrograms over the array geometry. W ith sufficient sampling, 
the Laplacian EGM also provides an approximation of current sources and sinks. This 
technique provides useful signal conditioning that can improve the detection of activation 
times and reduce sensitivity to noise [59, 32]. In this work, we will present a novel adaption 
of Laplacian EGMs for rapid and simplified measurement of longitudinal and transverse 
conduction velocities (see Chapter 7).
2.4.2.1 B od y Surface EG M s
The electric potentials that arise from cardiac excitation can be noninvasively measured 
from the surface of the body. Electrocardiograms (ECG), as depicted in Fig. 2.5, provide 
extensive information about the electrical function and health of the heart. The P-wave 
and QRS complex are indicative of atrial and ventricular activation, respectively. The 
T-wave is generated by ventricular repolarization. Atrial repolarization is masked by the 
QRS complex. Analysis of ECGs is useful for the detection of many cardiac illnesses, and 
various aspects of the ECG are employed for diagnosis. ECG features of interest include 
the timing, morphology of the various waves, and even the presence of a potential where no 
signal would otherwise be expected. Heart block is an example in which the timing of ECG 
features can be used to  detect an abnormality in the cardiac conduction system. In normal 
cardiac conduction, the time between the P-wave and the R-wave of the QRS complex, 
i.e., the PR  interval, is 120 to 200 ms. A PR  interval greater than 200 ms is considered 
to be heart block [85, 86]. Moderate to severe cases of heart block require placement of a 
pacemaker.
Pathologies that change the pattern of cardiac activation will likely change the mor­
phology of features observed in the ECG. For example, ectopic beats in the ventricles, 
known as premature ventricular contractions (PVC), are common in healthy hearts. PVCs 
are readily detectable in an ECG. Because excitation originates in the ventricles, there is 
typically no apparent P-wave. Additionally, the amplitude and width of the QRS complex 
both increase. The increased width of the ventricular activation signal is attributable to 
the inefficient capture of the Purkinje systems that rapidly distributes activation across
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the ventricles during sinus rhythm. PVCs in the absence of structural heart disease are 
generally considered benign and are of clinical significance only if they occur in extended 
runs [87].
A final example of ECG utility for diagnosing cardiac disease is the detection of myocar­
dial ischemia. Ischemia arises in the heart when the arterial blood supply reaching a portion 
of the myocardium is insufficient. This most often occurs in conjunction with coronary 
artery disease when one of the coronary arteries, which supply oxygen-rich blood to  the 
myocardium, becomes obstructed. In an ECG, ischemia can be detected as the presence of 
a body surface potential when the heart should otherwise be isoelectric. Specifically, the 
action potential of ischemic tissue is much shorter and has a lower amplitude than that of 
healthy myocardium. As the ischemic tissue repolarizes, a large potential gradient arises 
between the healthy and ischemic tissues that causes current to flow [88]. In the ECG, 
this ischemic current appears as an elevation or depression in the potential during the ST 
segment [89, 90]. Rapid detection of ischemia can be critical to the prevention of myocardial 
infarction, in which myocytes begin to  die, as well as the prevention of sudden cardiac death 
due to arrhythmias that can arise with the advent of myocardial ischemia [91].
These examples illustrate the broad utility of ECGs for monitoring cardiac health. 
Additionally, these examples illustrate how various factors can influence the appearance 
of electrograms. In later chapters, this work will focus on the use of cardiac surface 
electrograms to characterize the properties of the myocardium. As has been shown for 
features of the ECGs, indicators such as the timing and morphology of electrical signals are 
powerful metrics of the health and function of cardiac tissue.
2.4 .2.2 Cardiac Surface EG M s
During clinical electrophysiological studies, catheter-based electrodes are used to  mea­
sure EGMs from various locations on the endo- or epicardial surface of the heart. Though 
inherently more invasive than ECG recordings, cardiac surface electrograms generally have 
a high sensitivity to  local tissue properties. Intracardiac EGMs, obtained through catheter 
introduction into peripheral vasculature, are more commonly utilized than epicardial record­
ings, though the latter have recently been utilized with increasing frequency. In this setting, 
both unipolar and bipolar EGMs are utilized depending on the application and preference 
of the operator.
37
2.4.3 P otentia l M apping
Potential mapping in electrophysiology describes the analysis of EGMs in which par­
ticular attention is paid to the location from which the signals are acquired. Subsequent 
analysis for EGM morphological features then allows assignment of specific properties to an 
anatomical location. This approach is employed for both body surface EGMs and cardiac 
surface potentials, i.e., body surface potential mapping (BSPM) and electroanatomical 
mapping (EAM), respectively [92, 93, 94]. For example, a commonly used application 
for intracardiac potential mapping is known as activation mapping [58, 95]. In activation 
mapping, the local activation time (LAT) for a given electrode location is estimated from 
features in the electrogram. W ith LATs measured at multiple locations, it is possible to 
generate a visual representation, or map, of the cardiac activation sequence (see Fig. 2.6). 
Activation maps are particularly useful for localizing sites of ectopy or establishing the path 
of an anatomical reentrant arrhythmia. Another application of mapping is the measurement 
of potentials at relevant times in the cardiac cycle. On the body surface, this technique is 
employed to detect myocardial ischemia in which potentials during the ST segment become 
elevated. For intracardiac electroanatomical mapping, the peak-to-peak amplitude of the 
EGM during activation is frequently assessed to identify scarred or otherwise diseased tissue 
in a process known as voltage mapping [13, 15]. Voltage mapping is a type of potential 
mapping known as substrate mapping, which will be addressed in greater detail in the 
following section. Briefly, substrate mapping is the use of EGMs acquired from the surface 
of the heart to infer the functionality, health, or proarrhythmic potential of that region of 
tissue. Substrate mapping is commonly employed to guide the application of therapy in the 
treatment of arrhythmias and is a major focus for this work.
One critical aspect of potential mapping is the necessity to record the location of 
electrodes when EGMs are acquired. For BSPM, this necessity can largely be addressed 
through the use of digitizers, photography, or three-dimensional imaging systems. However, 
tracking the location of catheter-based electrodes that are introduced into the heart via 
venous access presents a unique challenge. Multiple imaging and catheter tracking systems 
have been developed, primarily with the objective of delivering therapy for arrhythmias, 
that can assist with the construction of electroanatomical maps. These systems, and their 
relative capabilities as they relate to the treatment of AF, are further addressed in Chapter 
4 [96, 97].
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2.4 .4  S u b strate  M apping
The electrophysiological properties of myocardium are intimately linked to the tissue-, 
cellular-, and molecular-level composition and structure of the tissue. Consequently, in one 
form or another, all cardiomyopathies will impact action potential impulse propagation. Due 
to the relative robustness of the cardiac conduction system, many of these effects will be 
insufficient to provoke disruption of sinus rhythm. Furthermore, even moderate disruption, 
in the absence of an appropriate trigger, will often fail to produce arrhythmogenesis (see 
Section 2.3.1 - Triggers and Substrates). However, cardiomyopathies do frequently facilitate 
arrhythmogenesis and necessitate the characterization of the diseased tissue. Identification 
and treatm ent of proarrhythmic substrates have generated significant interest over the last 
15 years. Magnetic resonance imaging (MRI) and other imaging modalities have recently 
shown promise for the characterization of cardiomyopathies including infarction and other 
gross scarring and fibrosis. These promising advances are discussed in detail in Chapter 4. 
In the electrophysiological mapping domain, advances have also been made in identifying 
the effect of cardiomyopathies on cardiac surface EGMs. The utility of these EGMs differs 
from more classic electrophysiological mapping studies in which the relative timing of signals 
from a given location is of primary interest. In substrate mapping, the EGMs are analyzed 
for indications tha t the underlaying tissue is proarrhythmic. As mentioned previously, this 
application of electroanatomical mapping was initiated by Marchlinski et al. who used 
the peak-to-peak voltage of EGMs to differentiate between infarct related scar and healthy 
tissue in patients with infarct-related VT [13]. Depicted in Fig. 2.11, this differentiation of 
substrate allowed this group to develop ablation strategies targeted at the slow conduction 
pathways in the infarcted region in order to term inate this anatomical reentrant arrhythmia. 
Soon after, the same concept was applied to the assessment of cardiomyopathy associated 
with atrial fibrillation. In this case, Verma et al. were able to show tha t patients with 
extensive AF remodeling also had large regions of low voltage EGMs before ablation [15]. 
Oakes et al. followed this study with a comparison of preablation voltage maps to atrial 
enhancement seen in preablation LGE-MRI images, which indicate regions of structural 
remodeling of the cardiac tissue [10]. The findings of this study suggest tha t low voltage 
regions correlate with proarrhythmic structural changes tha t occur during the entrenchment 
of AF.
These studies and others tha t followed demonstrated the potential utility of substrate 
mapping for identifying proarrhythmic substrates and the development of new treatm ent 
strategies based on the mechanisms of arrhythmogenesis. Given this impetus, other signal
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Fig. 2.11. Characterization of myocardial infarct with voltage mapping of the ventricles. 
Bipolar amplitudes recorded from a mapping and ablation catheter on the endocardial 
surface of the left ventricle assist in the identification of scarred versus viable myocardium. 
Based on comparison to  voltage mapping performed in structurally normal hearts, March- 
linski et al.[13] classified tissue with a bipolar amplitude of >1.5 mV as normal tissue, and 
<0.5 mV as dense scar. Used with permission from Marchlinski et al. Circ. 2000.
features that appear in intracardiac EGMs were assessed for association with diseased 
cardiac tissues. One such feature that sparked interest was fractionated EGMs. Frequently 
referred to as CFAEs ( “cafes”), or complex fractionated electrograms, these EGMs contain 
multiple spikes indicative of activation in a relatively small time span. The EGMs are often 
associated with fibrillatory conduction and disruption of the electrophysiological substrate 
in a manner tha t allows multiple activation waves to pass in proximity through uncoupled 
pathways. EGMs acquired during mapping of AF are assessed for the complexity of the 
CFAEs and are used to guide ablation therapy. By targeting areas with highly complex 
CFAEs, Nademanee et al. were able to report a high rate of success for terminating AF [98]. 
These findings have proven difficult to  reproduce in other centers but remain an active area
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of research.
Dominant frequency (DF) mapping is another substrate mapping strategy used for and 
acquired during AF. DF mapping analyzes the frequency content of EGMs by identifying 
the dominant frequency in the EGM’s power spectra. Sites with high DF are thought to 
represent drivers of arrhythmic activity either by micro reentry or rotors [17, 99]. These 
sites have been targeted with ablation therapy in order to remove the substrates tha t are 
responsible for the maintenance of AF. These approaches have also met with mixed success 
and are a major focus of current research.
In later chapters, this work explores the performance of substrate mapping for detecting 
diseased tissue using computer simulations. Additionally, other simulations are used to 
explore the feasibility of other markers as indicators of proarrhythmic tissue for substrate 
mapping. In this case, the primary features of interest are conduction velocity and conduc­
tion anisotropy. Though these parameters are frequently measured in experimental settings, 
they are rarely used in the clinical environment. As previously mentioned in the discussion 
of reentry, these factors are direct contributors to the arrhythmic potential of cardiac tissue. 
Through this work, we will demonstrate novel mapping strategies and analysis techniques 
tha t will facilitate the acquisition of these important metrics of substrate viability in the 
clinical setting.
2.5 Computer Models of Cardiac EP
The measurement of electric fields tha t are generated from within a living organism 
presents challenges to efforts aimed at characterizing the behavior and properties of those 
sources. The heart in particular, with constant movement, vital life-sustaining function, 
and encapsulation in the thoracic cavity, is difficult to assess. Numerous experimental and 
clinical techniques have been successfully developed for recording cardiac electric potentials. 
However, these studies can be very expensive, and ultimately, some variables are effectively 
uncontrollable in clinical and experimental settings. For these reasons, there is a rich history 
of mathematical modeling and simulation being used in the study of cardiac electrophysi­
ology. This section will briefly touch on facets of cardiac electrophysiology models relevant 
to this work. For a more comprehensive treatm ent of this topic, please refer to reviews by 
Rudy et al. [100], Vigmond et al. [101], or Winslow et al. [102].
Most modern computational models of cardiac electrophysiology are based on repre­
sentations of the underlying currents that generate action potentials in cardiac tissue. 
Due to the variation in action potential morphology tha t occurs in different regions of 
the heart (see Fig. 2.5), these representation, or membrane models, strive to reproduce
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these characteristic action potentials based on their respective compositions of ion channels 
(Fig. 2.12). For example, the Luo-Rudy model of a ventricular myocyte describes a cardiac 
action potential based on the activity of the constituent ionic currents [103]. This model has 
been revised over time to incorporate newly discovered channels or mechanisms that inform 
the generation of action potentials in the ventricular myocardium [104, 105]. Membrane 
models are based on the formalism of Hodgkin and Huxley in which the cell membrane is 
treated as an ideal capacitor in parallel with ion channels that are resistors to the flow of 
current across the membrane [106]. The transmembrane voltage (Vm) follows the equation 






where t is time, Cm is the capacitance of the membrane, Ij represents ionic current j, 
and I stim is an applied stimulus current [101, 107]. Such models are able to capture 
the characteristic features of cardiac action potentials and have been invaluable for the 
understanding of individual myocyte behavior. However, because of the computational 
overhead required to simulate these models, is it currently infeasible to construct whole 
heart models in which a transmembrane potential is computed for every myocyte.
Fig. 2.12. Depiction of ionic currents incorporated into a ventricular myocyte membrane 
model. Each channel is modeled as a resistor to the flow of ionic currents in parallel with 
the capacitance of the membrane. The conductance of each channel is determined by its 
molecular structure including gating and inactivating mechanisms. Used with permission 
from Shaw et al. Circulation Research. 1997 [105].
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The bidomain equations facilitate simulation of cardiac excitation by homogenizing the 
cardiac tissue into a syncytium, rather than solving a membrane model for every coupled 
myocyte [108]. Bidomain models discretize the cardiac tissue into a collection of points 
tha t average the electrical properties over small regions, e.g., gap junction conductivity 
and tissue anisotropy, and solve for a transmembrane potential at each point (Fig. 2.13). 
Throughout the model, the bidomain equations relate the intracellular potential (0j) to the 
extracellular potential (0j) through the transmembrane current density, (Im):
V - r i =  5 Im, (2.10)
V ■ reV^e =  —film I stim • (2.11)
where r i and r e are the intra- and extracellular conductivity tensors, respectively, 5 is the 
surface to volume ratio of the cardiac cells, and Im is the transmembrane current [108, 101].
Fig. 2.13. Two-dimensional bidomain representation of myocardium. The intra- and 
extracellular domains (orange and transparent gray planes, respectively) are discretized into 
small regions with anisotropic resistances in each direction as depicted by the blue network of 
resistors in both domains. At each point, or region, the intra- and extracellular domains are 
coupled by the capacitance of the membrane and the cumulative resistance of ion channels 
to the flow of ion current across the membrane (Im). This current-voltage relationship can 
be described in terms of the transmembrane potential (Vm), i.e., the difference in intra- and 
extracellular potential at each point (0i , 0e, respectively). Modified with permission from 
Vigmond et al. Prog Biophys Mol Bio. 2008 [101].
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W ith this formulation, the membrane models can be solved at each point in the model 
to provide values for the transmembrane potential. Next, the intracellular potential can be 
removed from Equations 2.10 and 2.12 with the relationship:
=  Vm +  0e. (2.12)
Finally, with addition and some recombination, a description of the extracellular poten­
tial (0e) in terms of the transmembrane potential (Vm) can be obtained [109].
V - (a* +  CTe)V0e =  - V -  CTjWm. (2.13)
The bidomain formalism provides a powerful tool for exploring electric fields generated 
by excitable membranes. Bidomain models allow for reconstruction of electrograms that 
result from cardiac excitation. W ith the bidomain, it is possible to adjust cell models 
and conductivity tensors to mimic a variety of cardiomyopathies tha t arise in the clinical 
setting. Bidomain simulations have been particularly useful in the study of arrhythmogenic 
mechanisms [110, 111, 112]. One downside of bidomain simulations is the requirement of 
significant computational resources to simulate realistic models. However, in recent years, 
great progress has been made towards improving the efficiency and time required to run 
these simulations. Much of this progress is based on distribution of the model for solving 
on multiple cores or graphical processing units (GPU) [113]. This dissertation utilized the 
Cardiac Arrhythmia Research Package (CARP) to solve bidomain simulations of cardiac 
electrophysiological mapping studies [20].
CHAPTER 3
ATRIAL FIBRILLATION
In the previous chapter, a model of arrhythmogenesis was proposed in which triggered 
electrical activity interacts with disrupted myocardial substrates to produce arrhythmic 
activity. Various examples of arrhythmic activity, e.g., AVNRT, heart block, etc., were also 
discussed to illustrate these mechanisms and how they are detected using ECG. In this 
chapter, we will delve further in one particular arrhythmia, atrial fibrillation (AF), using 
the context of the triggers and substrate to guide the exploration of contributing factors to 
AF.
3.1 Background and Significance of AF
AF is the most common clinically relevant cardiac arrhythmia causing complete disrup­
tion of atrial electrical activation and, by association, collapse of atrial mechanical function. 
The clinical significance of AF is primarily attributable to the cessation of coordinated 
contraction in which blood pools and coagulates in the left atrial appendage. These coagula 
can then break free, embolize in the cerebral vasculature, and precipitate an ischemic stroke. 
According to the CDC, AF increases the risk of stroke by «  fivefold for all ages, with 15% 
of all ischemic strokes traceable to AF [60, 114]. This alarming risk is compounded by the 
sheer number of people experiencing AF. In the United States alone, the prevalence of AF 
in 2010 was estimated to range from 2.7 to 6.1 million and is expected to rise to 5.6 to 
12 million in 2050 [115]. Estimates put the cost of AF treatm ent in the United States in 
excess of $6 billion per year [116]. Based on these figures, it is clear tha t AF is a significant 
detriment to human health. However, the pathogenesis of AF is complex, with multiple 
comorbidities, e.g., valvular disease, coronary artery disease, hypertension, diabetes, heart 
failure, advancing age, etc., increasing the likelihood of AF occurrence [117]. In fact, the 
occurrence of lone AF, or AF without any attendant comorbidities, is estimated to be 
around 10% [118, 119, 120]. Cast in this light, AF appears more as a debilitating symptom 
of atrial cardiomyopathy induced by the aforementioned comorbidities [121]. The remainder
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of this chapter will largely focus on this particular point, tha t is, AF is primarily a reflection 
of pathological alterations to the electrical and structural substrate of the atrium.
3.2 Detection of AF
Symptoms of AF may include racing of the heart, irregular or weak pulse, rapid fatigue, 
lightheadedness, shortness of breath, and chest pain. However, some people with AF have 
no symptoms and may go undiagnosed. Additionally, the duration of AF in patients can 
vary across a broad spectrum, with some patients experiencing episodes tha t last less than 
a minute whereas others are in constant AF. Along this spectrum, AF is typically divided 
into three categories: paroxysmal, persistent, and permanent (or long-standing persistent). 
Paroxysmal AF describes AF in which episodes self-terminate within 7 days of initiation. 
Persistent AF is characterized by episodes of AF tha t do not autonomously resolve within 
7 days and require termination through electrical or chemical cardioversion. Permanent or 
long-standing persistent AF is defined as continuous AF of greater than 12 months duration 
[7]. Permanent AF typically does not respond well to cardioversion, often reinitiating after 
only a few sinus beats. The severity of AF as based on these classifications is important in 
guiding treatm ent options for patients afflicted with this arrhythmia.
In addition to the presence of the symptoms mentioned above, standardized diagnosis 
of AF is accomplished by ECG. Classic features that indicate the presence of AF include 
absence of a P-wave, rapid heart rate, and irregular R-R intervals (Fig. 3.1) [122, 7]. In 
sinus rhythm, the P-wave is produced by the synchronized activation of the entire atria. 
The absence of a clear P-wave in AF is attributable to the uncoordinated and incessant 
activation of the atrial tissue. In some cases, this may appear as baseline noise in the 
ECG. In AF, the portions of the atria may be activating at rates of upward of 300 beats 
per minute. This high rate of activation will cause a rapid ventricular response, and the 
heart will race even when the patient is at rest. However, the high rate of atrial activation 
exceeds the maximum refractory rate of the AV node, and only a portion of the impulses 
tha t stimulate the AV node will actually transm it to the ventricles. The irregular activation 
patterns of the atria and the block of some impulses combine to cause increased variability 
of ventricular activation. This increased variability can be quantified by measuring the time 
between QRS signals from beat to beat (R-R interval). Occasionally, AF can produce ECG 
findings similar to those of atrial flutter, leading to misdiagnosis [123].
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Fig. 3.1. ECG and EGMs acquired from patient in AF. The ECG from lead II shows 
classic AF presentation including variable R-R interval, absence of P-wave, and rapid 
ventricular response. The atrial EGMs were acquired from two neighboring electrodes 
on a loop mapping catheter in the left atrium. The unipolar EGMs demonstrate the rapid 
and chaotic atrial electrical activity but also sense far-field ventricular activation (*). The 
ventricular signal is conspicuously absent in the bipolar EGM due to effective common mode 
rejection of far-field signal.
3.3 Initiation of AF
Initiation of AF is typically attributed to the classic reentry mechanisms introduced in 
Chapter 1. In 1998, Hassaguerre et al. demonstrated tha t the triggered activity necessary 
for reentry is primarily associated with ectopic foci located in the pulmonary veins [26]. 
In this work, the earliest site of activation was mapped with an endocardial catheter via 
percutaneous access. Subsequent ablation of these sites of ectopy with radio-frequency (RF 
energy) prevented a recurrence of AF in 62 % of patients at 8 months. This landmark finding 
helped to clarify the source of the trigged activity necessary to initiate reentry. Over 15 years 
later, the prevention of ectopic impulse propagation from the pulmonary veins remains a 
cornerstone of AF treatm ent and general mechanistic understanding [124, 125, 126, 127, 7].
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However, as previously discussed, triggers alone are insufficient to provoke sustained reentry 
and must interact with a proarrhythmic substrate, e.g., slow conduction pathways. Over 
the same 15 years, extensive research has focused on the nature of the substrate tha t is 
responsible for AF initiation and the mechanism of reentry that allows it to persist.
3.4 Entrenchment of AF
In the study of the AF substrate, it has been established that multiple cardiac tissue 
properties are altered in patients with AF. Importantly, findings from Wijffels et al. in 1995 
showed tha t alteration of these cardiac tissue properties progresses as AF persists to further 
entrench the arrhythmia [128]. This process, summarized as “AF begets AF,” encapsulates 
remodeling of both electrical and structural tissue properties that promote the initiation 
and maintenance of AF. However, as previously mentioned, multiple pathways can lead to 
AF, and no one AF substrate is quite like another. Consequently, it is difficult to attribute 
any one factor as the cause of AF, and the whole spectrum of factors must be considered. 
Regardless of the proarrhythmic features that may manifest in a given patient, sustained AF 
requires a trigger and a substrate, whatever tha t substrate may be. Sections 3.4.1 and 3.4.2 
will cover the electrical and structural properties tha t promote AF initiation and further 
remodel to facilitate the entrenchment of AF.
3.4.1 E lectrical R em od elin g
Through aggressive stimulation protocols, AF is inducible in any heart, albeit for short 
episodes in some cases [129]. This arrhythmic potential can be enhanced through continuous 
rapid activation of the atrial tissue. In 1995, two groups, Morillo et al. [130], and Wijffels 
et al. [128], reported on changes in the electrophysiological properties of the atria when 
pacing was used to maintain rapid activation rate (150 ms cycle length) in canines or 
perpetuate AF in goats, respectively. Both studies were able to demonstrate a significant 
shortening of the atrial effective refractory period (ERP) following periods of rapid atrial 
excitation (Fig. 3.2). Furthermore, in the goat model, it was shown tha t within a week 
of stimulated maintenance of AF, episodes became sustained, i.e., lasted over 24 hours, 
whereas the duration of control episodes was less than 10 seconds (Fig. 3.3). These findings 
led to the oft-repeated phrase coined in the Wijffels et al. paper tha t “AF begets AF.” The 
basis of this theory is tha t the arrhythmic conditions tha t present in AF induce adaptation 
of the electrophysiological substrate in a manner tha t entrenches atrial fibrillation. This 
adaptation is now commonly referred to as AF-induced electrical remodeling [131, 132].
Electrical remodeling can be traced primarily to alterations in ionic current and cellular
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Fig. 3.2. Illustration of the shortening of the atrial refractory period during the first 24 
hours of electrically maintained atrial fibrillation. Two electrograms (EGM) are shown for 
each state, i.e., control, 6 hours, 24 hours, in which the atrial effective refractory period 
(ERP) was evaluated. The top EGM for each state illustrates the coupling interval (S2) at 
which pacing capture failed due to the ERP when a train of 400 ms cycle length Si beats 
was followed by the indicated S2 stimuli. The lower EGM demonstrates successful capture 
when the coupling interval exceeds the ERP. The ERP progressively shortens over the 24 
hours of AF maintenance with 50 mHz burst pacing. Used with permission from Wijffels 
et al. Circ. 1995. [128]
excitability. In acute settings of rapid heart rate, as might occur with physical exertion, the 
shortening of action potential duration, known as restitution, is an essential physiological 
control that allows the heart to accommodate increased demand. Such restitution may play 
a role in the initiation of AF, but electrical remodeling is generally regarded as additional 
changes that occur over days and weeks of exposure to rapid activation rates. Yue et al. 
demonstrated progressive down-regulation of the transient outward K  + current ( I t o ) and 
the L-Type Ca++ current over 6 weeks of rapid atrial pacing tha t accounted for shortening 
of the atrial action potential duration and consequently the refractory period [133]. Through 
shortening of the refractory period, AF decreases the wavelength necessary for reentry to 
occur, facilitating both AF initiation and perpetuation.
In addition to changes in action potential generating currents, the response of the 
intramyocyte coupling connexin proteins to AF has also been studied. Multiple studies of 




pacing----- AF ■ Sinus Rhythm Duration of Fibrillation
Control L- v- v-v- V-u u IU u u u u V-u t- u ru U
■ AF-
Fig. 3.3. Prolongation of the duration of episodes of electrically induced atrial fibrillation 
maintaining AF for 24 hours and 2 weeks, respectively. Burst pacing (50 mHz) stimulation 
of the atrial tissue provoked stimulation of AF in chronically instrumented goats. AF 
was continuously reinduced following AF resolution to sinus rhythm in order to maintain 
fibrillation. Over the course of 2 weeks of this stimulus protocol, the duration of provoked 
AF episodes increased from seconds to hours to persistence, indicating that the AF induces 
changes in the electrophysiological substrate tha t entrench the arrhythmic behavior. Used 
with permission from Wijffels et al. Circulation. 1995. [128]
distribution and expression of atrial specific connexin 40 (CX 40) gap junctions. However, 
the results of these studies were inconsistent, with one study showing increased CX 40 
expression and movement of the protein position to the lateral membrane of the myocytes 
[134]. Other studies in persistent and longstanding AF indicated that CX 40 expression 
was decreased [135, 136]. This lack of consensus is not wholly surprising given the many 
different factors tha t can lead to AF, and may simply be a product of differing patient 
populations. Regardless, connexins play an important role in distributing depolarizing 
impulses to resting myocytes. Changes in the amount of current and directional flow of 
depolarizing current could contribute to reentry through multiple mechanisms, including 
the slowing of conduction velocity.
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3.4.2 Structural R em od elin g
Atrial fibrillation is strongly associated with structural disruptions of the myocardial 
substrate tha t create proarrhythmic conduction abnormalities [1, 137, 2, 121]. These 
disruptions may manifest as atrial fibrosis, dilatation, or dissociation of myofibrils [135]. 
It is clear tha t the extent of the substrate disruption, or structural remodeling, directly 
impacts the entrenchment of AF. Structural remodeling contributes to the entrenchment of 
atrial fibrillation both through disruption of action potential propagation and by increasing 
the maximum potential wavelength of a reentrant circuit [29]. Many factors including 
mitral valve regurgitation, hypertension, and congestive heart failure are known to induce 
remodeling of the structural substrate and promote AF. Conversely, the rapid ventricular 
activation rate caused by AF can initiate or exacerbate heart failure and further promote 
structural remodeling. In many cases, it is unclear what is cause and what is effect. Current 
understanding indicates tha t structural disruption of the atria promotes AF and, in a classic 
positive feedback loop, AF induces increased structural remodeling.
Dilation of the atria is a key aspect of structural remodeling mediated promotion of AF 
[138, 139, 140, 141]. In the absence of a tortuous path for reentry, a small atrium provides 
few and short paths for reentry to develop. In the wavelength model of the arrhythmic 
potential of a cardiac substrate, as introduced in Section 2.3.2, the CV and ERP were cited 
as the primary factors (Equation 2.4) in determining whether the wavelength of a given 
circuit would be sufficient to sustain reentry. Atrial expansion, however, demonstrates the 
inverse of this model. By simply increasing the atrial size, dilatation broadens the possible 
path length available for a reentrant circuit, irrespective of changes to CV or ERP. Patients 
with AF have frequently been observed to have left atrial volumes in excess of 150 mL, 
or nearly three times the normal size (<50 mL) of an atrium [142, 143], and occasionally 
even larger (Fig. 3.4) [144, 145]. Such extreme dilatation provides ample path length and 
pathways for the initiation and perpetuation of AF inducing reentry.
Extreme cases of atrial dilatation are most commonly attributed to valvular dysfunction, 
e.g., mitral valve regurgitation, hypertension, and congestive heart failure. Compromised 
function of the mitral valve permits reversed flow of blood into the left atrium during 
ventricular systole. This flow reversal is believed to create a hemodynamic burden on 
tha t atrial tissue tha t ultimately results in atrial dilatation [139]. This expansion of atrial 
size provides a clear path to increased wavelength and entrenchment of atrial fibrillation. 
However, as has been previously discussed, with atrial fibrillation cause and effect are 
frequently interchangeable. In 1990, Sanfilippo et al. reported on echocardiography findings
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Fig. 3.4. MRI of structurally normal and dilated left atria (LA). The top image depicts my, 
I hope, structurally normal LA. The bottom image shows an approximately slice matched 
dilated LA of a patient with AF. The AF patient’s LA is nearly 40 mL larger in volume 
than my own, in spite of my being 0.22 m taller and 18 kg heavier.
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from a cohort of patients recruited for a study on anticoagulation in AF [142]. As part of the 
enrollment for this study, patients received an echocardiographic assessment of both right 
and left atrial chamber volumes. Capitalizing on these data, this group examined the cohort 
of 246 patients for cases in which normal atrial volumes and no valvular or structural heart 
disease that might independently result in dilatation were observed. Of the original cohort, 
15 patients met the inclusion criteria and consented to receive a follow-up echocardiographic 
examination. The average time between the initial and secondary examination was on 
average 20.6 months (range, 12-28 months). In this small cohort, all patients experienced 
an increase in left and right atrial volume. The increase in volume for both the left and right 
atria was highly significant (45.2 mL to 64.1 mL and 49.2 mL to 66.2 mL, respectively). 
This increase in volume, in the absence of structural or valvular heart disease, was an early 
indication that AF itself had a deleterious effect upon the structural substrate of the heart.
Fibrosis, or the excesses deposition of extracellular matrix, is also strongly associated 
with AF entrenchment, and provides another strong indication that AF induces structural 
remodeling of cardiac tissue [67, 146, 137, 147]. Cardiomyocytes are surrounded by a matrix 
of proteins, e.g., collagen, tha t provides structural support to the tissue. The amount and 
organization of this extracellular substrate can strongly affect the cell-to-cell communication 
and mechanical function. Fibrosis can occur in most tissues and is usually in response to a 
physiological inflammatory response mechanism. Consequently, fibrosis is often seen in the 
context of wound healing, accumulation of oxidative injury tha t occurs with age, or in me­
chanical overload. On a microscopic level, cardiac fibrosis predominantly accumulates along 
the lateral aspect of myocytes, causing side-to-side uncoupling or dissociation of myofibrils. 
The presence of fibrosis disrupts cardiac impulse propagation by slowing conduction and 
altering conduction anisotropy by attenuating the close coupling of myocytes [30, 5, 148]. 
As with atrial dilation, fibrosis frequently manifests in the presence of valvular heart disease, 
hypertension, and heart failure and promotes the entrenchment of AF from paroxysmal to 
persistent. Once again, however, this pathway also appears to work in reverse with AF 
itself, causing enhanced fibrosis.
Structural remodeling is a key feature of AF domestication. Whereas the physio­
logical adaptations associated with electrical remodeling appear to rapidly accommodate 
AF entrenchment following initiation (within minutes to days), they also seem to return 
to normal status soon after the resumption of sinus rhythm. However, the substrate 
associated with AF structural remodeling develops more slowly (weeks to years) and is 
less amenable to reverse remodeling [149]. Features of structural remodeling including
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dilatation and fibrosis may take years to develop and may not completely dissipate upon 
the resumption of sinus rhythm [150, 151]. Recent studies using MRI to characterize the 
structural substrate in patients with AF have demonstrated the importance of structural 
remodeling on the entrenchment of AF. Oakes et al. [10], Mcgann et al. [11], and Marrouche 
et al. [152] were able to show that patients with extensive structural remodeling had a 
much higher likelihood of failing treatm ent of AF with catheter ablation (Fig. 3.5). More 
information about imaging techniques employed in the treatm ent of AF is available in 
Chapter 4. These findings support early and aggressive treatm ent on atrial fibrillation and 
the concomitant stressor that elicit structural remodeling of the atrial electrophysiological 
substrate [153, 154].
Fig. 3.5. Left atrial (LA) wall structural remodeling (SRM) on late gadolinium enhancement 
MRI (LGE-MRI) correlates with surgical biopsy specimens. Examples from three surgical 
patients who underwent both three-dimensional (3D) LGE-MRI scanning and biopsy of the 
LA wall. Control patient without atrial fibrillation (AF) shown in left (AaAc), AF patient 
with moderate amount of SRM in middle (BaBc), and AF patient with advanced SRM on 
right (CaCc). Three-dimensional LGE-MRI renderings show fibrosis/SRM in green with 
normal tissue in blue (top). Masson trichrome stains collagen blue and LA myocytes red 
(middle, standard staining; bottom, subtraction images). Red box shows biopsy location. 
Used with permission from Mcgann et al. Circ. Arrhythmia Electrophysiol. 2014. [11]
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3.5 Mechanisms of AF
The mechanisms behind AF initiation and perpetuation have been the source of interest 
and debate for over a century. As mentioned in Section 3.3, the mechanism of AF initiation 
was largely settled with the work of Hassaguerre et al., when ectopic beats were demon­
strated to trigger fibrillation in humans [26]. However, the nature of fibrillatory conduction 
tha t drives AF to persist remains a controversial topic. Two candidate sustaining mech­
anisms are: 1) spatially localized sources, e.g., rotors (spiral waves) that drive fibrillation 
or, 2) nonlocalized spatially meandering mechanisms, e.g., multiwavelet reentry (Fig. 3.6) 
[155, 117].
Support for stable sources of functional reentry, in the form of rotors or spiral waves, 
as a sustaining mechanism for AF has come from various sources [156]. Optical mapping 
studies of AF in sheep have shown stable rotors to drive AF [157]. However, until recently, 
scant evidence existed to support this type of AF driver in humans. Specialized signal 
processing of basket catheter recordings by Narayan et al. purports to show proof of stable 
rotors in patients with AF [99]. Furthermore, targeted ablation of these rotor sites was 
reported to have a beneficial effect in preventing AF recurrences. These findings have 
sparked considerable interest in mapping techniques geared towards the detection of rotor
A B
Fig. 3.6. Proposed AF sustaining mechanism. A -  Posterior view of left (red) and right 
(blue) atria depicting AF as driven by a stable mother rotor, triggered by pulmonary vein 
ectopy (yellow star), tha t spawns other spiral waves. B -  Depiction of multiwavelet reentry 
where numerous wavefronts simultaneously capture dissociated regions of myocardium.
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activity, e.g., dominant frequency mapping. The limited resolution of current clinical basket 
catheters and the challenge of interpreting EGMs acquired during AF suggest the need for 
further exploration of the role of stable reentry as a sustaining mechanism of AF.
Multiwavelet reentry is predicated on the utter disruption and fragmentation of action 
potential impulses such that at any given time, multiple dissociated wavefronts exist and are 
able to capture new reentry pathways and spawn new wavelets at a faster rate than other 
wavelets annihilate due to conduction block. This mechanism of sustaining AF was first 
proposed by Moe and Abildskov [158] and has more recently been championed in the work 
of Allessie et al. [159, 5], Konings et al. [160], and de Groot et al. [4]. This model of AF 
perpetuation requires the electrical activity of the atria to become so fragmented and chaotic 
tha t waves of activation may literally pass one another across microscopic dissociations of 
muscle fibers and the endo- and epicardial layers of the atrial. This transmural dissociation 
becomes so complete that interlayer communication of wavelets appears at only a few pre­
served intramural connections and manifests as epicardial breakthrough when recorded from 
the surface of the heart. These findings are based on recordings from the epicardial surface 
of human hearts using high-resolution plaque electrodes. Unlike the basket electrodes, these 
plaques have small interelectrode spacing, but have much less overall coverage of the atria. 
Much like the rotor mapping, the analysis of the fibrillatory EGMs requires extensive signal 
processing with notable dependence on heuristic interpretation of what signal constitutes 
local tissue excitation.
At this stage, evidence for both sustaining mechanisms of AF has been reported and 
may indicate tha t different types of AF may occur in different populations with different 
comorbidities. It is also possible tha t some as yet unrealized process is at work. Ongoing 
work into the characterization of the sustaining mechanisms is a very active and developing 
field of research.
3.6 Management of Atrial Fibrillation
A thorough review of the treatm ent options in the management of atrial fibrillation is 
well beyond the scope of this document. For detailed coverage of this topic, the reader 
may refer to published consensus statements and review articles [7]. In this work, a very 
brief introduction will be provided on some of the medical and treatm ent options currently 
available for the treatm ent of AF.
56
3.6.1 A nticoagu lation
Ischemic stroke is the primary concern for patients with newly diagnosed AF. During AF, 
the left atrial appendage does not efficiently contract, causing blood to pool and potentially 
coagulate. If this coagulum embolizes, it can travel to the brain, block vital arterioles, and 
cause downstream cell death through ischemia. In response to this heightened risk, patients 
with AF are placed on anticoagulation therapy. In the past, such therapy typically meant 
warfarin (coumadin), which can be difficult to titra te  and may lead to episodes of internal 
hemorrhage. Recently, a number of new anticoagulants have entered the market and have 
compared favorably to warfarin, e.g., rivaroxaban, apixaban, or dabigatran. For further 
information on aspects of anticoagulation in AF, please refer to a review article by Lip et 
al. [161].
3.6.2 R h yth m  V ersus R ate  C ontrol
Antiarrhythmic medications known as rhythm control drugs have been developed to 
prevent or terminate cardiac arrhythmogenesis. Rhythm control medications come in 
different classes depending on what ion channel they augment. For example, amiodarone 
is a class III antiarrhythmic agent tha t acts on K+ channels to prolong phase 3 of the 
action potential. Extending the action potential prevents arrhythmogenesis by extending 
the refractory period. Amiodarone is a potent antiarrhythmic drug, but, like most rhythm 
control agents, can have potent side effects, e.g., pulmonary fibrosis, thyroid dysfunction, 
etc. Interestingly, one paradoxical yet established effect of antiarrhythmic medications 
is proarrhythmia [162, 163, 164]. Prolongation of the action potential clearly inhibits 
reentry through the extension of the refractory period, but may render the heart susceptible 
to arrhythmia, such as life-threatening torsades de pointes (also known as polymorphic 
ventricular tachycardia) tha t can occur in conditions of long QT intervals and dispersion of 
QT intervals. These considerable risks associated with rhythm control therapy necessitate 
careful selection of drugs based on the unique presentation of each patient. Ultimately, 
many AF patients, especially the old and persistently fibrillating, have little to gain with 
rate control therapy [165, 166].
AF can induce a rapid ventricular response that can induce palpitations and if allowed to 
persist may trigger the onset of heart failure. For patients in which rhythm control fails, or 
is contraindicated, it is still desirable to mitigate the tachycardic ventricular response to AF. 
Rate control therapy uses pharmaceutical agents tha t target neurohormonal mechanisms 
tha t dictate cardiac rate under normal physiological conditions. For example, agents known 
as “beta-blockers” modulate the sensitivity or function of beta-adrenergic receptors tha t are
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the primary signaling target for rate accelerating factors such as epinephrine. Coupled with 
effective anticoagulation therapy, rate control strategies can mitigate the effect of AF on 
the rest of the heart. However, it is generally conceded tha t this approach leaves the atria 
susceptible to the chronic effects of AF-induced remodeling (see Section 3.4) [165, 166].
3.6 .3  Intervention
Before the advent of minimally invasive percutaneous cardiac catheterization, surgical 
techniques were developed for treating AF. First performed in 1987, the Cox maze procedure 
gained access to the atrium through medial sternotomy and cardiac bypass in order to create 
permanent lines of block that could prevent fibrillatory conduction through compartmental- 
ization of the heart [167]. These lines of block were created by literally cutting through the 
atrial wall and and then stitching the cut back together. This approach for AF management 
was refined and culminated in the Cox max III procedure, which has reported a success 
rate of over 90% [168]. This high rate of success made the Cox maze III a natural choice for 
cases in which open-heart surgery was already indicated, e.g., mitral valve repair. However, 
such invasive surgical procedures come with considerable risk to the patient. Nevertheless, 
the Cox maze III procedure remains the gold standard for interventional abolition of AF. 
Regardless of this efficacy, the focus of AF intervention has shifted to the percutaneous 
catheter ablation due to the reduced invasiveness of these approaches.
In Section 3.3, the work of Hassaguerre et al. was introduced as a defining study for cur­
rent understanding of the mechanism of AF initiation [26]. In addition to the identification 
of ectopic triggers as the source of AF initiation, this work was able to demonstrate that 
targeted destruction of trigger sources with radio frequency ablation (RFA) could potentially 
cure AF. This finding has informed the basis of interventional treatm ent of AF since the turn 
of the century. However, due to the risk of pulmonary stenosis tha t can arise with ablation 
of ectopic sources in the pulmonary veins (PV) [169], ablation strategies have shifted from 
one of source targeting to one of source isolation. Specifically, Pappone et al. and others 
pioneered a strategy of PV isolation that would create ablation lesions surrounding, but 
not in, the PVs that would block ectopic activation attem pting to enter the atria at large 
[124, 125, 126]. This anatomical rather than functional approach to rhythm management 
represented a significant departure from traditional electrophysiological procedures that 
exert great effort to identify proarrhythmic accessory pathways or ectopic sources. However, 
this approach has shown reasonable success at terminating paroxysmal AF. At present, 
pulmonary vein isolation remains fixed as the cornerstone of AF intervention, and numerous 
technologies and systems have emerged in an attem pt to simplify and optimize the task.
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However, high rates of AF recidivism following PV isolation, particularly in patients with 
persistent AF, have led the electrophysiological community to return to the concept of 
compartmentalization previously associated with the Cox maze procedure.
Numerous compartmentalization or substrate modification strategies have been pro­
posed in an attem pt to improve the success of ablation procedures in patients with persistent 
AF. An in-depth description of these strategies and their relative merits is beyond the 
scope of this document. However, given that substrate mapping strategies are germane 
to this topic, it is worth mentioning tha t ablation strategies based on substrate mapping 
(see Section 2.4.4) primarily fit in this category, i.e., adjunctive ablation based on the 
identification of substrates tha t either support initiation of AF or assist its perpetuation. 
These adjunctive ablation strategies may be purely anatomically driven as with PV isolation 
where connecting lines of ablation lesion are made between the PV encirclement lines, 
between other nonconductive barriers, e.g., valves, or debulking strategies tha t seek to 
reduce that amount of tissue tha t can harbor fibrillatory conduction in areas known to be 
problematic, i.e., the LA posterior wall (Fig. 3.7). Other approaches use electrophysiological 
recording from the cardiac surface, or substrate mapping, to identify tissue characteristics 
tha t are believed to reflect the proarrhythmic potential of local tissues.
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Fig. 3.7. Left atrial lesion sets used for radio frequency ablation (RFA) of atrial fibrillation. 
A -  Lesion set depicting standard pulmonary vein isolation (white lines). B and C -  
Stepwise strategy of RFA in which a roof line (B) and additional lines of ablation are used 
to compartmentalize the atria. Used with permission from Mun et al. Heart. 2012 [170].
CHAPTER 4
MULTIMODAL IMAGING IN ATRIAL 
FIBRILLATION
Modern clinical electrophysiology is inextricably linked with radiology. Fluoroscopy, 
ultrasound, MRI, and CT all play significant roles in the treatm ent of patients with cardiac 
arrhythmias, and in particular atrial fibrillation. The following chapter appeared in the 
collection Multimodal Cardiovascular Imaging: Principles and Clinical Applications and 
covers the use of medical imaging in the treatm ent of AF [34]. It appears here in the 
published format with the permission of McGraw-Hill, the publisher.
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SECTION III: C ard iovascu lar M u ltim o d a l Im aging in Key C lin ica l P roblem s
CHAPTER 25
ATRIAL FIBRILLATION
Rob MacLeod and J. J. E. Blauer
INTRODUCTION________________________
Atrial fibrillation (AF) is the most com m on form of cardiac 
arrhythmia, so a review of the role imaging in AF is a natural 
topic to include in this book. Further motivation comes from 
the fact that the treatm ent o f AF probably includes more dif­
ferent forms o f imaging, often merged or combined in a variety 
o f ways, than perhaps any other clinical intervention. A typical 
clinical electrophysiology lab for the treatm ent o f AF usually 
contains no less than six and often m ore than eight individual 
monitors, each rendering some form of image-based informa­
tion about the patient undergoing therapy. There is naturally 
great motivation to merge different images and different imag­
ing modalities in the setting o f AF, bu t this is also very chal­
lenging as a result o f a host o f factors, including the small size, 
extremely thin walls, large natural variation in atrial shape, and 
the fact that fibrillation is occurring so atrial shape is changing 
rapidly and irregularly. Thus, the use o f m ultimodal imaging 
has recently become a very active and challenging area o f image 
processing and analysis research and development, driven by an 
enorm ous clinical need to understand and treat a disease that 
affects approximately five million Americans alone, a num ber 
that is predicted to increase to almost 16 million by 2050.1
In this chapter, we attem pt to provide an overview of the large 
variety o f imaging modalities and their uses in the management
and understanding of AF, with special emphasis on the most 
novel applications o f magnetic resonance imaging (MRI) tech­
nology. To provide clinical and biomedical motivation, we 
outline the basics o f the disease together with some contem po­
rary hypotheses about its etiology and management. We then 
describe briefly the imaging modalities in common use in the 
management and research o f AF, and then focus on the use 
o f MRI for all phases o f the management o f patients with AF 
and indicate some of the major engineering challenges that can 
motivate further progress.
■  CLINICAL PROFILE OF AF
AF is a growing problem in modern societies, with an enor­
mous impact on both short-term  quality o f life and long-term 
survival.2 Approximately 0.5% of people age 50 to 59 years have 
AF, and 9% of people age 80 to 89 years have AF, and these 
prevalence are increasing.1,3 Although many people with the 
condition go untreated, AF is associated with an almost two­
fold increase in the risk o f mortality. AF patients experience a 
dramatically increased rate o f stroke (from 1.5% for those age 
50 to 59 years to 23.5% for those between age 80 and 89),4 a risk 
that, by contrast, decreases with age in the norm al population. 
Treatm ent o f AF represents a significant health care burden, 
with the annual costs estimated at approximately seven billion 
US dollars.5
Restoring and maintaining norm al sinus rhythm remains one 
of the major goals in treating patients with AF. One treatm ent 
modality is a combination o f cardioversion and antiarrhythmic 
drugs6; however, only 40% to 60% of the AF population is 
maintained in regular rhythm 1 year after such treatment. The 
treatm ent itself may also have serious adverse effects7-9 and must 
usually continue for the lifetime of the patient. By contrast, 
maintaining sinus rhythm without the use o f antiarrhythmic 
drugs seems to be associated with increased survival.10 The 
inadequacies o f drug-based treatm ents for AF have long been 
the m ajor motivation for finding a truly curative approach to 
m aintain sinus rhythm and suppress AF.
■  MECHANISMS OF AF
The mechanisms underlying AF have been the topic o f exten­
sive research over many years, and there is consensus that the 
disease, like most cardiac arrhythmias, has two components, 
the tissue substrate and some initiating electrical events or trig­
gers. Perhaps the m ost complete description o f the substrate 
o f AF comes from Wijffels et al, who first postulated that the 
longer the atria spend in the state o f fibrillation, the more dif­
ficult it becomes to reverse the condition (ie, “Atrial fibrilla­
tion begets atrial fibrillation”).11 Their conclusions were based 
largely on animal studies in which rapid pacing of the heart 
induced AF through a continuous process o f electrical and then 
structural remodeling, a transition that is initially reversible 
bu t then becomes essentially permanent. Rapid pacing of the 
heart does not, o f course, occur spontaneously, and the etiol­
ogy of the disease in humans is thought to be closely linked to 
the gradual and inevitable elevation o f fibrosis in the atria that 
comes with age12,13 and that predisposes a heart to AF whether
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or not associated conditions such as heart failure are present.14 
In animals subjected to the rapid pacing protocols developed to 
induce AF, treatm ent with a drug that suppresses the formation 
of fibrosis reduced the likelihood of developing AF compared 
with control animals,15 hence the clear link between fibrosis 
and the AF substrate. As we will discuss later, one application of 
imaging, especially MRI, is directed at identifying and quantify­
ing the extent o f fibrosis in the left atrium  and thus identifying 
the progression of the disease substrate.
The role o f triggers in AF is also motivation for novel imag­
ing approaches. W ith electrical and electroanatomic mapping 
(ie, recording electrical activity from a num ber o f known sites 
on a surface the heart), it is possible to identify the sites o f trig­
gers and thus also localize causes o f induction o f AF. Leaders in 
mapping triggers of AF are Haissaguerre and coworkers,16-19 who 
identified trigger sites both in the atria and especially within the 
pulmonary veins o f the left atrium. Once identified and local­
ized, it is possible to electrically isolate these triggers, which was 
the unknown consequence o f an earlier surgical technique for 
AF management, known as the Cox maze procedure, first per­
formed in 1988.20 This operation isolates not only the pulmonary 
veins bu t also different regions o f the atria by creating a “maze,” 
a tortuous path for electrical conduction in the atria, reducing 
the ability o f triggers to interact with a substrate that could sus­
tain arrhythmias. Modern, catheter-based ablation approaches 
seek to achieve similar goals by applying very focused energy to 
the endocardial surface o f the atria to isolate the triggers known 
to exist in the pulm onary veins17 and create the same maze of 
broken conduction in the left atrium .16,21,22 The electroanatomic 
mapping approaches necessary to guide such interventions are, 
however, invasive and often time consuming, so there remains 
a pressing need to develop noninvasive imaging approaches to 
localize trigger sites. C urrent research in AF management seeks 
to develop imaging based on MRI,23-25 ultrasound,26 and com ­
puted x-ray tomography27 to visualize the ablation lesions and 
thus direct the intervention.
■  IMAGING AND AF
We outline in subsequent sections the use o f a broad range of 
imaging modalities in AF management and then focus on a
comprehensive approach to the management o f AF using MRI 
for all phases o f evaluation and intervention. The m ost novel 
approaches to imaging in AF are in the areas o f merging m ulti­
ple modalities and in the rapid expansion o f the use of MRI. The 
rationale for this growth is that, unlike other modalities, MRI is 
naturally suited to detect changes in soft tissue characteristics 
and hence capable o f revealing the progress o f substrate in AF 
and in visualizing the creation o f lesions during ablation. These 
capabilities, combined with the ability to reveal atrial anatomy 
at high resolutions, make MRI the natural adjunct to all phases 
o f management o f AF patients.
OVERVIEW OF CURRENT IMAGING 
MODALITIES
The use o f imaging is ubiquitous in clinical electrophysiol­
ogy, especially in interventions that require remote access to 
the heart by means o f catheters. One the one hand, imaging 
is required to guide the catheter, and on the other hand, the 
catheter itself often captures and conveys functional and diag­
nostic information that m ust be integrated into the procedure. 
Figure 25-1 summarizes the most com m on modes of display­
ing information in a typical electrophysiology study, and we 
describe here briefly these modalities. The focus o f subsequent, 
more detailed discussion will be MRI, the modality that is now 
the topic o f extensive research and development.
■  FLUOROSCOPY
Fluoroscopy is an x-ray-based m odality that has been a 
m ainstay o f cardiac catheterization procedures from  their 
inception. Like all x-ray-based imaging, fluoroscopy can 
reveal dense materials like bone and metallic objects (eg, 
electrodes, devices, catheters) but, w ithout contrast agents, 
is no t capable o f visualizing soft tissue o r blood. In cath­
eter ablation, fluoroscopy serves primarily to guide cath­
eter navigation and to direct the transseptal puncture o f 
the atrial septum  that is necessary to access the left atrium . 
W ith contrast agent injection, it is also possible to visualize 
vessels and cardiac cham bers using fluoroscopy. Significant
A B C D
FIGURE 2 5 -1 .  Overview o f im aging m odalities in com m on use fo r atrial fibrilla tion evaluation and ablation. The figure shows examples o f fluoroscopy (A ), com puted tom ography 
( B), electroanatomic m apping (C), and intracardiac echocardiography (D) as they are used fo r guid ing ablation o f atrial arrhythmias. LI, left inferior; LIPV, left in ferior pulm onary 
vein; LS, left superior; LSPV, left superior pu lm onary vein; LUPV, left upper pulm onary vein; RI, right inferior; RIPV, right in ferior pu lm onary vein; RS, right superior; RUPV, right 
upper pu lm onary vein.
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strengths o f  fluoroscopy include the ability to perform  real­
tim e imaging at fram e rates o f  tens per second, the simplicity 
provided by very evolved technology, and ready availabil­
ity. Acknowledged weaknesses include the poor soft tissue 
contrast and the cum ulative exposure to ionizing radiation. 
M ore fundam entally, fluoroscopy is generally considered 
to be a tw o-dim ensional m odality so that revealing three­
dim ensional cardiac shape is difficult.
M odern fluoroscopy systems seek to address these lim ita­
tions by providing multiple, orthogonally oriented cameras 
(biplaner fluoroscopy) and rotational angiography systems for 
full, three-dimensional reconstructions of venous and cardiac 
shape during catheterization procedures,28,29 all at the low­
est possible field strengths. The anatomic models obtained by 
rotational angiography systems approach the resolution and 
accuracy of com puted tomography (CT) and MRI images. 
Furthermore, because imaging occurs intraprocedurally, the 
resulting models can be better aligned to the coordinate system 
in which the procedure occurs and are less vulnerable to intra- 
vascular volume changes and shifts in body position and shape 
that may limit the accuracy of remotely acquired MRI and CT 
images.30,31 Acquisition o f geometric information in the same 
reference frame and at the same time of procedures significantly 
aids the integration o f imaging modalities by obviating the need 
for registration.32
■  ELECTROANATOMIC MAPPING AND IMAGING
Electroanatomic mapping (EAM) is an essential com ponent of 
cardiac ablation procedures that has been used widely since the 
mid-1990s.33-38 All such systems produce a patient-specific geo­
metric model of the endocardium together with electrograms at 
num erous sites on that surface. There are two competing EAM 
technologies, CARTO from Biosense W ebster (D iam ond Bar, 
CA)39 and EnSite from St Jude Medical (St. Paul, M N),33 which 
differ in the m anner by which they generate the electrical signals 
on the endocardium. CARTO measures potentials directly by 
touching a manually steered catheter sequentially to the heart 
surface and can thus be used on both  the endocardial and 
epicardial surfaces. Its m ajor weakness is the time required to 
sample enough points to create true maps o f electrical activity, 
which can present challenges when the underlying arrhythmias 
are unstable and poorly tolerated by the patient. The EnSite 
technology differs in that it is based on simultaneously record­
ing from an inflatable catheter containing 80 electrodes that 
is placed inside the chamber o f interest. The system solves the 
resulting bioelectric field inverse problem in terms o f endocar­
dial potentials from a single heartbeat, reducing the burden on 
patients with unstable arrhythmias.
More recently, clinicians have adopted EAM for evaluation 
and guidance during ablation o f AF,34-36 bu t here, the goal is 
often simpler— to measure only the amplitude o f electrical 
activity in the posterior wall o f the left atrium  and thus evaluate 
the success o f ablation. EAM is just as essential in the context of 
MRI-guided AF ablation, and such systems have been developed 
for this application.24
■  ECHOCARDIOGRAPHY/ULTRASOUND
Various modalities o f ultrasound-based echocardiography are 
used in the management o f AF. Transthoracic echocardiog­
raphy (TTE), transesophageal echocardiography (TEE), and 
intracardiac echocardiography (ICE) are routinely used before, 
during, and after catheter ablation o f AF, always with the goal of 
providing detailed and fine-scale anatomic information. We will 
briefly describe the context in which each of these modalities is 
commonly used.
Transthoracic Echocardiography
TTE is routinely used for screening and evaluation purposes 
in the management o f AF, typically to screen for underlying 
heart disease, including heart failure, valvular heart disease, and 
left ventricular hypertrophy.40 Additionally, TTE can be used 
to assess left atrium  size and anatomy.41 Postablation TTE can 
be used to detect pericardial effusion and to evaluate left atrial 
function and size.42 Although other imaging modalities outper­
form TTE in these tasks, TTE remains an effective, readily avail­
able, noninvasive, and relatively inexpensive modality.
Transesophageal Echocardiography
TEE has shown high sensitivity and specificity for the detection 
of left atrial throm bus before ablation treatm ent.43 It is also 
useful for assessment o f the location and num ber o f pulm o­
nary veins when CT and MRI are not feasible. Due to patient 
discomfort (the probe m ust be placed in the esophagus at the 
left o f the heart) and need for airway management, TEE has not 
traditionally been used intraprocedurally.42
Intracardiac Echocardiography
ICE has become a standard imaging utility in m ost modern 
electrophysiology laboratories because o f its high spatial and 
temporal resolution, achieved in part from the immediate prox­
imity o f the sensor and the heart. ICE is capable o f visualizing 
the anatomy of the left atrium, including the pulm onary veins 
and appendage, as well as other local anatomy including the 
aorta, mitral valve, and esophagus. In AF ablation procedures, 
the ultrasound catheter is navigated intravenously to the right 
atrium  and is used to guide transseptal punctures, navigate 
ablation catheters, confirm electrode-tissue contact, and titrate 
energy delivery.44-47 Additionally, ICE plays a critical role in 
the prevention and detection o f complications by m onitoring 
the formation o f throm bus or coagulum, pericardial effusion 
and tamponade, and flow acceleration indicative o f pulmonary 
vein stenosis.48-51 Limitations o f ICE include the requirement 
for additional intravenous access and confinement to two­
dimensional imaging.
■  ANATOMIC MRI/MULTISLICE CT
Multislice CT (MSCT) and MRI-based angiography are rou­
tinely performed before ablation to define left atrial and pul­
monary vein anatomy and size. Models o f the relevant cardiac 
anatomy, generated from these images, are created to help guide
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intraprocedural navigation and tissue targeting.52-54 Trade-offs 
exist between the selection o f MSCT or MRI for angiogra­
phy. MSCT-based angiography is faster and has higher spatial 
resolution, whereas MRI does not require exposure to ion­
izing radiation. M ost patients with pacemakers or implantable 
cardiac defibrillators are also ineligible for MRI. High-fidelity 
representations o f the anatomy can be generated from  both 
modalities, and consequently, both are considered acceptable 
for this purpose. Both modalities are also used after ablation to 
identify complications such as pulm onary vein stenosis, atrioe- 
sophageal fistula, and reverse remodeling (ie, decrease in atrial 
volume).42,55-59 MRI and MSCT have also been successfully used 
to identify surrounding structures that may be at risk o f collat­
eral injury during AF ablation, including coronary vessels and 
the esophagus.60-62
■  MERGING OF MODALITIES
Clearly, no imaging modality is a panacea for all o f the require­
ments inherent in the assessment and treatm ent o f a disease 
with such diverse and complex imaging needs as AF. Often a 
merging of modalities is necessary or at least desirable to achieve 
the necessary coverage o f anatomic and functional information 
to manage the disease. The challenges presented by merging 
imaging modalities include the need to align or register images 
acquired in different coordinate systems and different resolu­
tions and then to present them to the operator in a way that is 
flexible and intuitive enough to be useful.
The centerpiece o f contemporary integrated image merging 
systems tends to be the EAM system, which includes the nec­
essary merging, registration, and visualization hardware and 
software. The goal o f such systems is almost always to use a 
previously acquired angiography (by MRI or MSCT) to provide 
a geometric substrate for the subsequent EAM of the heart.63-69 
This registration step usually relies on operator identification of 
landmarks common to both the angiography and the EAM to 
rigidly align them  in the coordinate system of the EAM system. 
Further refinements o f the alignment are then updated as more 
points are sampled for the EAM. M uch of the mismatch that 
remains can be attributed to the differences in the MSCT and 
MRI data acquired sometimes days before the procedure. O ther 
sources o f error in the match o f MRI and MSCT models to 
intraprocedure anatomy include respiration, patient movement, 
and changes in cardiac rhythm.70,71 Real-time integration of ICE 
imaging with the EAM system has recently emerged as a means 
to allow intraprocedural generation and updating o f anatomic 
models, further improving navigational accuracy.72,73
MRI-BASED EVALUATION OF ATRIAL TISSUE
Cardiac MRI has become the gold standard for imaging and 
analysis of numerous cardiac conditions. Generally, MRI is lim­
ited by comparatively slow image acquisition and reconstruction 
times, low resolution, susceptibility to noise, and magnetic field 
incompatibility of some patients. However, the two primary 
benefits o f MRI are soft tissue contrast and absence o f ionizing
radiation. These two strengths come to bear significantly in 
the arena o f AF management. First, AF is known to influence 
cardiac structural properties in a process known as remodel­
ing. Second, the stated goal o f AF ablation is to modify, isolate, 
or abolish arrhythmogenic tissues. In both cases, the soft tissue 
contrast available in MRI provides insight for physicians into the 
entrenchment o f AF and success o f scar formation, respectively. 
Finally, modern ablation procedures still rely heavily on fluoros­
copy for procedural guidance. The introduction o f AF ablation 
procedures into the MRI environment opens the door for the 
departure o f ionizing radiation from the management o f AF.
Late gadolinium-enhanced (LGE) MRI is used to evalu­
ate alterations in tissue structure associated with num er­
ous cardiomyopathies.74,75 To acquire LGE images, a dose o f 
chelated gadolinium contrast agent is administered intrave­
nously as would be done for standard magnetic resonance 
angiography. Following the injection, the gadolinium is allowed 
time to wash clear o f norm al myocardium, and an inversion- 
recovery prepared gradient echo pulse is acquired to detect 
regions o f tissue where the contrast agent remains sequestered. 
Any region in which perfusion has decreased or extracellular 
space has increased will appear bright in LGE images due to 
enhanced concentrations of gadolinium relative to surrounding 
tissues.76
■  EVALUATION OF POSTABLATION SCAR FORMATION
The first reported use o f LGE-MRI of atrial tissue to assess abla­
tion lesions came from Peters et al.77 In this prospective study, 
contrast enhancement was found in the left atrium and pulm o­
nary vein ostia o f all patients who had previously undergone 
radiofrequency (RF) ablation o f AF 1 to 3 months previously. 
These findings were supported by M cGann et al,78 who quanti­
fied the extent o f enhancement observed in the left atrial wall 3 
m onths after ablation using the methods outlined in Fig. 25-2 
and compared extent o f scar to procedural outcomes. In this 
study, patients who experienced a recurrence o f AF were found 
to have less enhancement (12.4 ± 5.7%) compared with patients 
who did not experience recurrence (19.3 ± 6.7%, P = .004).78 
Subsequent studies have expanded on these initial findings to 
show that lesion remodeling stabilizes by 3 months after abla­
tion and that the extent and continuity o f lesions encompass­
ing the pulm onary veins play an im portant role in preventing
recurrences.79-81
The ability to noninvasively assess the lesion sets created 
in AF ablation procedures can provide valuable feedback to 
electrophysiologists searching for the optimal ablation strat­
egy. Although freedom from AF after a single intervention will 
remain the goal for procedural success, LGE-MRI can help 
explain how and why a particular lesion set succeeds or fails at 
terminating AF and provide direction in subsequent ablation 
procedures.
■  EVALUATION OF AF SUBSTRATE
As previously noted, AF is associated with structural rem odel­
ing o f the left atrium . M otivated by the success o f LGE-MRI in
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FIGURE 2 5 -2 . A lgorithm  fo r quantification o f postablation scar burden in the left atrium  (LA). The wall o f the  LA in late gado linium -enhanced magnetic resonance imaging scans 
(top le ft) is segmented on a slice-by-slice basis (top center). Once isolated (top  right), a histogram o f the LA wall pixel intensities is generated (bottom  right), and the rising phase 
o f the prim ary mode is used to  predict normal tissue pixel intensities. Pixel intensities three standard deviations above the mean o f norm al tissue is marked as scar (bottom  center). 
Overlays o f pixels marked as scar onto original images shows good correlation w ith  hyperenhancement. Ao, aorta; DE-MRI, delayed-enhanced magnetic resonance imaging.
identifying structural heart disease and, in particular, fibrosis, 
Oakes et al82 analyzed LGE-MRI scans from a cohort o f  81 AF 
patients and six norm al volunteers to explore the relationship 
between contrast enhancem ent and AF structural rem odel­
ing. This study revealed a positive correlation between low- 
voltage tissue regions in EAMs (bipolar voltage amplitude 
<0.5 mV) and left atrial wall enhancem ent (r2 = 0.61, P < .05). 
Furtherm ore, patients with m ild (<15%, n = 43), moderate 
(15%-35%, n = 30), and extensive (>35%, n = 8) am ounts o f 
left atrial wall enhancem ent were found to have significantly 
different rates o f AF recurrence at a mean follow-up of 9.6 
m onths (14%, 43%, and 75%, respectively). These findings 
suggest that the degree o f  left atrial wall enhancement, which 
is assumed to reflect extent o f fibrosis in the atrial tissue, is a 
predictor o f failure for ablation. Based in part on these results, 
a staging system for determ ining the am ount o f enhancement 
has been proposed. Figure 25-3 shows the Utah staging sys­
tem, with examples o f  LGE-MRI scans from  each o f the four 
stages. U nder this system, patients with U tah stage III or IV
enhancem ent are no t considered to be ideal candidates for 
ablation therapy.
The utility o f the Utah AF stage s is currently under extensive 
evaluation, both at our institution and through a multicenter 
clinical study involving m ajor AF centers from around the 
world.
REAL-TIME MRI FOR ABLATION OF AF
As outlined in the Introduction, catheter-based ablation o f the 
left atrium  represents the m ost com m on intervention to cure 
or at least suppress the symptoms of AF. To carry out abla­
tion requires considerable imaging support in order to identify 
anatomy, evaluate substrate, and determine success o f the 
intervention. Conventional approaches to AF ablation make 
use o f fluoroscopy, CT, intracardiac ultrasound, and EAM. 
N ot only is MRI used as a preprocedural m ethod to generate 
anatomic images, bu t also its broader use represents the leading 
edge of research in real-time imaging to support the guidance
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FIGURE 2 5 -3 .  Utah staging system fo r stratifying the am ount o f preablation enhancem ent o f the le ft atrial wall. Images in each o f the fo u r panels show examples o f late 
gadolinium-enhanced magnetic resonance images, w ith  enhanced regions color coded in green and normal tissues colored in blue.
of catheters and the evaluation o f lesion formation in a three­
dimensional form. The need to combine anatomic and func­
tional inform ation continues to drive the development o f novel 
merging and registration approaches.34
■  CATHETER ABLATION OF AF
The past decades have seen significant progress in under­
standing the underlying mechanisms of AF that sustain its 
persistence,11,17 and this knowledge has led to the treatm ent 
paradigm of AF ablation, which is the targeted destruction of 
tissue predominantly in the left atrium  in order to isolate electri­
cal triggers and reduce the ability o f the atrium  to sustain rapid 
activation. AF ablation, typically based on RF energy delivery 
through a venous catheter, has already produced encouraging 
results and is the topic o f innumerable research reports, bu t it 
has yet to reach its full potential. Despite the fact that ablation, 
when successful, allows the patient to discontinue the use of 
antiarrhythmics anticoagulants, the success rate o f ablation in 
maintaining regular sinus rhythm  without the use o f such m edi­
cations is still only 60% to 80%.83 Moreover, the penetration of 
ablation, although difficult to measure with accuracy, appears 
to lie well below the need; there are fewer ablations carried out 
each year than there are new cases o f AF. In an effort to increase
the penetration o f this potentially curative approach, there have 
been many modifications to the ablation procedure aimed at 
improving outcome and hence prom oting the adoption o f the 
ablation approach.16,34,72,84-89 Despite such progress, daunting 
technical challenges to carrying out successful ablation remain, 
and many of these are related to imaging.
Currently, AF ablation is performed using catheters that can 
be visualized under fluoroscopy and/or projected onto a three­
dimensional virtual shell acquired through EAM during the 
procedure.34 There are multiple challenges associated with these 
approaches. First, it is impossible for the operator to visualize 
the catheter tip/tissue interface; hence, delivery o f RF energy is 
based on guidance from the morphology of local electrogram or 
by using the virtual shell from EAM to assure that the catheter 
tip is in contact with the atrial wall. However, both o f these 
approaches have known errors that can exceed 1 cm,90 lead­
ing to frequent delivery o f inappropriate lesions that may only 
partially damage the atrial tissue, prom oting tissue recovery and 
hence reoccurrence o f the arrhythmia. Moreover, this lack of 
visualization o f the catheter tip can result in localized heating of 
blood, thus leading to char formation, a m ajor cause o f embolic 
stroke during the ablation procedure.91 Defining a technology or 
a system that would allow accurate visualization o f the catheter 
tip/tissue interface would overcome this m ajor problem for the
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FIGURE 2 5 -4 . Visualization o f catheter during real-time magnetic resonance im aging (MRI). Each panel shows a slightly diffe rent view o f the MRI-compatible catheter superim ­
posed on the local MRI image together w ith  a rendered mesh o f the right atrium  and superior and in ferior vena cava from  this animal.
operator. Another major challenge o f the ablation procedure is 
the lack o f an imaging modality that allows immediate assess­
m ent o f tissue damage as the RF energy is applied. MRI is the 
m ost obvious and perhaps only imaging system that could over­
come this problem.
Although MRI has the inherent capability o f visualizing soft 
tissue and thus providing both anatomic and functional guid­
ance for RF ablation o f AF, there are challenges to creating a 
viable MRI-based approach. First, it is necessary to develop an 
MRI-compatible catheter and associated software that allows 
visualization o f the catheter during navigation and energy deliv­
ery within the atrial chamber. This catheter and software must 
be part o f a system that tightly integrates the diverse instrum en­
tation required to complete a clinical atrial ablation procedure. 
The system m ust exploit the benefits o f soft tissue contrast 
unique to MRI (near real-time visualization o f myocardial 
interfaces and ablation lesions) while providing a smooth work­
flow for the physician and technicians. Recent reports showing 
progress toward these ends by our and other groups23-25 suggest 
that a full AF ablation procedure in hum ans, although still very 
challenging, is likely.
■  MRI-COMPATIBLE CATHETERS
The development o f an MRI-guided system for AF ablation is 
completely novel in terms of the devices and support systems 
that are required to create a working system. MRI-compatible 
catheters have just begun to appear in the literature23,33,52,92 but 
are still prototypes and have not been used in any hum an abla­
tion studies. Similarly, the real-time MRI guidance systems 
required to place the catheters in the appropriate locations are 
in their infancy, with only sparse reports o f placing an MRI- 
compatible catheter in the hum an heart under MRI guidance.52 
Most o f the other elements o f the contemporary AF ablation 
instrum ents— the lasso catheter, the coronary sinus catheter,
and the needle required to carry out transseptal punctures— are 
also only just under initial development and have yet to receive 
approval for use in humans.
We have participated in the development o f catheters that are 
MRI compatible, steerable in a way similar to standard clinical 
catheters, and capable o f both delivering RF energy and record­
ing endocardial electrograms.25 It is possible to track the loca­
tion o f the catheters and to display their position superimposed 
on the real-time MRI images and with a geometric shell model 
of the atria and great vessels that we create from volumetric MRI 
scans recorded in the early phases o f the procedure. Figure 25-4 
shows an example o f MRI images recorded during a real-time 
ablation procedure in which the catheter is visible superimposed 
on the orthogonal MRI images. Also visible in the image is a 
polygonal surface or shell o f the right atrium  and inferior and 
superior vena cava, created by segmenting a previously acquired 
high-resolution scan of the animal’s atrial anatomy.
■  VISUALIZATION OF IMAGING RESULTS
Scientific visualization is an essential step in using imaging 
data, and the unique and challenging needs o f AF ablation con­
tinue to drive new approaches. For example, EAM requires the 
integration o f spatial information describing the shape o f the 
endocardial surface with time signals, electrograms recorded 
from that surface, and parameters extracted from them. In 
addition, there is volumetric inform ation from MRI and CT 
that can be visualized as s sequence o f two-dimensional images 
bu t is much richer when rendered in a three-dimensional form. 
Naturally, there is a need to merge these two (and other) forms 
of anatomic and functional information, and novel visualization 
technology continues to improve such merging in a setting of 
interactive m anipulation and rendering.34
We have developed techniques that combine not only visu­
alization o f volume- and surface-based approaches bu t also
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FIGURE 2 5 -5 .  M ultim odal visualization o f ablation lesions from  an experim ent using magnetic resonance im aging (MRI) during and after lesion form ation. The images show the 
results o f electroanatomic m app ing (A ), late gado linium -enhanced MRI ( B and C), and gross dissection o f the  right atrium  from  an anim al experim ent ( D).
projection o f the inform ation from the volume to the surface. 
Figure 25-5 shows an example o f such a visualization in which 
Fig. 25-5A shows an EAM from an animal experiment showing 
three clusters o f lesions performed under fluoroscopy guidance; 
the red dots in panel A show the lesion sites. Figure 25-5B shows 
the LGE rendering of the same heart, performed in the MRI 
scanner directly after the ablation procedure. We then used seg­
m entation o f the volume images to define the endocardial sur­
face and projected the inform ation from the MRI scan onto that 
surface, shown in Fig. 25-5C. Confirmation o f the actual lesion 
locations is evident from dissection docum ented in Fig. 25-5D.
The motivation o f such projection approaches is to present 
information from multiple modalities (in this case, EAM of 
electrogram amplitude and MRI tissue changes) in a common 
reference frame (in this case, the endocardial surface). Such 
merging of information provides for quantitative analysis and 
comparisons and also a means o f conveying information in a 
form that is familiar to the clinicians (in this case, electrophysi­
ologists who are highly conversant in the conventions o f endo­
cardial and epicardial mapping).
■  REAL-TIME DETECTION OF LESION FORMATION
The m ost significant advantage o f MRI-guided ablation is its 
potential to obtain rapid feedback on tissue changes during 
the ablation procedure— to watch the lesions form. There is no 
viable modality at this time that can determine the effectiveness 
of ablation; even electrical mapping approaches only measure 
depressed electrical activity in the endocardium that may return 
within weeks o f the ablation and cause a recurrence o f AF. MRI, 
on the other hand, has the potential to visualize changes in tis­
sue structure related to perm anent cell damage following the 
application o f energy and thus establish the presence and depth 
in the atrial wall o f terminally destructive lesions. Visualization 
of lesion formation and extent would improve the effectiveness 
and the safety o f RF ablation procedures.
To visualize lesion formation with MRI requires acquisition 
of high-quality images in rapid sequence in order to achieve
adequate spatial and temporal resolution. As with all imaging 
modalities, there is a trade-off in MRI between the time needed 
to acquire the image and the quality of that image. Furthermore, 
real-time imaging o f the heart is driven both by the need to 
capture information rapidly enough to avoid blurring due to 
cardiac and respiratory m otion and the desire to optimize image 
quality to see small changes within structures that are only a 
few millimeters thick. Another challenge specific to ablation is 
the need to see changes quickly enough to allow the operator to 
control the time and the energy dose in order to create lesions 
that are deep enough, bu t not so deep as to degrade the struc­
tural integrity o f the heart wall.
In animal studies within our group, we have achieved image 
refresh rates o f up to 5.5 frames per second based on custom­
ized MRI scan sequences and have been able to visualize lesion 
formation within 10 to 15 seconds o f onset o f RF energy.25,93 
Figure 25-6 shows just one example o f such a case, in which 
catheter placement is docum ented in Fig. 25-6A, followed by 
a sequence o f images (using a different MRI scan sequence) 
that reveal the formation of the lesion in Fig. 25-6B to 25-6F. 
Figure 25-6G shows a postm ortem  image in the same plane, and 
Fig. 25-6H contains a photographic record o f the lesion seen 
immediately after the experiment. To our knowledge, this is the 
first report of visualizing lesion formation as it occurs in any tis­
sues o f the heart. We have also compared lesion sizes measured 
from MRI imaging with those determined through postmortem 
dissection and shown excellent agreement.25
SUMMARY
Imaging has always been an essential com ponent o f the m an­
agement o f all forms of cardiac arrhythmias, and its use will 
continue to expand in pace with improvements in the imaging 
acquisition technology, the image processing and analysis, and 
the integrating software that can efficiently support the clinical 
workflow. In the setting o f AF, the use o f MRI is making par­
ticular advances as its utility in all phases o f the disease becomes
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FIGURE 2 5 -6 . Detection o f acute atrial lesion. A . Image from  a three-dim ensional scan to  locate the catheter tip . B-F. T2-weighted dark blood images acquired before ablation 
(B ) and after ablation at 20 seconds (C), 50 seconds (D ), 2.5 minutes (E), and 8 m inutes (F). G. Postmortem, high-resolution, delayed-enhancem ent magnetic resonance image. 
H. Photo o f excised heart. Blue arrow indicates the position o f the catheter tip  a t septal wall. Red arrows indicate the  location where the lesion was created using a 30-second 
ablation w ith  30 W. LA, left atrium ; RA, right atrium.
evident. Preablation imaging provides a means to stage patients 
and determine their best treatm ent options; the emergence of 
the Utah AF staging system suggests a very specific means by 
which image analysis and quantification can indicate disease 
status and risk. Similar techniques provide a means of noninva- 
sively determining the outcome of AF ablation by mapping the 
formation of scar to both evaluate interventional success and to 
guide subsequent interventions, should they be necessary. The 
Comprehensive Arrhythmia Research and M anagement Center 
has carried out over 600 scans on over 250 patients to date and 
is now collaborating with similar laboratories around the world 
in multicenter trials of these MRI-based approaches. The results 
of these studies could completely transform the way that AF is 
treated when it arises and even enable preventative measures 
that are simply impossible w ithout a means of tracking the tis­
sue changes that preface the onset of electrical symptoms 
The potential for imaging and especially MRI in the treatm ent 
of patients with AF is equally exciting and bright. We have now 
carried out over 30 animals studies to date in developing the 
prototype MRI-guided navigation system and are focused on 
developing and testing such a system for use in humans. We 
have created lesions both  under fluoroscopy and real-time MRI 
guidance in the atria and ventricles of anesthetized dogs and 
swine and then carried out detailed imaging both of the entire
animal thorax and of the excised preserved heart. In  the process, 
we have made advances in MRI-compatible catheter design, 
exploitation of novel sensing coils, incorporation of tracking 
coils into catheter housings, improvement in pulse sequence 
design for rapid acquisition, integrated interactive display of 
images and devices, and image processing and analysis tools for 
postprocedure evaluation of results. O ther groups have made 
similar progress, and there is little doubt that the first hum an 
studies
A major initial goal of these studies was to ensure that it is 
indeed possible to visualize lesions soon after ablation, despite 
the thin atrial walls and small extent of RF lesions. Figure ?? 
shows an example of such a result in which we sampled from 
the same slice before, during, and repeatedly after application 
o f the RF energy.93
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CHAPTER 5
PERFORMANCE OF VOLTAGE 
M APPING
Substrate mapping provides in-procedure feedback and guidance for the ablation of 
cardiac arrhythmias. W ith substrate mapping, it is assumed tha t the electrograms ac­
quired from a given location are representative of the local electrophysiological properties. 
However, many factors influence the generation of an electrogram. For the catheter, con­
siderations such as the size and spacing of electrodes, the type of reference used, contact 
with the tissue, and the orientation of the catheter with respect to the tissue an wavefront 
may affect electrogram morphology. For the tissue, the fiber orientation, the direction of 
impulse propagation, and the presence and size of abnormal substrate also may affect EGM 
morphology. The combined influence of these factors is sufficient to cast doubt on the 
particular meaning of any electrogram observed to have unique or abnormal properties. 
Consequently, it is imperative to characterize the effect of these various factors on the 
performance of substrate mapping for identifying arrhythmogenic myocardium. This chap­
ter contains the results of a study previously published in the Journal o f Cardiovascular 
Electrophysiology titled, “Sensitivity and Specificity of Substrate Mapping: An In Silico 
Framework for the Evaluation of Electroanatomical Substrate Mapping Strategies” [171]. 
This study focuses on voltage mapping, one type of substrate mapping, and the effect of 
various geometric factors on the ability of voltage mapping to detect abnormal myocardium. 
This work appears in the published format with permission from the journal.
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Geometric Factors in Voltage Mapping. Background: Voltage mapping is an important tool for 
characterizing proarrhythmic electrophysiological substrate, yet it is subject to geometric factors that 
influence bipolar amplitudes and thus compromise performance. The aim of this study was to characterize 
the impact of catheter orientation on the ability of bipolar amplitudes to accurately discriminate between 
healthy and diseased tissues.
Methods and Results: We constructed a 3-dimensional, in silico, bidomain model of cardiac tissue con­
taining transmural lesions of varying diameter. A planar excitation wave was stimulated and electro­
grams were sampled with a realistic catheter model at multiple positions and orientations. We carried 
out validation studies in animal experiments of acute ablation lesions mapped with a clinical mapping 
system. Bipolar electrograms sampled at higher inclination angles of the catheter with respect to the tissue 
demonstrated improvements in both sensitivity and specificity of lesion detection. Removing low-voltage 
electrograms with concurrent activation of both electrodes, suggesting false attenuation of the bipolar 
electrogram due to alignment with the excitation wavefront, had little effect on the accuracy of voltage 
mapping.
Conclusions: Our results demonstrate possible mechanisms for the impact of catheter orientation on 
voltage mapping accuracy. Moreover, results from our simulations suggest that mapping accuracy may be 
improved by selectively controlling the inclination of the catheter to record at higher angles with respect to 
the tissue. (J Cardiovasc Electrophysiol, Vol. 25, pp. 774-780, July 2014)
bipolar electrogram, computer-based model, electroanatomical mapping, voltage mapping
Introduction
Cardiac substrate mapping is a class of electroanatomical 
mapping in which proarrhythmic tissues are identified based 
on features of the local electrograms (EGMs). EGM features 
commonly interrogated for signs of pathology include sig­
nal amplitude, the power spectrum, and fractionation (“volt­
age,” “DF,” and “CFAE” mapping, respectively).1-3 A com­
mon thread among these mapping techniques is the frequent 
reliance on bipolar EGMs which are valued in clinical elec­
trophysiology for their sensitivity to local electrical proper­
ties. However, various geometric factors, e.g., perpendicular
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alignment of the electrode pair relative to the direction of the 
advancing activation wave, may influence bipolar EGM mor­
phology and thus impact the accuracy of substrate mapping.
In voltage-based substrate mapping, the peak-to-peak am­
plitude of bipolar EGMs, typically from a single, representa­
tive activation sequence, is recorded and displayed on a geo­
metric representation of the chamber being mapped. Multiple 
studies have demonstrated that diseased tissues, i.e., scarred 
or fibrotic, produce smaller bipolar amplitudes (BPAs) than 
are observed in healthy tissues.1,4 However, studies using 
voltage mapping to localize lesions have reported both over- 
and underestimation of lesion size.5-8 The plausible sources 
of these errors in voltage mapping are manifold but one pos­
sibility is the variability in BPAs that arises due to geometric 
uncertainty in electrode placement and orientation. Recently, 
Otomo et al. explored the effect of transmural ablation le­
sions on EGMs recorded with a mapping catheter oriented 
either perpendicular or parallel to the cardiac wall at the ab­
lation site.9 Their findings clearly demonstrated that EGM 
morphology changes due to the geometric positioning of the 
catheter. We have extended this line of inquiry using ex­
periments and in silico studies, and to our knowledge, no 
previous study has systematically linked the effects of the 
geometric parameters on BPAs to the accuracy of voltage 
mapping-based detection of myocardial injury or disease.
A thorough and precise study of the effects of geometric 
parameters including catheter size, orientation, placement, 
and electrode configuration on the localization of cardiac
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tissue lesions is not practical using purely experimental ap­
proaches. Even with large mammal models it is not currently 
feasible to capture and control all the relevant parameters 
with adequate accuracy. In contrast, an approach based on 
computational modeling and simulation provides complete 
control over all relevant parameters and the ability to mimic 
the conditions in the heart. The requirements of such an in 
silico study include the ability to create realistic models of the 
myocardium and electrodes, to solve the associated bioelec­
tric spread of excitation and extra-cardiac potentials, and to 
display and analyze the results quantitatively. The numerical 
methods and software for such a modeling pipeline are now 
available10-12 and well enough refined to serve as a reliable 
platform for such a study.
The specific aims of our study were to identify and quan­
tify the impact of some known but clinically uncontrolled 
geometric factors on cardiac substrate mapping. We used a 
myocardial slab in which we introduced lesions and then 
simulated the spread of activation through the tissue. We 
then introduced a geometrically realistic model of a clinical 
mapping and ablation catheter and simulated catheter place­
ment at different sites and orientations relative to the tissue 
surface. By imposing a range of thresholds to distinguish 
between normal and subnormal bipolar voltage amplitudes, 
including accepted clinical thresholds, we predicted the sites 
of lesions, compared the results to the known locations, and 
then created receiver operating characteristic (ROC) curves. 
Based on this metric of performance, we could then iden­
tify the critical sources of error and determine the resulting 




We executed a bidomain simulation of the spread of ac­
tivation through an electrically isotropic slab model of atrial 
myocardium with the Cardiac Arrhythmia Research Pack­
age software.13 The model geometry was a 50 x 50 x 5 mm 
slab composed of isotropic hexahedral elements with 0.18 
mm edge length. The slab was completely immersed in a 
bath that was 3 mm deep on all sides except for the mapping 
surface, where the bath was 10 mm deep. Within the my­
ocardial slab, we incorporated cylindrically shaped, trans­
mural lesions of 4, 6, 8, and 10 mm diameter. One edge of 
the geometry was stimulated to produce a planar wavefront, 
and, according to standard practice, we scaled conductivi­
ties to produce physiologically realistic conduction velocities 
(0.56 m/s). The Courtemanche-Ramirez-Nattel cell model of 
atrial myocyte kinetics14 simulated the excitation of normal 
myocardium whereas lesions were modeled as passive vol­
ume conductors.
A realistic catheter geometry (8 F diameter, 4 mm long 
tip, 2 mm long distal ring electrode with 2 mm interelec­
trode spacing) was used to sample the electric potential on 
the simulated heart surface at 1 kHz sampling frequency. A 
random sampling of 1,000 points on the surface of the tissue 
(738 on normal tissue, 190 on lesions, and 72 removed from 
analysis due to stimulus artifact in the EGMs), all at least 
5 mm from the slab edge, determined the placement of the 
simulated catheter tip. The sampling of points was weighted 
such that the density of points on lesions was 3 times higher
than that of normal tissues. With the catheter tip fixed at 
each of these 928 surface points (Fig. 1A), we then tilted the 
catheter through 116 uniformly distributed orientations in 3 
dimensions (Fig. 1B). At each location and orientation of 
the catheter, we computed the extracellular potentials at the 
electrodes for the entire time series to reconstruct unipolar 
and bipolar EGMs (Fig. 1C).
There were 2 parameters in this study that we assumed 
would affect performance. The first was the angle of the 
catheter shaft relative to the tissue, defined as the inclination 
angle. A value of zero corresponded to all electrodes of the 
catheter lying flat on the tissue surface and a value of 90 
degrees to a full perpendicular catheter orientation (Fig. 1A). 
We evaluated the sensitivity and specificity of lesion detec­
tion through the full range of catheter inclination angles. The 
second parameter of interest was the orientation of the bipo­
lar electrodes relative to the activation wave front. However, 
curvature in the wave front caused by the lesions impeded 
consistent calculation of the angle between the bipolar elec­
trode axis and the wavefront. To overcome this limitation 
we used the difference in activation times, annotated at the 
maximum negative slope of the distal and proximal unipo­
lar EGMs,15 as a marker of wave front arrival,9 a metric we 
term ALAT, or absolute difference in local activation time 
expressed as:
ALAT(M1 -  M2) =  LAT(M1) -  LAT(M2),
where M1 and M2 correspond to the 2 unipolar electrode 
sites. Small values of ALAT indicate (near) simultaneous 
arrival of activation at both electrodes, i.e., that the wave 
front direction is approximately perpendicular to the axis of 
the catheter. Given the anticipated error under such condi­
tions, we evaluated the sensitivity and specificity of lesion 
detection when EGMs with small ALAT were removed from 
analysis.
Animal Model
Simulations provide considerably more control over rele­
vant parameters than experiments, but they also require val­
idation. While the scope of validation by experiment was 
inherently limited in this study, we were able to generate 
data to support our approach from dedicated animal studies 
approved by the University of Utah Institutional Animal Care 
and Use Committee. The details of this experimentation were 
previously reported by Ranjan et al. and are revisited in de­
tail in the Supporting Information16 Briefly, voltage mapping 
of swine right atria was performed before and after the cre­
ation of point ablation lesions. Gross pathological examina­
tion and analysis of the spatial characteristics of low-voltage 
regions facilitated estimation of the extent of injury surround­
ing lesions and calculation of sensitivities and specificities 
for voltage mapping.
Statistical Methods
All repeated measurements are expressed as mean ±  stan­
dard deviation. Student’s t-test, accompanied by the Holm- 
Bonferroni method for multiple comparisons, was used to 
test for significance. Significance was achieved at values of 
P < 0.05.
Sensitivity and specificity are reported as true positive 
ratio (TPR) and false positive ratio (FPR =  1-specificity), 
respectively, as defined by a standard confusion matrix.
Blauer et al. Geometric Factors in Voltage M apping 775
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Figure 1. In  silico  m odel o f  electroanatom ical substra te  m apping. A . T hree-dim ensional slab  m odel w ith  activa tion  w ave propagating  fro m  righ t to left 
an d  extracellu lar po ten tia ls  d isp layed  w ith  co lor on the m esh. The w h ite  spheres show  random ly se lec ted  p o in ts  on the surface w here the ca theter tip was 
po s itio n ed  f o r  the  recording o f  EG M s. The catheter, d isp layed  a t an  inclina tion  o f  ~ 3 0  degrees, is  representative o f  devices u se d  clin ica lly  (8  F, 4  m m  tip, 
2 m m  spacing). B. Illustra tion  o f  the ca theter p o sitio n s  used  to sam ple  electrogram s. W hite spheres represent 11 6  transform ations o f  the proxim al electrode  
around the surface po in t. C. Representa tive  electrogram s acquired  fro m  sam e location  in m odel before (L), a n d  a fter s im ula ted  lesions w ere included  in the 
m odel (R). E A M  =  electroanatom ical m ap; E G M s =  electrogram s; P h iE  =  extracellu lar po ten tia l; M 1 an d  M 2 =  unipolar s ignals fro m  distal an d  proxim al 
electrodes, respectively.
Briefly, postablation points within the range of impact of 
each lesion were expected to show low voltage. Conversely, 
points sampled outside of the region impacted by ablation 
were anticipated to demonstrate normal bipolar amplitudes. 
A range of voltage thresholds for defining low voltage 
(0.25-3.0 mV) was tested to calculate receiver operating 
characteristic (ROC) curves for both models. We also used 
the Matthew’s correlation coefficient (MCC), a performance 
metric for summarizing a confusion matrix in a single 
value.17-19 MCC values range from —1 to +1, with a value 
of +1 indicating perfect correlation, or prediction. In this 
study, MCC was used to assess the performance of substrate 
mapping through a range of voltages.
Results
Computational Model
Figure 2 shows the mean bipolar amplitude, over the 116 
recording orientations, at each mapping site from the lesion 
model. For all points, the mean bipolar amplitude for EGMs 
recorded on lesions, 2.00 ±  1.01 mV (n =  22,040), was 
significantly lower than BPAs from healthy tissue, 3.24 ±  
0.91 mV (n =  85,608).
Figure 2. M ea n  o f  11 6  BPAs recorded a t each m apping  site. B ipo lar am pli­
tudes w ere recorded a t 928  locations (co lored  spheres) on the lesion m odel 
(norm al tissue is co lored  ligh t gray  an d  lesions are black). The m ean o f  
all b ipo lar am plitudes recorded a t each o f  928  sites (n =  116) determ ines 
sphere color.
8 0  0 80
Comparison o f Voltage Mapping Accuracy in 
Computational and Experimental Models
The fidelity of lesion detection with voltage-based sub­
strate mapping, for both the in silico and in vivo mod­
els, was assessed by computing sensitivity, specificity, and 
MCC values over a range of physiologically realistic low-
voltage thresholds ranging from 0.25 to 3.0 mV in incre­
ments of 0.25 mV. ROC curves and plots of MCC as a func­
tion of low-voltage threshold demonstrated a similar depen­
dence of both models on threshold selection, an example of 
which is shown in Figure 3. As might be anticipated, vary­
ing the voltage threshold for lesion detection demonstrated
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Figure 3. B aseline evaluation  o f  lesion detection  accuracy. Top: B aseline  
TPR an d  F PR  o fle s io n  d e tec tio n fo r  the in v ivo a n d  in silico  m odels w ere cal­
c u la ted  a t vo ltage cu to ffs  ranging fro m  0 .25  to  3 .0  mV. B ottom : M C C  p lo tted  
as a fu n c tio n  o f  the low -voltage cu to ff  illustra tes the  perfo rm a n ce  o f  su b ­
stra te  m apping  in each m odel a t a g iven  voltage. TPR =  true p o sitive  ratio; 
F P R  =  fa lse  po sitive  ratio; M C C  =  M a tth e w ’s correlation coefficient. For a 
h igh  quality, fu l l  co lor version o f  this figure, p lea se  see Journal o f  C ardiovas­
cular E lectrophysio logy’s w ebsite: w w w .w ileyonlinelibrary.com /journal/jce
tradeoffs in sensitivity and specificity of the ROC curves. 
For the in vivo measurements, limiting the expected extent 
of low-voltage tissue to the 3.5 mm radius region of directly 
ablated myocardium resulted in relatively higher sensitivity 
and lower specificity compared to a more relaxed boundary 
that accounted for low voltages caused by injury responses 
surrounding lesion (10 mm radius). Results from the in silico 
model showed similar characteristics to the in vivo model, 
but with a generally improved specificity and higher volt­
ages for lesions and normal tissues (Fig. 3). The following 
sections expand on this overall characterization of substrate 
mapping accuracy. Specifically, we evaluated the results un­
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Figure 4. E ffect o f  inclination  angle  on in s ilico  vo ltage m apping  accuracy. 
The upper p a n e l conta ins R O C  curves that dem onstrate the sensitiv ity  and  
specific ity  o f  vo ltage m apping  as BPAs recorded a t low  inclination  angles 
are rem oved by increm ents o f  15  degrees. The low er p a n e l conta ins p lo ts  
o f  M a tth e w ’s correlation coefficient w hich  show  the e ffect o f  progressively  
rem oving low  inclination recordings on the perform ance  o fvo lta g e  m apping  
as a fu n c tio n  o f  the low -voltage threshold. The blue curves, m a rked  w ith  cir­
cles, ind icate  the baseline conditions show n in the  previous figure. For a high  
quality, fu l l  co lor version o fth is  figure, p lea se  see  Journal o fC a rd iovascu lar  
E lectrophysio logy’s w ebsite: w w w .w ileyonlinelibrary.com /journal/jce
Effect of Catheter Inclination Angle on Lesion Detection
Figure 4 contains ROC curves in which bipolar 
EGM recordings acquired at low inclination angles were 
progressively removed, in increments of 15 degrees, from 
the sensitivity analysis. As the figure shows, such removal 
of low inclination EGMs, i.e., those for which the proximal 
electrode is near the cardiac surface, dramatically improved 
the ROC performance and the peak MCC values. For ex­
ample, removing all EGMs with an inclination of less than 
30 degrees improved the TPR and FPR over baseline by 
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0.60 to 0.91. Improvements beyond 30 degrees were only 
incremental.
Effect of Catheter Orientation with Respect to Activation 
Wave on Lesion Detection
It is generally known that variations in alignment of the 
activation wave and the bipolar electrodes can alter the shape 
and amplitude of bipolar EGMs, reducing BPAs when the 
wavefront arrives at both electrodes simultaneously. To eval­
uate the effect of this parameter on the accuracy of lesion 
detection, we employed the same strategy as in the previous 
section by successively removing from consideration EGMs 
with small ALAT values (0,1, and 2 milliseconds). As de­
scribed in the Methods section, ALAT is an indirect metric of 
alignment between activation wavefront and electrode axis. 
The fact that this metric is based on signal morphology also 
allows application to both simulated and measured EGMs 
and we included both in this evaluation.
Figure 5 shows ROC and MCC curves following removal 
of recordings with |ALAT| of < 0, 1,  and 2 milliseconds 
compared to baseline results. For both the in silico and in 
vivo models, we detected little change in overall accuracy, 
as measured by the amplitude of the associated MCC, by 
removing low ALAT values. This finding was confirmed 
visually in Figure 5 by the observation that the ROC curves 
superimposed closely for all cases. Note that in the curves 
based on in vivo measurements, we applied separately the
3.5 mm and 10 mm assumptions for injury proximity to the 
lesion.
Discussion
Voltage mapping is a valuable clinical tool for the identi­
fication of arrhythmogenic myocardial tissue. However, the 
use of bipolar EGMs introduces geometric factors that may 
cause errors in the classification of diseased and healthy tis­
sues. Previous studies have sought to determine optimal BPA 
voltage thresholds for identifying diseased tissue,1,8 but were 
unable to consider the effect of these geometric factors on 
mapping accuracy. This study systematically explored the in­
fluence of electrode inclination angle and orientation on the 
ability of voltage mapping to detect changes in the myocar­
dial substrate. Our findings elucidate possible mechanisms 
for improper classification of tissue type and suggest novel 
recording strategies that could improve voltage mapping 
accuracy.
The first factor whose role in lesion detection we inves­
tigated was the inclination angle of the catheter relative to 
the endocardial surface. Considering only BPAs recorded 
at inclinations above 30 degrees improved the quality of 
substrate classification by 51.7% (m Cc  of 0.6 to 0.91). At 
higher inclination angles, the bipolar electrode pair main­
tained common-mode rejection while reducing potentially 
confounding electric potentials sensed by the proximal elec­
trode when located nearer the cardiac surface. Our simula­
tions suggest that ensuring an inclination angle of >30 de­
grees could substantially improve lesion localization. Recent 
advances in catheter tracking and sensing, e.g., contact force 
measurement technology or real time MRI catheter tracking, 
are emerging technologies that could enable such control of 
catheter angle.20-22
The second geometric parameter we considered was the 
orientation of the catheter with respect to the activation wave­
front. Perpendicular alignment of the electrode pair with the 
direction of the activation wave front may cause artifactual 
attenuation of the bipolar amplitudes resulting in healthy tis­
sue being classified as scar.23 While such errors would appear 
to be avoidable through directed electrode placement, robust 
determination of orientation of the catheter to the activation 
wave is not currently feasible in clinical cardiac mapping. 
We attempted to use signal processing to reduce the asso­
ciated errors by identifying low-voltage bipolar EGMs with 
near simultaneous activation in their respective unipolar sig­
nals and removing them from consideration.9 Our strategy 
assumed that small ALAT EGMs would disproportionately 
produce false positive, low-voltage recordings. However, in 
both the in silico and in vivo models, the removal of small 
ALAT EGMs had a mostly harmful effect on voltage map­
ping performance. Further examination of this finding re­
vealed that small ALATs also frequently occurred when the 
catheter was at high inclination angles with respect to the 
tissue. Thus, true low-voltage EGMs recorded at higher in­
clination angles were improperly removed, because of their 
small ALATs, causing a decrease in sensitivity that offset 
any gains in specificity. While false low voltages caused by 
wavefront-EGM alignment tend to have small ALAT values, 
the reverse is not consistently true. However, these findings 
are specific to the electrode configuration and distribution 
of catheter orientations employed in this study. It is possible 
that other mapping devices, or distributions of catheter orien­
tation, e.g., both bipolar electrodes always in tissue contact, 
may reveal utility for bipolar EGM discrimination based on 
the ALAT value.
Simulation allowed precise definition of the lesion bound­
aries in the model in a way that was not possible in our 
in vivo experimental studies (see Supporting Information). 
Gross pathological evaluation from the experiments did pro­
vide confirmation of lesion presence and size, however, BPA 
varies around the boundaries of lesions in ways that still 
inhibit precise post hoc determination. To deal with such 
variations, we assumed 2 regions around the lesions (radii of
3.5 mm and 10 mm) that contained low-voltage EGMs and 
evaluated the performance of measured signals separately 
for these 2 cases. With these assumptions, we attempted to 
incorporate into the analysis the variable and unpredictable 
effects of acute factors, beyond necrosis and tissue death, that 
are known to impact the amplitude of bipolar EGMs, e.g., 
stunning and edema. As noted, performance under these 2 
assumptions was different in expected ways and provided a 
realistic basis for comparison with—and validation of—the 
results from simulations.
Calculation of MCC in this study returned a metric of ac­
curacy in the detection of lesions as a function of threshold 
voltage. Through the various permutations of parameters, 
we found that the best BPA threshold remained relatively 
stable varying from 2.0 to 2.25 mV. This consistency sup­
ports the notion that establishing a carefully chosen voltage 
threshold is both feasible and useful to classify tissue type 
in clinical practice. However, because these findings were 
based on porcine and computational models, any extension 
of these values to clinical mapping studies is limited. Rather, 
we focused on evaluating factors that affect the performance 
of any low-voltage threshold as a discriminator of tissue 
type.
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Figure 5. E ffect o fsim u lta n eo u s e lectrode activa tion  on the a ccuracy o f  voltage m apping  in s ilico  (left colum n) an d  in v ivo (right colum n). The top p a n els  in 
both colum ns conta in  R O C  curves fro m  w hich  E G M s w ith  low  A L A T  values, indicating perp en d icu la r  a lignm ent o f  the w avefront d irection a n d  the bipolar  
axis, w ere removed. The low er p a n els  contain M a tth ew 's  correlation coefficient as a fu n c tio n  o flo w -vo lta g e  threshold  f o r  the  sam e E G M s. For a h igh  quality, 
fu l l  co lor version  o f  this figure, p lea se  see Journal o f  C ardiovascular E lectrophysio logy’s w ebsite: w w w .w ileyonlinelibrary.com /journal/jce
Finally, the 3-dimensional (3-D) slab geometry we used 
is a simplified computational model that does not incorpo­
rate such factors as variation in wall thickness, or curvature 
of cardiac tissue. As such, a future step will be to incorpo­
rate more realistic geometric and tissue features into such a 
model. Even with such a simple model, we have illustrated 
in a novel way the impacts of realistic constraints of bipolar 
EGM-based cardiac mapping and validated some of those 
results with experiments. Extending the study to a more re­
alistic, 3-D geometric model is straightforward so that this 
study can also serve as a feasibility test and motivator for 
additional complexity.
Conclusion
This study explored the utility of computational mod­
els for evaluating complex clinical scenarios that cannot be 
replicated in experiments. The specific case for this study
was evaluating geometric parameters for their role in induc­
ing uncertainty in cardiac mapping. The in vivo measure­
ments provided qualitative validation of part of the simula­
tions, instilling confidence that other simulation results were 
also valid. Our findings suggest that for parameters that are 
too difficult to control in experiments, e.g., inclination an­
gle, simulation provides a tractable and powerful means to 
lend insight into the interactions of these factors. Further­
more, the results of this study support our initial hypothe­
sis that different catheter orientations substantially impact 
the accuracy of diagnostic recordings, and suggest that con­
trolling for optimal orientation would greatly improve the 
characterization of diseased myocardial substrates. Future 
confirmation of these findings could lead to improvements in 
catheter design and mapping technique. Such improvements 
in substrate characterization could extend the utility of volt­
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Figure 1. In vivo model of electroanatomical substrate 
mapping. A. Voltage maps acquired in a porcine right atrium 
pre- and postablation displaying bipolar amplitude. The pur­
ple spheres represent ablation points, all other points repre­
sent measurement sites colored according to bipolar ampli­
tude.
Figure 2. Evolution of BPA with respect to distance from 
ablation site. Left—postablation points (red) and preablation 
points (blue) are plotted based on their BPA and distance 
from the centroid of the nearest ablation site. Right—mean 
and error bars (3 standard deviations) of the pre- (blue) and 
postablation (red) voltage maps as a function of distance from 
ablation sites based on kernel regression analysis.
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Supplemental Material 
Methods: Description of Animal Model Studies
University of Utah Institutional Animal Care and Use Committee approval was obtained for all 
animal experimentation. Five juvenile swine weighing 30 to 35 kgs were sedated with a cocktail 
of Telazol 4.4 mg/kg, Ketamine 2.2 mg/Kg and Xylazine 2.2 mg/Kg intra-muscularly and were 
placed on mechanical ventilation. Anesthesia was maintained with intravenous injections of 
30-40 mg/Kg of pentobarbital. The femoral veins and arteries were accessed via cut down 
technique. 11 Fr. sheaths (St. Jude Medical, Austin, TX) were placed in the right and left femoral 
vein and were used to insert a mapping and ablation catheter. A 6 Fr. sheath was placed in the 
right femoral artery and was used for blood pressure monitoring and obtaining periodic arterial 
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Figure 1: In vivo model of electroanatomical substrate mapping. A. Voltage maps acquired in a 
porcine right atrium pre- and postablation displaying bipolar amplitude. The purple spheres 
represent ablation points, all other points represent measurement sites colored according to 
bipolar amplitude. B. Representative electrograms acquired from the same location in the right 
atrium pre- and postablation. EAM - electroanatomical map, M1 and M2 - unipolar 
electrograms from the distal and proximal electrodes of a mapping catheter, M1-M2 - bipolar 
electrogram.
Anesthetized animals were moved to the electrophysiology lab with fluoroscopy (Artis Zeego, 
Siemens USA, Malvern, PA) and a CARTO XP electroanatomical mapping system (Biosense 
Webster, Diamond Bar, CA). A non-irrigated 4 mm tip NaviStar (Biosense Webster, Diamond
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Bar, CA) catheter was used for electro- anatomical mapping. Baseline voltage maps were 
acquired and followed by the creation of two ablation lesions approximately 1 cm apart by
delivering RF energy at 30 W for 30 seconds each in a temperature-controlled mode (60° C 
cutoff). During ablation we acquired mapping points every 5 to 10 seconds to ensure the catheter 
did not move. The center of each successfully ablated regions in the electroanatomical maps was 
estimated by calculating the centroid of all points acquired during the ablation. Immediately 
following the final ablation, the entire RA was remapped with particular emphasis on the areas 
surrounding the ablation sites with 142 ± 59 (min = 72, max = 194) points acquired per map 
(Figure 1A). The bipolar amplitude, ALAT, and Euclidean distance from the nearest ablation 
lesion center were calculated for each mapping point. Following the ablation and mapping 
studies, we intravenously injected each swine with 2,3,5-Triphenyl-2H-tetrazolium chloride (2% 
TTC), which demarcates ablated and infa.rct.ed tissues by staining live tissue red12. This step was 
immediately followed by lethal injection of intravenous potassium chloride.
Methods: Estimating the Extent of Ablation Injury
Ablation of cardiac tissue is known to cause immediate changes to the electrophysiological 
properties of directly targeted regions as well as surrounding tissues. These changes include cell 
death through membrane rupture, protein denaturing, stunning, and edema, all of which are 
known to affect BPAs to some degree3-6. Due to these factors it is challenging to appropriately 
demarcate which low voltages are due to actual injury (true positives), and those that arise 
because of factors unrelated to the health of the myocardial substrate (false positives). 
Consequently, we evaluated the extent of ablation injury, first, by gross pathological examination 
of the lesion sets, and, second, by analysis of postablation BPAs surrounding the lesion sites. The 
gross pathological analysis provided a stringent bound of ablation impact within which low 
voltage BPAs were strongly expected. We selected the loose bound based on analysis of the 
spatial transition of BPAs from low to normal voltages as distance from the lesion increased. 
These two bounds (described in more detail below) characterize the range of sensitivities and 
specificities that might be achieved with voltage mapping.
Gross Pathology of Ablation Lesions Lesion formation was confirmed by gross pathological 
assessment of the RA tissue. Lesion size was recorded based on two orthogonal measurements of 
the edge to edge diameter. Specifically, we acquired photographs of each lesion set, including a 
reference metric ruler, with a digital camera (Canon,Tokyo, Japan). The image analysis software 
GraphicConverter X v7.6.1 (Lemkesoft GmbH, Peine, Germany) was used to convert pixel size 
to millimeters via the reference ruler and then measure the lesion diameter with digital calipers 
using the boundary of the TTC staining. If the lesion shape was eccentric, its two principal axes 
were measured, otherwise axis orientation was arbitrary.
Kernel Regression Analysis Low voltage BPAs in the postablation maps were observed fre­
quently beyond the anticipated burn radius (~ 3-4 mm, Figure 2). We assumed that these low 
voltages were associated with the acute but transient injury responses to ablation. To estimate the 
outer range of low voltage BPAs, we used an approach known as kernel regression which is a 
non- parametric technique for estimating the conditional expectation of a random variable78. 
Software implementations of this technique are available in the open source statistical analysis 
package, R (The R Project for Statistical Computing, http://www.r-project.org). We used kernel
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regression to analyze the relationship between BPAs (pre- and postablation) and the site of EGM 
acquisition relative to the lesion center. The mean BPA and ± 3 standard deviations were 
calculated for the pre- and postablation maps and the distance at which the respective error bars 
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Figure 2: Evolution of BPA with respect to distance from ablation site. Left -  Postablation 
points (red) and preablation points (blue) are plotted based on their BPA and distance from the 
centroid of the nearest ablation site. Right -  Mean and error bars (3 standard deviations) of the 
pre- (blue) and postablation (red) voltage maps as a function of distance from ablation sites 
based on kernel regression analysis. The 3.5 mm cutoff represents the mean radius of lesions as 
measured by gross pathology. The 10.0 mm cutoff is the point at which the pre- and post 
ablation error bars cross in the kernel regression analysis.
Results: Animal Model
We performed electroanatomical mapping, ablation, and gross pathological analysis in all 
animals. There were no low voltage regions, i.e., areas with multiple, closely spaced low voltage 
recordings, in the preablation mapping of the swine right atria. The mean preablation bipolar 
amplitude was 4.74 ± 2.62 mV (n = 666). Following ablation, low voltage BPAs were observed 
in proximity to all attempted ablation sites (for an example, see Figure 1B). The mean diameter 
of all lesions was 7.3 ± 1.6 mm (n = 20 measures of 10 lesions, max = 10.1 mm, min = 4.5 mm). 
The lesions were mostly circular in shape with only one lesion presenting an anisotropy ratio 
greater than 2:1. Reasoning that tissue directly targeted by ablation would have the greatest 
likelihood of displaying low BPAs we estimated these regions based on the mean radius of the 
lesions from the gross pathological analysis and chose 3.5 mm from the lesion center as the 
stringent boundary. BPAs acquired within the stringent bound showed significantly lower 
voltages, 0.84 ± 1.64 mV (n = 78), than EGMs acquired outside the 3.5 mm stringent bound 
(3.38 ± 2.58 mV, n = 632). Figure 2 illustrates the spatial transition of post-ablation BPAs from 
low voltage at points near ablation centers to normal voltage at points remote from ablation. The
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error bars (± 3 standard deviation) of the pre- and postablation kernel regression plots intersected 
at 10 mm from the lesion center. We selected this distance as the loose bound for the expectation 
of low voltages surrounding an ablation lesion. BPAs within the loose bound (10.0 mm from the 
lesion center) had significantly lower voltages (1.78 ± 1.71 mV, n =351), than bipolar EGMs 
acquired outside the 10 mm threshold (4.39 ± 2.71 mV, n = 359).
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CHAPTER 6
CONDUCTION VELOCITY M APPING
Many metrics of electrogram morphology used for substrate mapping are indirectly 
associated with mechanisms of arrhythmogenesis. For example, low voltage electrograms 
likely indicate scarred or otherwise abnormal tissues, but in many cases, scarring can have 
an anti-arrhythmogenic affect, as seen with scarring created during ablation procedures. 
Conduction velocity (CV) is an electrophysiological measure that is directly related to 
arrhythmogenic mechanisms (see Section 2.2.4). However, in current clinical practice, there 
are no established techniques for robust characterization of CV properties. This inability to 
robustly characterize CV properties of the cardiac substrate is primarily attributable to the 
anisotropic nature of conduction in the heart. In other words, recording of sinus activation in 
the heart cannot elucidate the anisotropy of conduction. In experimental studies, conduction 
anisotropy is measured by pacing from dense electrode arrays or measurement systems from 
which the spread of activation can be captured. Although clinical systems are capable of 
pacing-based stimulation of the myocardium, current clinical multielectrode arrays lack 
sufficient spatial sampling density to fully characterize the spread of an activation impulse 
away from the pacing site. This chapter presents novel approaches we have developed 
to facilitate robust CV property characterization with a clinical loop catheter using a 
repetitious stimulation and recording protocol. A final hinderance that this paper addresses 
is an approach for normalization of CV measures from multiple stimulus sites to account 
for variations in the CV properties that occur as an activation impulse moves away from a 
stimulus site, i.e., an increase in CV as the wavefront curvature decreases. This work was 
presented as a conference paper in the proceedings of Computing in Cardiology 2014 [172]. 
It is presented here in its published form with permission.
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Abstract
Ectopic activation and conduction may give rise to ar­
rhythmias when a diseased myocardial substrate exists. 
Electrophysiological mapping studies that record electri­
cal properties of the heart in sinus rhythm may fail to un­
cover pro-arrhythmic substrates that are triggered by ec- 
topy. In this study we use simulation and experimental 
models of clinical, trackable, loop catheters to interrogate 
regions of myocardium by stimulating and recording with 
multiple activation patterns. Longitudinal and traverse 
conduction velocities of the tissue were acquired from the 
pacing protocol. Artifacts resulting from variable distance 
between the recording electrodes and pacing site were also 
detected and removed. This study demonstrates that the 
mapping o f local tissue properties with variable activation 
patterns is feasible and can expose features o f the electro- 
physiological substrate that can not be recovered during 
sinus conduction.
1. Introduction
The onset and entrenchment of atrial fibrillation (AF) is 
strongly associated with remodeling of the atrial myocar­
dial substrate. As a results, as remodeling progresses, ab­
lation strategies based solely on compartmentalization lose 
efficacy. Consequently, great clinical interest has centered 
on substrate mapping strategies that can identify proar- 
rhythmic tissues for targeted therapy. In this scenario in­
tracardiac electrogram (EGM) parameters such as voltage 
amplitude and presence and degree of fractionation are 
employed as markers of tissue with abnormal conduction 
properties [1,2]. However, traditional mapping strategies 
for AF, whether recorded in sinus rhythm or AF, have ne­
glected the effect of variable activation patterns on EGM 
parameters of interest.
A key feature of an ectopically triggered beat in the 
heart is that the resulting activation does not follow the 
same conduction patterns as a normal sinus beat. Thus, 
it is even conceivable that sinus conduction may mask the 
remodeled and pro-arrhythmic substrates that can only be
exposed by extrasystole. In this study, we demonstrate the 
feasibility of mapping electrophysiological substrate fea­
tures using varied activation patterns by pacing and record­
ing within the same region of heart using a clinical loop 
catheter.
To demonstrate the feasibility of substrate mapping with 
controlled activation patterns, we selected conduction ve­
locity (CV) as our initial parameter of interest. Conduction 
velocity is an important factor in the initiation of re-entry 
and is affected by substrate remodeling (heterogeneity and 
slowing) [3]. We explored factors associated with mea­
surement of CV in this manner, and evaluated the infor­
mation such measurements provide about myocardial sub­
strate.
Figure 1. Anisotropic conductivity model of excitation 
propagation initiated by loop catheter pacing. Extracellu­
lar potential of this model is shown 10 ms after the start 
of pacing from the white hexagonal region. The purple 
spheres indicate the position of recording electrodes. The 
black arrows indicate the fiber orientation of the model.
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Figure 2. Characterization of local conduction properties with loop catheter. Left Column -  Vectors at recording electrodes 
(purple spheres) point away from pacing site. Length and color correspond to conduction velocity (CV). Center Colum -  
CV vectors normalized to fixed distance from pacing site. Right Column -  Compact representation of regional conduction.
2. Methods
This study incorporated computation modeling and di­
rect recording of electrograms in large mammal experi­
ments. In both cases, a pacing protocol involving stimu­
lation from bipolar electrodes on a 10 pole loop catheter 
was performed to interrogate the conduction properties of 
the tissue. Specifically, a depolarization wave was acti­
vated by pacing from each pair of adjacent electrodes on 
the loop catheter, i.e., 1-2, 2-3,...,9-10, to stimulate the 
region contained by the loop with 9 different activation 
patterns. EGMs from the non-pacing electrodes were ac­
quired for each activation pattern and from them, activation 
times were determined from unipolar EGMs by computing 
the maximum negative slope, or from bipolar EGMs by a 
nonlinear energy operator [4]. CV was calculated as the 
distance, from the pacing site to the recording electrode, 
over the time to activation. CVs and directions from the 
respective studies were visualized using SCIRun[5].
2.1. Simulation
We implemented a 3-dimensional bidomain simulation 
of the spread of activation from pacing sites on slab 
models of atrial tissue with the Cardiac Arrhythmia Re­
search Package (CARP) software [6]. The models were 
a 26.0x26.0x3.0 mm slab composed of isotropic hexa- 
hedral elements with 0.1 mm edge length immersed in
1.0 mm of bath surrounding all slab surfaces. For each 
activation pattern, we computed complete activation of the 
slab using the Courtemanche-Ramirez-Nattel cell model of 
atrial myocyte kinetics [7]. Pseudo-EGMs were generated 
at each electrode (1 kHz sampling frequency) for the entire 
50 ms of simulation. Model conductivities were varied to 
produce both isotropic and anisotropic models (Figure 1).
2.2. Characterization of Conduction
The relationship between conduction velocity and the 
distance of the recording electrode from the pacing site 
was plotted and fit by linear regression. The slope of this 
regression was then used to normalize all CVs as though 
they had been recorded 20 mm from the pacing site.
CVs and their respective directions of conduction were 
compared to the fiber orientation of the computational 
models. Specifically, the angle between the fiber axis and 
directions of minimum and maximum conduction velocity 
were qualitatively assessed for correlation.
2.3. In Vivo Experimentation
The feasibility of pacing and recording from a sin­
gle loop catheter for assessment of conduction velocities 
was tested during experimentation on a single canine. A 
10 pole trackable circular mapping catheter (Lasso Nav, 
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Figure 3. Linear regression of CV versus distance of the 
recording electrode from the pacing site. The slope for the 
anisotropic (top), isotropic (center) computational models, 
and in vivo model (bottom) was used to normalize all CV 
measurements to 20 mm from the pacing site.
the right atrium via percutaneous access of the femoral 
vein. The electrode array was placed in the high right 
atrium on the lateral wall and positioned such that clear 
EGMs were visible on all channels. Pacing was achieved 
with 600 ms cycle length, 10 mA, and 2 ms pulse width 
stimulation. Myocardial capture was confirmed then lo­
cation and electrogram recordings were acquired with a 
CARTO 3 electrophysiological recording system.
3.1. Simulation
Activation times were found for all loop catheter elec­
trodes in the computational model. CV and the direction 
of conduction were plotted as color-mapped vectors over 
the model (Figure 2, Left column), where both the color 
and magnitude correspond to the CV. In both the isotropic 
and anisotropic models CVs measured from electrodes in 
proximity to the pacing site showed slower CVs than ob­
served at distant recording electrodes.
3.2. Characterization of Conduction
Figure 3 shows a linear regression of conduction ve­
locity as a function of conduction distance. In the cen­
ter column of Figure 2, the CVs are normalized to a 
fixed distance (20 mm) by the slopes of the respective re­
gressions. In the isotropic model (top row of Figure 2) 
the pre-normalization vectors (leftmost column) demon­
strate anisotropy of CVs inconsistent with the spread of 
activation in the model. The normalized vectors (mid­
dle column), in contrast, indicate a uniform spread of ac­
tivation that is consistent with the model conductivities. 
Anisotropy is apparent before normalization in the CVs of 
the anisotropic model, however, the CVs from electrode to 
electrode are inconsistent, even when oriented in the same 
direction, due to variable proximity of the recording elec­
trodes to the paced sites. The normalization improves the 
consistency of CVs among vectors pointing in the same di­
rection (visible in the center and right column of the second 
row of Figure 2). In the anisotropic model, the direction of 
highest CV lay along the fiber orientation (see Figure 1). 
As a compact representation of the conduction properties, 
the normalized vectors from each recording site were pro­
jected onto a point at the center of the loop catheter (Fig­
ure 2, right column).
3.3. In Vivo Experimentation
The pacing protocol to stimulate myocardial tissue with 
multiple activation patterns was successfully carried out at 
2 locations in the canine model. Activation times were 
acquired on a median of 5 (min = 3, max = 6) bipolar 
channels for each pacing site. The number of interpretable 
EGMs was limited due to pacing artifact that saturated 
channels near the pacing site or by channels with no de­
tectable activation signals. Similar to the simulation re­
sults, CV also increased with distance of the recording 
electrode from the pacing site. Figure 4 shows the result of 
normalizing and plotting CV vectors from measurements 










Figure 4. Compact representation of inter-loop conduction 
properties of right atrium at two sites. Both sites were in­
terrogated with multiple activation patterns by bipolar pac­
ing between electrodes around the loop. Normalized CV 
vectors indicate direction and velocity of conduction.
4. Discussion
Our study based on simulation and animal experimen­
tation shows that interrogation of regions of myocardium 
with multiple activation patterns can elucidate basic con­
duction properties of that tissue, e.g., CV and anisotropy, 
in a way that corrects for possible artifacts from the loca­
tion of the pacing cite. The results of such evaluations of 
the myocardial substrate may be useful to establish patient 
specific ablation strategies for arrhythmias like AF.
The rate of conduction from a focal pacing site is not 
constant even in the immediate area around the pacing 
site, and increases as the depolarization wave propagates 
outward [3]. Consequently, electrodes in proximity to the 
pacing site will observe relatively slower conduction than 
distant electrodes. The normalization by distance we pro­
pose allows for inter-electrode comparison of CVs and im­
proves the characterization of local conduction properties. 
The maximum conduction distance for these models was 
about 20 mm and the acceleration of conduction remained 
relatively constant over these distances.
Previous studies have reported using loop catheters to 
record CV from planar wavefronts during sinus conduction 
[8], however, their results have been indicative of conduc­
tion in the longitudinal direction only, i.e., parallel to the
predominate fiber orientation. More generally, wavefronts 
initiated by local pacing have longitudinal and transverse 
aspects that permit characterization of the anisotropy of 
conduction. The findings of this study demonstrate how 
both longitudinal and transverse CVs may be recovered 
with this protocol.
The primary tenet of this controlled activation pattern 
mapping protocol is that sinus conduction is inherently 
stable and not prone to arrhythmogenesis. Thus, elec- 
troanatomical substrate mapping of tissue properties dur­
ing sinus rhythm may fail to identify pro-arrhythmic sub­
strates that are unmasked by ectopy and non-sinus conduc­
tion. However, this protocol is a preliminary effort and fur­
ther considerations, e.g., CV restitution, may be required to 
robustly identify tissues with arrhythmogenic conduction 
properties. Robust characterization of the atrial conduction 
substrate may facilitate better understanding of the mech­
anisms behind AF initiation and provide better targets for 
therapeutic interventions.
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The Mean Laplacian EGM study is closely related to the previous chapter. As previously 
discussed, conduction velocity (CV) and the anisotropy of conduction are important indica­
tor of proarrhythmic potential. One pervasive limitation of CV measurement, however, 
is the necessity of determining activation times for every electrode measuring impulse 
propagation. This study presents a novel strategy for measuring CV and conduction 
anisotropy, without the requirement of activation time assignment, by assessing the mean 
Laplacian electrogram as computed over a clinically feasible electrode array.
7.1 Abstract
The velocity and anisotropy of conduction are important parameters when evaluating 
pro-arrhythmia risk. However, methods to quantify these parameters in a fast and reliable 
way are not currently available in the clinical electrophysiology laboratory.
The purpose of this study was to develop a method that allows for fast and reliable 
estimation of cardiac conduction and anisotropy.
Experimental data were obtained by electrical mapping of isolated guinea pig hearts 
using a multi-electrode array. Computer simulations were performed in a 3-dimensional 
bi-domain model incorporating tissue anisotropy. For both experimental and simulated 
data, conduction velocities (CV) and anisotropy were calculated and compared to distinct 
features of the mean Laplacian electrogram (MLE) which is a spatial average of Laplacian 
electrograms.
The QRS region of the MLE showed two distinct peaks. In animal experiments, the 
temporal locations of the peaks were sensitive to pharmacological manipulation of conduc­
tion. Importantly, the first and second peak correlated well with longitudinal (r=-0.52) 
and transverse (r=-0.82) CV, respectively. The simulations demonstrated that the MLE 
was dependent on the angle of rotation of the electrode array relative to fiber orientation. 
Mathematical analysis resulted in an optimized array design without rotational dependence.
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The simulations were further used to link the morphology of the optimized MLE to the 
spatial development of the wavefront, resulting in highly accurate descriptors of longitudinal 
and transverse CV as well as anisotropy.
We have developed a novel signal, the mean Laplacian electrogram, that enables fast 
and reliable estimation of conduction velocity and anisotropy.
7.2 Introduction
The conductive properties of cardiac tissue are an important part of the arrhythmogenic 
substrate. Various diseases, e.g. ischemia, infarction, and fibrosis, alter the conductive 
properties of the myocardium creating favorable conditions for ectopy and reentry [84, 
173, 174]. Specifically, cardiomyopathies that cause a decrease in conduction velocity (CV) 
favor arrhythmogenesis by decreasing the critical wavelength necessary to foster reentry [53]. 
However, the CV of an excitation wave moving through myocardial tissue will depend on 
the alignment of the wave direction and the underlying orientation of the muscle fibers [39, 
40, 175]. Conduction along the fiber direction (longitudinal) will progress much faster than 
conduction across the fibers (transverse). Although this anisotropy is a normal feature of 
cardiac conduction, abnormal anisotropy may result in conduction block and the generation 
of reentrant arrhythmias [176, 177, 178].
Changes to the anisotropy of CV have been observed with aging and in conjunction with 
cardiomyopathies that promote microfibrosis and remodeling of gap junction expression 
and localization [179, 135]. In the experimental laboratory, multidetector arrays, e.g., 
plaque electrodes or optical mapping systems, facilitate the creation of activation maps 
at high temporal and spatial resolution that track the spread of activation through the 
myocardium [58]. Such approaches allow calculation of longitudinal CV (CVL), transverse 
CV (CVT), and thus anisotropy [33]. However, these techniques are not easily adaptable for 
clinical use. Currently, no technique is available that allows for fast and reliable estimation 
of CV and anisotropy in clinical EP studies. Robust clinical characterization of CV and 
anisotropy during minimally invasive electrophysiology (EP) studies would be a valuable in 
characterizing proarrhythmic substrates in patients.
Laplacian electrograms (LEs) are typically computed from a grid of unipolar electrodes 
(UEs) in an approximation of the second order spatial gradient of the surface potential, 
which results in a local estimate of current sources or sinks [84]. One consequence of this 
approximation is that potentials from remote sources are cancelled out and only the local 
information is preserved, allowing for robust detection of cardiac activation times [59, 32]. 
From these complementary features, we speculated that a signal based on spatial averaging
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of LEs might provide information about the local spread of activation and anisotropy of 
CV.
Here, we describe a novel method to combine information from a grid of UEs into 
a single signal, the mean Laplacian electrogram (MLE). We explore the hypothesis that 
distinct features of the QRS region of the MLE signal correlate directly with local cardiac 
conduction velocities in the underlying tissue. We also perform computer simulations in 
order to elucidate the electrophysiological underpinnings of the signal.
7.3 Methods
All animal procedures were carried out according to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996) and were approved by the Institutional Animal Care and Use 
Committee of the University of Utah (Protocol No. 09-09008).
7.3.1 E xperim en ta l P roced ures
The experimental procedure has been described in detail previously [180]. Briefly, 
Langendorff perfused guinea pig hearts were electrically mapped by recording UEs from 
the anterior epicardial surface. The recording electrodes were ordered in a regular 8 by 
8 grid with 2 mm interelectrode spacing. One of the four central electrodes was used to 
pace the heart at a cycle length of 300 ms. The signals were high- and low-pass filtered at 
0.03 and 500 Hz, respectively, and digitally sampled at 4 kHz. Hearts were perfused with 
a solution consisting of 1.25 mM CaCl2, 140 mM NaCl, 4.5 mM KCl, 5.5 mM dextrose,
0.7 mM MgCl2, and 10 mM HEPES (pH 7.4). Conduction was slowed by adding either 1 
^M flecainide (USP, Rockville, MD) or 30-50 ^M carbenoxolone (Sigma-Aldrich, St. Louis, 
MO) to the perfusate.
7.3.2 Sim ulation  P roced ures
All simulations were performed using a 3-dimensional bidomain slab model of electrically 
anisotropic myocardial tissue created using the SCIRun problem solving environment [181] 
and implemented using the Cardiac Arrhythmia Research Package (CARP) software [20]. 
The dimensions of the slab were 26x26x3 mm and it was composed of isotropic hexahedral 
elements with 0.1 mm edge length immersed in 1.0 mm of bath solution surrounding all 
slab surfaces. The excitable properties of the model were based on the cellular model of 
Courtemanche et al. [24] Conduction velocity and anisotropy were varied by scaling the 
longitudinal and transverse conductivities independently. Extracellular potentials corre­
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sponding to UEs were computed at different locations and evaluated at a sampling rate of 
1 kHz.
7.3.3 D a ta  A nalysis
Conduction velocities (CV) were calculated based on activation time maps as described 
previously [180]. Local Laplacian potentials were calculated according to Janse et al. [84] 
with the exception of a unit conversion. Local Laplacian electrograms (LE) were calculated 
for electrodes for which there were at least 7 surrounding electrodes that could be included 
in the calculation. This restriction excluded the outermost electrodes in the grid and the 
pacing electrode, resulting in a total of 35 LEs. The 35 LEs were then averaged to obtain 
a single signal, which we refer to as the mean Laplacian electrogram (MLE). The temporal 
locations of the two separate peaks in the QRS region of the experimentally measured MLE 
were parameterized by the time to peak onset (TP) of each peak. By analogy to activation 
time assignment in a UE, the TP was defined as the time from the pacing artifact to the 
maximum negative downstroke of the relevant peak (Fig. 7.1 C).
7.3.4 S ta tistica l P rocedures
All statistical calculations were performed using R (v3.0.2; http://www.R-project.org), 
specifically the functions ‘stats’ (v3.0.2), ‘boot’ (v1.3-9), ‘smatr’ (v3.4-3) and ‘simple- 
boot’ (v1.1-3). The correlation between the two measures of conduction (CV vs TP) was 
quantified using the sample Pearson correlation coefficient (r). Bootstrap distributions 
of the r-values were generated based on 5000 bootstrap replicates and 95 % confidence 
intervals (CI, bias-corrected and accelerated) were estimated. A correlation was deemed 
significant if the CI did not include 0 and was labeled according to the r-value as very strong 
(r>0.8), strong (0.8>r>0.6), moderate (0.6>r>0.4), or weak (r<0.4). For experimental 
data, differences in means were compared using Welch’s t-test. Unless otherwise specified, 
experimental data are summarized by the mean and standard deviation (SD). For the 
simulation data, CV estimates obtained with the standard vector based approach were 
compared directly with the MLE approach by means of a type II linear regression (major 
axis) analysis [182] and 95 % CIs were estimated for the fitted parameters (slope and 
intercept). If the CI for the slope included 1, it was taken to indicate no significant bias 
between variables.
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Fig. 7.1. Representative unipolar, Laplacian, and mean Laplacian electrograms. A. 
Example of an MLE recorded from the ventricles of a guinea pig heart during three paced 
beats is shown. Asterisks indicate the pacing stimuli. The QRS complex and T-wave 
of the second beat are labeled. B. Unipolar, Laplacian and Mean Laplacian electrograms 
corresponding to the boxed region in A are shown on an expanded timescale for comparison. 
Note the distinct two peaks in the MLE. C. Illustration of the quantification of the temporal 
location of the peaks in the MLE. See details in the text.
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7.4 Results
7.4.1 Q uantification  o f C on d u ctiv ity  from  th e  M LE
The aim of this study was to develop a novel and reliable estimate of conduction velocity 
and anisotropy in cardiac tissue that can be implemented in the clinical EP laboratory. To 
this end, we have explored the properties of the mean Laplacian electrogram (MLE), which 
is the average of multiple LEs. Fig. 7.1 A shows an MLE recorded from a guinea pig heart 
during epicardial pacing from the center of the recording array. A total of three beats are 
shown and it can be seen that the MLE displays recognizable deflections similar to a QRS 
complex and a T-wave. Fig. 7.1 B shows the QRS region of a representative UE, the LE 
for the same electrode, and the resulting MLE for comparison. The MLE displays two very 
distinct downward deflections which we refer to as peaks. As a first step to understand the 
origin of the peaks in this spatially averaged signal, the temporal locations of the peaks were 
quantified by the time to peak onset (TP) defined as the time from the pacing artifact to 
the maximum negative downstroke of the peaks. Thus, TP1 and TP2 refer to the temporal 
locations of the first and second peak, respectively.
As the LE represents local current singularities (positive deflections are current sources 
and negative deflections are current sinks) in the tissue underneath the recording electrode, 
we surmised that the peaks in the QRS region of the MLE represented the major current 
sinks in the tissue under the recording array. This leads to the hypothesis that the 
peaks are representative of the principal components of current flow in the tissue and thus 
that their temporal location would be sensitive to changes in CV. To test this hypothesis 
experimentally, we pharmacologically slowed conduction using flecainide, a sodium channel 
blocker, or carbenoxolone, a gap junction uncoupler, in guinea pig hearts. Fig. 7.2 A shows 
activation time isochrone maps from a representative heart recorded under control (top) and 
flecainide (bottom) conditions. Conduction slowing in the presence of flecainide is evident 
from the closer spacing of the isochrones compared to the control. The corresponding MLEs 
are shown in Fig. 7.2 B and, in line with our hypothesis, the temporal locations of both peaks 
are shifted to the right. Next, we investigated whether the temporal location of the peaks 
correlated with transverse and longitudinal components of conduction velocity. In Fig. 7.2 C, 
CVL is plotted against TP1 (open squares) and CVT is plotted against TP2 (filled squares) 
for control (n=15), flecainide (n=5), and carbenoxolone (n=8) conditions. Importantly, for 
the correlation analysis to be valid, data values need to be independent so that the analysis 
presented in Fig. 7.2 C includes only unpaired data. For the same reason, longitudinal and 
transverse data were analyzed separately. For CVL versus TP1, the correlation coefficient
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Fig. 7.2. Conduction velocity and anisotropy correlates with features of the MLE. A. 
Representative activation time isochrone maps recorded from a guinea pig heart under 
control or flecainide conditions. The closer spacing of isochronal lines with flecainide 
demonstrates slowing of conduction. B. MLEs corresponding to the maps in A. Note that 
the temporal location of both peaks are shifted to the right as indicated by the shift in TP1 
and TP2. C. Plot of CV calculated from the maps in A versus TP1 (for longitudinal CV) and 
TP2 (for transverse CV). The corresponding correlation coefficients and CIs are indicated.
D. Plot of anisotropy based on CV versus anisotropy based on TP. The corresponding 
correlation coefficients and CIs are indicated. Please note that the regression lines (ordinary 
least squares regression) in C and D are for visual purposes only.
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was moderate (r=-0.52 (CI -0.15-0.76)) while correlation between CVT and TP2 was 
strong (r=-0.82 (CI -0.74-0.92)). The relationship between CV anisotropy (ratio of CVL 
to CVT) and the ratio of TP1 to TP2 is shown in Fig. 7.2 D. Although the correlation was 
only moderate (r=-0.42 (CI -0.17-0.62)), which is likely due to the variation in TP1 (see 
Fig. 7.2 C), it is significant and supports the hypothesis that the peaks in the QRS region 
of the MLE capture the conductive properties of the tissue.
To evaluate whether the MLE-derived measurements could also be used to detect conduc­
tion slowing directly, we performed a comparison of experiments in which paired data (n=13) 
were available for both control and pharmacologically slowed conduction. First, evaluating 
conduction velocity in the standard way, significant reductions of 21±6% (p<0.001) and 
30±10% (p<0.001) were detected for CVL and CVT, respectively (Fig. 7.3) A). These 
numbers compared well against changes in TP1 and TP2 of 20±18% (p=0.003) and 40±20% 
(p<0.001), respectively, demonstrating that the MLE can be used to detect conduction 
slowing (Fig. 7.3 B).
Fig. 7.3. Detection of conduction slowing. The graphs show paired comparisons of 
longitudinal CV (A), transverse CV (B), TP1 (C), and TP2 (D) under control conditions and 
under conditions of pharmacologically induced conduction slowing. P-values from Welch’s 
t-test are indicated.
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7.4.2 R ep rod u ction  o f th e  M LE by C om puter S im ulations
To better understand the electrophysiological origin and meaning of the MLE, we 
performed computer simulations of a slab model of cardiac tissue and reconstructed the 
signals from a 8x8 electrode grid similar to the one used in the ex vivo experiments. 
Fig. 7.4 A (top panel) shows the activation time map from a representative simulation 
and corresponding MLE with the electrode array rotated in two different angles with 
respect to fiber orientation (denoted 0 and 45 degrees, top and bottom panels, respectively). 
Interestingly, for the 0 degree orientation, which is very close to the orientation of the 
array in the ex vivo measurements, the reconstructed MLE similarly displayed two distinct 
peaks. However, rotation of the electrode array resulted in a more complex morphology 
of the MLE. As the reason for this rotational dependence was not immediately clear, we 
reexamined the mathematics behind the calculation of the MLE. Since each individual LE 
is calculated using a 3x3 coefficient stencil (Fig. 7.4 B) the LE can effectively be considered 
a weighted linear combination of the nine electrodes included in the stencil. Consequently, 
as the MLE is a simple spatial average of the LEs, it too can be obtained directly from 
a linear combination of electrodes. Thus, instead of calculating the MLE as the average 
of 35 LEs, the corresponding mathematical expression can be rearranged and simplified 
substantially (see Supplemental Material). The resulting expression can be organized in a 
matrix representation including all electrodes on the grid. The equivalent 8x8 coefficient 
stencil is shown in Fig. 7.4 C. Interestingly, the stencil revealed that the central electrodes do 
not contribute to the MLE (coefficients of zero) and that there is a markedly heterogeneous 
contribution among the electrodes with non-zero coefficients. This unequal contribution of 
especially the corner electrodes explains the rotational dependence of the MLE based on 
the 8x8 electrode array.
7.4.3 D evelop m en t o f a C lin ically  A d ap tab le  E lectrod e C onfiguration
For clinically practical purposes, it would be advantageous to derive a circular configura­
tion of the electrodes, as such a design can more easily be implemented in a catheter-based 
solution than a rectilinear grid.
A potential solution can be obtained by considering only the electrodes with non-zero 
coefficients in the stencil shown in Fig. 7.4 C. Conceptually, these non-zero electrodes are 
identical to two squares with electrodes along the sides: An outer square with electrode 
coefficients of positive sign and an inner square with electrode coefficients of negative sign. 
Transforming the shape of the squares into two concentric circles results in a design similar to 
the one shown in Fig. 7.5. In Fig. 7.5 A, the localization and coefficients of two concentric
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Fig. 7.4. Reconstruction of the MLE in a bidomain simulation of conduction. A. 
Representative simulated activation time maps and corresponding MLEs with the 8x8 
recording array rotated at different angles with respect to fiber orientation. Notice the 
fractionation of the MLE as the array is rotated 45 degrees. B. Matrix representation of the 
3x3 coefficient stencil used to calculate the Laplacian electrogram for each of the 36 central 
electrodes. C. Matrix representation of the equivalent 8x8 coefficient stencil of the MLE. 
Notice the resulting cancellation of the central coefficients and the heterogenous weight of 
the corner coefficients.
rings (dual ring array) with 20 electrodes each are indicated along with the formula for 
calculating the corresponding MLE. The resulting MLE can be calculated as the sum of the 
potentials recorded on the outer ring minus the sum of the potentials recorded on the inner 
ring. Potentially, such an electrode configuration can be implemented on a fixed diameter 
circular recording catheter, as suggested on the diagram in Fig. 7.5 B.
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Fig. 7.5. Representation of the revised rotationally independent recording configuration. A. 
The recording electrodes are organized in two concentric rings of different diameter (Dual 
Ring Array). Analogous to the coefficient stencil in 4C, the electrodes on the inner ring 
have a negative coefficients (-1) and the electrodes on the outer ring positive coefficients 
(+1). The corresponding MLE is calculated by subtracting the sum of the inner electrodes 
(0i) from the sum of the outer electrodes (0o) as indicated by the formula. B. Tentative 
design of a fixed diameter recording array with the inner and outer electrodes placed on the 
same ring.
We turned again to simulations to evaluate the dual ring array (DRA) configuration. A 
representative simulated activation time map is shown in Fig. 7.6 A with the DRA electrode 
configuration overlaid. The corresponding MLE, calculated using the formula in Fig. 7.5 A, 
is shown in Fig. 7.6 B. In contrast to the MLE based on the 8x8 grid configuration, the 
two peaks are much less distinct. A first major peak can easily be recognized. However, 
a second peak is hard to discern with confidence. This was not entirely unexpected as the 
distinct peaks were a feature of the heterogeneous coefficients assigned to the electrodes 
on the 8x8 grid (Fig. 7.4 C). To improve the interpretation of the features of the MLE 
signal, we compared the temporal evolution of the signal to isopotential maps during the 
first 25 ms of the simulation. The comparison showed that the location of the major peak 
(P1) corresponded to the time when the propagating wavefront first passed the outer ring 
electrodes (Fig. 7.6 C) longitudinally relative to the fiber direction. Similarly, a second 
peak (P2) coincided with the end of the wavefront passing the last of the inner electrodes 
(Fig. 7.6 D) transverse to the fiber orientation. As the end of the wavefront passed the last 
electrodes on the outer ring, the MLE crossed the isoelectric line (Fig. 7.6 E; zero crossing 
(ZC)) also along the transverse direction. Importantly, knowing the exact location of the 
wavefront and thus the distance from the pacing site corresponding to these MLE landmarks 
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Fig. 7.6. Simulation of MLEs based on the Dual Ring Array. A. Simulated activation time 
map with the position of the DRA electrodes indicated. B. The MLE corresponding to the 
map in A. The temporal location of the first and second peaks as well as the zero crossing 
are indicated. C-E. Isopotential maps corresponding to the time points of the first peak 
(C), the second peak (D), and the zero crossing (E). The arrows point to the electrodes 
closest to the propagating wavefront at each time point. The pacing site is indicated as a 
larger dot in the center of the maps in C-E.
We performed a series of 20 simulations in which longitudinal and transverse conductivi­
ties were varied to produce a range of conduction velocities . The simulations were repeated 
with DRA configurations of 10, 15, and 20 electrodes on each ring as well as at three angles of 
rotation for each DRA configuration. For CVL versus P1, CVT versus P2, and CVT versus 
ZC, the correlations were quantified for each angle of each DRA configuration, giving a total 
of 9 correlation coefficients for each combination. Fig. 7.7 A shows the resulting correlation 
coefficients. The graph demonstrates that P1 and ZC consistently correlate very strongly 
with the traditional measures of CV (r>0.95 for all correlations) while P2 is less reliable. 
In general, it was more difficult to identify the second peak in the MLEs while the first 
peak and the zero crossing were easily identified, which is reflected in the variability of 
the correlation coefficients. Importantly, for the best performing MLE landmarks, P1 and 
ZC, the correlations were fairly insensitive to both the number of electrodes and angle of
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Fig. 7.7. Comparison of CV and anisotropy estimates for the DRA-based MLE and 
activation time map methods. A. Plot of correlation coefficients describing the relationship 
between CV calculated from activation time maps versus different features of the MLE. The 
dotted line indicates r=0.95. P1, first peak. P2, second peak, ZC, zero crossing. B-D. Plots 
of the relationship between CV calculated from activation time maps versus CV calculated 
from the MLE for longitudinal CV (B), transverse CV (C), and conduction anisotropy (D). 
The solid lines represent the type II (major axis) regression line. The line slope and the 
corresponding CI is indicated for each regression.
rotation. For both P1 and ZC, we further performed a type II linear regression to estimate 
the potential bias in CV compared to the traditional method of CV estimation (Fig. 7.6 B 
and C). Compared to CVL and CVT, P1 and ZC respectively showed no significant bias,
i.e., the slope of the regression line was not different from 1 (P1, slope=0.91 (CI 0.80-1.04); 
ZC, slope=0.98 (CI 0.91-1.06)). Additionally, the ratio of P1 to ZC estimates of CV 
also correlated very strongly with CV anisotropy (ratio of CVL to CVT) (r>0.95 for all 
correlations) and showed no significant bias (slope=1.10 (CI 0.98-1.25), Fig. 7.6 D). Taken 
together, the simulation results indicate that the DRA based MLE can be used to robustly 
estimate longitudinal and transverse conduction velocities and the resulting anisotropy from 
a single signal without the need of assigning activation times to multiple individual UEs.
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7.5 Discussion
The MLE is a novel strategy for extracting fundamental features of action potential 
propagation in cardiac tissue. The estimation of CVs through pacing and activation map­
ping has been extensively studied in clinical and experimental settings [39, 33, 41] and one 
persistent complication is the difficulty of assigning activation times to complex and/or noisy 
UEs. Using high-resolution plaque electrodes permits the application of signal processing 
techniques, such as computation of LEs, after which activation times can be more readily 
determined [59, 32]. However, plaque electrodes and high-resolution mapping both present 
challenges for routine clinical electrophysiology procedures. Similarly, the measurement of 
both CVL and CVT to estimate conduction anisotropy is theoretically feasible using current 
multielectrode mapping systems. However, the addition of multiple channels from which 
activation times must be determined and then analyzed as a whole to compute CVL and 
CVT compounds the previous problem making clinical adoption prohibitive, and as yet 
unrealized. The approach of the MLE permits rapid characterization of electrophysiological 
features of impulse propagation over the spatial domain of the mapping array.
Our analysis of the experimental data demonstrates that the morphological features 
of the MLE are closely related to discrete events in the propagation of excitation that 
occurs following local pacing of the myocardium. The temporal location of the two primary 
peaks appear to correlate well with longitudinal and transverse components of conduction. 
The computer simulations were able to reproduce our experimental data and added the 
finding that the MLE morphology was heavily dependent on the rotation of recording 
array with respect to fiber direction. By serendipity, this aspect was not identified in 
the experimental data, very likely due to a fairly robust placement of the array in all of the 
experiments. We were able to trace the source of the rotational dependence mathematically 
to the heterogeneous weighing of the contribution of the electrodes located in the corners 
of the array. Furthermore, through the simulations, we were able to develop a dual-ring 
electrode configuration and identify the optimal hallmarks of the MLE to extract measures 
of conduction. The dual-ring configuration should make the general approach more readily 
adaptable for clinical use.
The study clearly demonstrates the value of computation models for explicating complex 
electrophysiological phenomena and their relationship to recording arrays. The computa­
tional models utilized in this study clarified the interactions between wavefront propagation 
and the geometry of the plaque array that produce the characteristic features of the MLE. 
This ability to visualize and rapidly permute through many possible scenarios was critical
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to the discovery of the rotational sensitivity of the plaque array, and development of the 
rotationally invariant DRA. Furthermore, experimental evaluation of the effect of a range 
of conductivities on the morphological features of the MLE would have been prohibitive. 
Given the ready availability of simulations software, the field is approaching a point when 
investigation of measured electrophysiological phenomena is incomplete without validation 
based on robust computation models.
At its most basic level, the MLE can be interpreted as a summation of electrograms 
acquired from an array of bipolar electrodes oriented radially around a pacing site (Fig. 7.5). 
The relatively simple array geometry and signal processing of the MLE makes it a promising 
tool for the characterization of cardiac conduction properties, i.e., CVs and anisotropy of 
conduction. The conversion of the MLE sampling array from a plaque array to the DRA 
configuration substantially improves the feasibility of deploying an MLE sensing array in a 
percutaneous electrophysiology study.
Clinical deployment of the MLE in patients with atrial fibrillation (AF) could facilitate 
assessment of substrate remodeling and its impact on impulse conduction in the atria. 
The AF atria are subjected to many remodeling processes that have been shown to impact 
impulse propagation [5]. Many of these remodeling processes appear to differentially impact 
the transverse aspect of myocytes to a greater extent than the longitudinal aspect [30]. In 
light of these observations, robust examination of the anisotropy of conduction could provide 
valuable insight into the state of AF induced remodeling. Of note, the experimental findings 
of this study are based on ventricular recordings from guinea pig ventricles. However, 
because of the potential for clinical application of this approach in the atria, the simulations 
were run using an atrial myocyte model and a tissue slab with thickness most akin to atrial 
tissue (3 mm). In spite of this difference, the basic morphology of the MLE was conserved 
between the experimental and simulation studies.
7.6 Conclusion
We have developed a method in which a novel single electrical signal, the mean Laplacian 
electrogram (MLE), constructed from a number of simultaneously recorded unipolar elec­
trograms, can be used to quantify both velocity and anisotropy of conduction without the 
need to assign activation times to individual electrograms and without explicit knowledge 
of the spatial propagation of the wavefront. In consideration of the clinical feasibility, the 
simplicity of the signal analysis, and the value of robust characterization of conduction 
properties, the MLE is a promising addition to current substrate mapping strategies.
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7.8 Supplementary Material
The idea of the electrode array is to obtain an approximation to the surface Laplacian of 
the potential distribution, 2. Mathematically, this is represented for the continuous function
^ (x,y) as
_ 2 , d  2 2 d  2 2
v  2 = d i 2 + dy2 ■ (7-1)
From Taylor series, it is possible to determine discrete approximations to the surface 
Laplacian as the 3 x 3 stencil
1 / 1 4 1 I
S =  -  I 4 -20  4 I . (7.2)
6 V 1 4 1 /
One obtains an approximation to the surface Laplacian by considering a 3 x 3 array of 
measured potential 2i,j
(
2i-1 ,j-1  2 i,j - 1  2 i+1,j-1 \
2i-1,j 2i,j 2i+1,j I ■ (7.3)
2i-1,j+1 2i,j+1 2i+1,j+1 J
The approximation to the surface Laplacian is obtained from the Frobenius product of 
two matrices S and $(i, j ), i.e., the Laplacian at the node (i,j) denoted Lij is given by
Lij =  S :$ ( i , j )  (7.4)
where the operator ‘:’ represents the Frobenius product. In long hand, we have
Lij =  6 (2i-1,j-1 + 42i,j-1 + 2i+1,j-1 + 42i-1,j- 2 0 2 i,j + 40i+1,j + 2i-1,j+1 + 42i,j+1 + 2i+1,j+1).
(7.5)
Finally, the MLE is determined as the average over all possible Lapalcian Lij . That is, 
for an n x n potential electrode array,
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M L E  N E E L . ,  (7.6)
i=2 j=2
for the Laplacians L,  which exist and N is the total number of Laplacians which do 
exist. For example, for the 8 x 8  array currently in use, assuming that all 63 recording 
electrodes perform correctly, then 35 Laplacians can be obtained.
Hence for the 8 x 8  electrode array considered here, the coefficient stencil is given by
(  1 5 6 6 6 6 5 1
5 -11 - 6 -6 - 6 -6 -11 5
6 - 6 0 0 0 0 -6 6
1 6 - 6 0 0 0 0 -6 6
216 6 - 6 0 0 0 0 -6 6
6 - 6 0 0 0 0 -6 6
5 -11 - 6 -6 - 6 -6 -11 5
1 5 6 6 6 6 5 1
(7.7)
To see why this is reasonable from a mathematical point of view, consider a continuous 
variation in potential, 0, over some two-dimensional domain Q. The surface Laplacian is 
then
d 20 d20
l ( x ,y , t )  =  V 0  =  —  + (7.8)
d x 2 d y 2
Averaging the Laplacian over the region Q is again equivalent to taking the integral over 
the region, hence
L(t) =  / /  l (x ,y ,t)d x d y  = V 20dQ =  ® V 0  ■ ndu (7.9)
J JQ J JQ JdQ
which follows from the divergence theorem. Here dQ represents the boundary of the 
region Q, n is the outward point normal to Q, and du  represents a line element along the 
boundary d Q. Essentially, the average Laplacian can be obtained from a knowledge of the 
normal derivatives of the potentials around the boundary of the domain, regardless of the 
shape of the domain.
CHAPTER 8
CONCLUSIONS AND FUTURE WORK
Substrate mapping can identify arrhythmogenic tissues in which the morphology of 
electrograms indicates the condition of the local myocardium. Detection and localization of 
proarrhythmic features can then guide appropriate treatment. However, the current tools 
and metrics used for clinical substrate mapping are often inadequate to control critical 
system parameters and identify direct indicators of diseased tissues. Bidomain simulations 
can help address these limitations through evaluation of substrate mapping techniques. The 
implementation of such simulations forms the unifying premise of this dissertation. Through 
the three primary aims of this work, we have demonstrated the ability of multiscale com­
putation models to: 1) assess factors that influence the performance of substrate mapping, 
2) guide the development of novel substrate mapping strategies, and 3) explicate poorly 
understood phenomena in electrophysiological signals. In addition to these contributions, 
the use of such models provides direct benefits in terms of mitigated cost, reduced use of 
animal studies, and decreased time required for hypothesis testing.
8.1 Aim 1: Near-Field Electrograms
In the first study, bidomain simulations of a voltage mapping study were performed 
to assess geometric factors that influence the morphology of EGMs, and consequently the 
ability to detect diseased tissue based on a voltage threshold. This study confirmed the 
common assumption that improper electrode alignment with the wavefront of the activation 
impulse could produce low voltage EGMs. More interestingly, however, was the finding 
that particular electrode orientations, with respect to the tissue, were important to the 
performance of voltage mapping. Specifically, near-perpendicular orientation of the bipolar 
electrodes, relative to the cardiac tissue, demonstrated both insensitivity to the direction of 
the activation impulse and enhanced sensitivity and specificity for the detection of abnormal 
myocardium. This finding has significant implications for clinical operators who utilize 
voltage mapping strategies, but who lack tools capable of controlling this parameter. The
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findings of this study are also likely to be relevant for other substrate mapping strategies 
that rely on the use of bipolar EGMs.
The improved accuracy for voltage mapping provided by perpendicular orientations can 
be interpreted in terms of EGM referencing. In current clinical cardiac electrophysiology, 
EGMs are acquired with one of two possible referencing schemes. The first, and most 
commonly used, is a bipolar reference. The other is a unipolar reference with Wilson’s 
central terminal, or another distant electrode, acting as the anodal reference (see Section 
2.4.2). As previously discussed, the concept of a unipolar EGM is a misnomer, and thus 
bipolar and unipolar references simply, if insufficiently, describe a spectrum in which the 
anodal electrode is either close to or relatively removed from the exploratory electrode. 
In the case of the perpendicularly oriented bipolar electrode pair, we have adopted the 
term “near-field unipolar EGM,” or simply “near-field EGM,” to describe the acquisition 
of an EGM with the distal electrode touching the tissue, and the reference electrode in the 
blood pool no closer to any cardiac tissue than the tissue being probed by the exploratory 
electrode. The beneficial properties of near-field EGMs include features typically associated 
with bipolar EGMs, i.e., common mode rejection of far-field signals and unipolar EGMs, i.e., 
consistent EGM morphology and insensitivity to the direction of wavefront propagation. 
These findings make near-field EGMs an attractive option for clinical electrophysiology, 
and in particular for substrate mapping procedures. However, immediate application of 
the near-field EGMs is prevented by persistent limitations in the control and guidance of 
the electrophysiological mapping catheter. Specifically, navigating a catheter to locations 
of interest throughout the heart is already a challenge that requires substantial training. 
Requiring the catheter to reach all locations at a perpendicular orientation may be infeasible 
for many locations in the heart. Moreover, robust confirmation of proper alignment is 
limited with current catheter navigation systems.
In response to the limited ability to acquire near-field EGMs with current clinical 
electrophysiological systems, we have conceived a novel diagnostic recording catheter that 
inherently acquires near-field EGMs wherever an exploratory electrode comes in contact 
with the myocardium. This catheter-based electrode array is similar to diagnostic mini­
basket catheters in current clinical use. However, a simple modification to the basket 
array, in which a reference electrode is placed at the center of the basket, allows all EGMs 
to be acquired with near-field EGM referencing. With this design, the basket forms a 
protective barrier that prevents the central reference electrode from coming in contact 
with the cardiac tissue. Additionally, because the central electrode is equidistant from
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the exploratory electrodes located on the splines of the basket, the reference is consistent 
for all channels. Patent protection for the perspective catheter concept has been initiated, 
and negotiations have begun with an industrial partner to develop a prototype of the device 
(Fig. 8.1).
Development of an electrode array in which the reference anode remains situated in the 
blood pool is a straightforward design specification. Validation of near-field electrograms 
as superior measurements for characterization of the cardiac electrophysiological substrate, 
however, requires careful consideration. Specifically, direct measure of a known cardiac 
substrate, i.e., scar tissue, must be acquired using standard clinical systems as well as 
the near-field electrogram recording system. Various experimental and clinical systems are 
available to create mappable substrates, including radio-frequency ablation or intracardiac 
injection of alcohol. Following the creation of scar tissue, an MRI can be used to characterize 
the location and extent of scaring. Finally, direct measurement of electrograms from the 
surface of the scarred tissue using typical clinical systems for comparison to near-field 
electrogram measurements would allow for comparison of the relative and absolute mapping 
accuracy.
Fig. 8.1. Concept for diagnostic catheter capable of acquiring near-field EGMs. This 
basket-type catheter contains a central reference electrode surrounded by splines containing 
multiple exploratory electrodes, which allows for clinical mapping with near-field EGMs.
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8.2 Aim 2: Conduction Velocity Mapping
The second study provides an example of how multiscale modeling of cardiac elec­
trophysiology can guide the development of novel mapping strategies. In this study, a 
bidomain model of atrial myocardium was implemented in which an action potential could 
be stimulated at multiple points around a representation of a clinical loop catheter. The 
intent of this pacing protocol was to stimulate the tissue with multiple activation patterns 
to elucidate the underlying properties of substrate, e.g., the fiber orientation or presence 
of conduction slowing. The primary challenge with such an approach is based on the 
acceleration of the action potential impulse as it propagates away from the pacing site 
due to changes in the wavefront curvature. Because the electrodes of the loop catheter 
are at variable distances from the pacing site, electrodes at greater distances detect higher 
conduction velocities (CV) than do closer electrodes. However, because the bidomain model 
has sufficient fidelity to capture this characteristic, we were able to determine, over the 
small distances encompassed by the loop array, that the change in conduction velocity 
with distance could be modeled and corrected for with a linear function. This finding was 
supported by measurements acquired from an experimental model and demonstrates the 
utility of multiscale models of cardiac electrophysiology.
Having shown that CVs can be measured from a loop catheter in the experimental 
model, and can be normalized according to the distance of the recording electrode from the 
pacing site, the next step for this project is to develop methods for reconstructing the local 
conduction properties and assessing how they vary depending on the activation pattern. In 
Chapter 6, we demonstrated that the normalized vectors can be projected to the center 
of the loop array. The collection of projected vectors contains a great deal of information 
about the local conduction properties, but it is difficult to interpret relevant information 
from this representation, i.e., longitudinal and transverse conduction velocity, or conduction 
anisotropy. One possible approach for simplifying this information is a dimensionality 
reduction-based approach known as singular value decomposition (SVD). Similar to other 
decomposition strategies, e.g., eigenvalue, or Fourier decomposition, an SVD of the vector 
data identifies the principal axes of variation in the data. This approach would theoretically 
identify, as the first principal axis, the direction in which action potential impulses conduct 
the fastest, i.e., the direction of longitudinal CV (Fig. 8.2). The next component, or axis, 
would then be perpendicular to the first axis and would provide an approximation of the 
transverse CV. This novel approach for evaluating cardiac conduction properties could be 
repeated throughout the heart and is feasible with current catheter technology.
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Fig. 8.2. Singular value decomposition (SVD) of conduction velocity vectors. Top 
- Conduction velocity (CV) vectors acquired with multiple activation pattern mapping 
protocol that have been normalized for distance from the pacing site and projected to 
the center of the loop array. Bottom - The first two principal axes recovered from SVD of 
CV vectors indicating the direction of longitudinal and transverse conduction (red and blue 
cones, respectively.)
8.3 Aim 3: Mean Laplacian Electrogram
The third study is a prime illustration of the ability of cardiac electrophysiological 
simulations to help clarify the mechanisms that govern the genesis of electrical signals 
from the heart. In the case of the mean Laplacian electrogram (MLE), it was readily 
apparent that the observed peaks were somehow related to the spread of activation across 
the recording array. However, it was not until the mathematical basis of the MLE acquisition 
was clarified and simulations were run that the morphology of the MLE could be thoroughly 
explained. Additionally, it was through permutation of model parameters that the impact 
of the plaque array’s rotational asymmetry was established. With these pieces in place, it 
was possible to conceptualize the dual ring array (DRA) for simplified and clinically feasible 
sampling of the MLE.
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The MLE is an attractive option for CV measurement, compared to the approach in the 
second study, because it obviates the need to identify activation times for multiple channels. 
Of course, the primary limitation of this approach is that no current clinical electrode arrays 
quite meet the DRA specifications. Future work on this project will be focused on extending 
the mathematics that allow acquisition of the MLE from a DRA array to an array in current 
clinical use.
The findings of these studies have shown the ability of multiscale modeling to sufficiently 
replicate cardiac electrophysiological processes in order to examine, interpret, and refine 
substrate mapping procedures. Consequently, not only do the findings from the individual 
aims contribute to the development of novel strategies for substate mapping, but the work 
as a whole provides a compelling argument for the use of simulations in the development 
and validation of electrophysiological diagnostics. Interestingly, the workflow of hypothesis 
testing, experimentation, and validation was found to be flexible in terms of whether 
simulation or experimentation came first. In the first two studies, computational models 
were used to develop and test new mapping strategies that were then tested in experimental 
animal studies. On the other hand, the MLE signal was first examined with experimental 
data and then validated with computational studies that elucidated the mechanism that 
drives the genesis of the MLE signal. Naturally, risks are associated with simulation studies, 
e.g., oversimplification of complex physiological processes or overfitting when a model lacks 
sufficient degrees of freedom. However, with this approach, in which experimental and 
computational studies are closely coupled and carried out in parallel, it may be possible 
to avoid many of these pitfalls. With the continued development of electrophysiological 
modeling systems, and the increasing complexity of signal processing applied to cardiac 
EGMs, we may well have reached a stage where characterization of electrical signals from 
the heart is incomplete until robust computational models can both replicate the behavior 
and explore factors, such as orientation with respect to the tissue (Aim 1) or rotational 
asymmetry (Aim 3), that may influence interpretation of the signals.
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